🧬 Early-onset colorectal cancer: a distinct tumor ecosystem?
• 🌐 Stromal enrichment: Younger MSS tumors exhibit ↑ stromal/epithelial ratio, validated in 712 tumors.
• 🔀 EMT signaling: ↑ inferred FN1, GDF, ACTIVIN & SPP1 interactions suggest enhanced tumor–stroma crosstalk.
• 🧬 Transcriptional rewiring: ↑ lncRNA expression, including poorly characterized transcripts, in younger MSS tumors.
• 🔬 Genomic landscape: CNA patterns largely conserved across ages, with a trend toward greater intratumoral heterogeneity (P=0.056).
• 🎯 Therapeutic opportunities: Stromal remodeling & EMT-associated signaling emerge as potential vulnerabilities.
📄 doi.org/10.1038/s41591-026-04721-y
Jean-Charles Soria
Jean-Charles Soria, né le 20 avril 1971, est un médecin oncologue et un chercheur français. More on Wikipedia
-
soria
@jsoriamd
-
soria
@jsoriamd
🧬 Cancer Progress 2026: remarkable gains & a rapidly evolving therapeutic frontier fueled by science
• 📉 Mortality: US cancer death rate ↓ 35% since 1991 → >4.8M deaths averted
• 💊 Innovation: 11 new anticancer therapies FDA-approved in the past 12 months—10 molecularly targeted, including the first PROTAC in breast cancer
• 🛡️ Immunotherapy: 15 ICBs now span 23 cancer types
• 📈 Survival: 5-year survival across cancers reached 71% versus 49% in the mid-1970s
cancerprogressreport.aacr.org/progress/
#aacr -
soria
@jsoriamd
AI in Pharma R&D: time to move from better models → better medicines
• 🎯 Optimize what matters: improving Phase II success has far greater potential impact than simply accelerating hit discovery
• 💊 Ligand ≠ drug: AI can generate binders rapidly—but efficacy requires the right biology, exposure, safety & patient
• 🧬 Better data ≠ more data: biological data are highly contextual; what matters is predictive validity for human outcomes
• 📊 Benchmark ≠ impact: model accuracy matters only if it improves a real R&D decision—advance, redesign or stop
• 🔄 Next frontier: start with the clinical question → generate fit-for-purpose human biology → integrate clinical feedback → continuously improve the model
👉 Perhaps the end of the beginning: less “technology push,” more “science pull.”
#ai #drugdiscovery #drugdevelopment #precisionmedicine
www.nature.com/articles/s41573-026-01496-2 -
soria
@jsoriamd
🦠 Programmable bacteria as cancer immunotherapy? A fascinating new study in STM
👏 Congratulations to Mathieu Rouanne, Nicholas Arpaia, & colleagues.
🔬 Engineered E. coli Nissle delivering CXCL13 directly into the bladder:
• Recruited & organized B- and T-cell immunity
• Induced tumor-specific antibodies
• Synergized with PD-1 blockade
• Produced durable tumor control and long-term survival in preclinical bladder cancer models
A compelling example of how synthetic biology could reshape the tumor immune microenvironment and expand the cancer immunotherapy toolbox.
📄 www.science.org/doi/10.1126/scitranslmed.adv7600 -
soria
@jsoriamd
🧬 ADC innovation requires payload diversification—not just target diversification.
• 🔄 The ADC pipeline is increasingly dominated by TOP1 inhibitor payloads, raising concerns about resistance mechanisms and overlapping toxicities.
• 💡 Trastuzumab deruxtecan illustrates that historically unsuccessful cytotoxics can become effective payloads when redesigned for antibody-mediated delivery.
• 🎯 Future payload selection should prioritize pharmacologic behavior—proliferation-restricted activity, favorable pharmacokinetics, sustained intracellular target engagement, and controlled bystander effects—rather than maximal in vitro potency.
• 🔬 Legacy cytotoxics (e.g., antifolates, nucleoside analogs), degraders, immune-stimulants represent an underexplored source of mechanistically distinct ADC payloads.
• 🚀 Broadening payload diversity may expand therapeutic opportunities, delay class-wide resistance, and define the next generation of precision ADCs.
doi.org/10.1016/j.trecan.2026.04.001 -
soria
@jsoriamd
🧬 We've been developing ADCs as targeted drugs. Biology says otherwise.
• ❌ Target expression alone poorly predicts benefit
• 🔀 ADC efficacy emerges from the interaction between tumor cells, TME, payload, linker, and immune biology
• 🧠 Precision ADCs require multidimensional biomarkers—not better IHC
• 🧪 Longitudinal biopsies, ctDNA and spatial profiling should become important parts in ADC trials
• 🎯 The next generation of ADCs will be defined as much by patient selection as by molecular engineering
doi.org/10.1016/j.ccell.2026.05.004 -
soria
@jsoriamd
🧬 Liquid biopsy can now profile the tumor microenvironment (TME)
• 🧪 Deep-learning analysis of cfDNA methylation profiles inferred spatial TME ecosystems directly from plasma
• 🌐 Plasma-derived “liquid ecotypes” captured distinct immune/stromal ecosystems linked to geography within tumors (margin vs core)
• 🎯 Liquid TME profiling predicted ICB response: immune-active SE7/SE8 → benefit; stromal/hypoxic SE4 → resistance
• 📊 In melanoma, liquid ecotypes showed stronger survival associations than PD-L1 or TMB in several analyses
• 🔄 This enables a new paradigm: serial, non-invasive monitoring of the evolving TME ecosystem during therapy
www.nature.com/articles/s41586-026-10452-4
#liquidbiopsy #precisiononcology -
soria
@jsoriamd
Lung cancer 2030: from treating disease → intercepting evolution
• 🧬 Evolution-guided care: integrate genomics + epigenome + proteome to map tumor trajectories
• 🧪 MRD- based trials: ctDNA-driven escalation/de-escalation → treat microscopic disease, not relapse
• 🔀 Target plasticity: drug-tolerant persisters & lineage switching as primary therapeutic targets
• 🎯 New modalities: ADCs, TCEs, degraders to expand beyond classic oncogene
• 🌍 Shift upstream: prevention (IL-1β axis), and risk-adapted screening
👉 Future = anticipate, intercept, and adapt
aacrjournals.org/cancerdiscovery/article-abstract/doi/10.… -
soria
@jsoriamd
🧬 Beyond PD-L1: thymic health emerges as a host determinant of ICB response
• 🧠 Host biology matters:thymic health (CT-derived proxy of T cell maturation) predicts outcomes across 3,476 immunotherapy-treated patients
• 📉 Clinical impact: high thymic health → ↓progression & ↓mortality (HR ~0.5–0.65) in NSCLC, independent of PD-L1/TMB
• 🔬 Mechanistic link: higher thymic health correlates ↑TCR diversity, & ↑circulating T cells
• 🌍 Tumor-agnostic signal: predictive across lung, melanoma, breast, renal cancers → complements tumor-centric biomarkers (PD-L1/TMB)
www.nature.com/articles/s41586-026-10243-x -
soria
@jsoriamd
🧬 Turning intracellular kinases into druggable surface targets
• 🔀 Trafficking switch: Src flips to the surface via autophagolysosomal exocytosis
• ⚡ Active outside: eSrc phosphorylates extracellular proteins (e.g., ADAM17) → tumor growth
• 🎯 Tumor-selective: present on cancer cells, absent on normal cells
• 🧬 Class effect: other lipid-anchored proteins (Lyn, Hck) also exposed
• 🧪 Therapeutic angle: enables antibody targeting (TCE, ADC, radioligand) of a “non-druggable” kinase
www.science.org/doi/10.1126/science.aec1778 -
soria reposted
IASLC
@IASLC
At #ttlc26, @DRCamidge shared powerful insights shaped by both clinical expertise and personal experience living with #lungcancer.
His presentation reminds us why continued innovation in #lungcancer research is essential to improving patient outcomes every day.This media couldn't be displayed. See it on the original post. -
soria
@jsoriamd
🫁 Lung cancer in never smokers: actionable implications for practice
• Driver-rich biology: 78–92% actionable (EGFR/ALK); low TMB → limited ICI benefit → perform broad NGS upfront.
• Etiology: germline risk (EGFR T790M, APOBEC3A/B), CHIP-driven inflammation, radon, second-hand smoke (~20–25% ↑ risk), PM2.5. (air pollution)
• Screening: LDCT benefit proven in smokers; in never-smokers, consider only high-risk subgroups (e.g., family history).
• Adjuvant precision: EGFR TKIs improve outcomes post-resection—test early-stage disease.
• Prevention horizon: IL-1β targeting and neoantigen vaccines under investigation.
www.sciencedirect.com/science/article/pii/S2405803325003152 -
soria
@jsoriamd
🧬 Hallmarks of cancer—what’s new beyond the original 6
• Evading immune destruction is now a core acquired capability, reflecting multi-layered TME immunosuppression and T-cell exhaustion biology.
• Deregulating cellular metabolism was added as a hallmark capability (beyond “Warburg”) to capture diverse metabolic rewiring that supports growth and survival.
• Unlocking phenotypic plasticity is the newest hallmark (introduced 2022): epigenetic flexibility enabling state switching, heterogeneity, and adaptive resistance.
• These “new” hallmarks sit within an expanded framework that also emphasizes hallmark-enabling characteristics, hallmark-conveying TME cells, and systemic interactions.
• Original 6 (reminder): sustaining proliferative signaling; inactivating growth suppressors; resisting programmed cell death; establishing replicative immortality; inducing/accessing vasculature; activating invasion & metastasis.
doi.org/10.1016/j.cell.2025.12.049 -
soria
@jsoriamd
🧬🛡️ HER2-low tumors escape HER2 ADCs by losing the target
• True HER2 loss is uncommon in HER2-amplified disease but frequent in HER2-low, where HER2 isn’t oncogenic
• On HER2 ADC therapy, ~50% of tumors reduce HER2; among reducers, ~half become IHC 0
• Reduced HER2 → impaired ADC internalization, not payload resistance
• ERBB2 ECD variants disrupt antibody binding and phenocopy antigen loss
• Suggested strategy: multi-target payload delivery to bypass target dependence and improve durability
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… -
soria
@jsoriamd
📊🧬 Cancer in 2026 — key facts for oncologists
• Burden: ~2.11M new cancer cases and ~626K deaths projected in the US (2026).
• Mortality: Cancer death rates ↓34% since the early 1990s, averting ~4.8M deaths.
• Survival: Overall 5-yr relative survival reached 70%(2015–2021), up from 49% in the mid-1970s.
• Advanced disease: 5-yr survival for distant-stage cancers improved 17% → 35%, with major gains in lung, melanoma, & rectal cancer.
• Unfinished work: Lung cancer remains the leading cause of cancer death
acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70043 -
soria
@jsoriamd
Targeted protein degradation in AML is defined by target biology, degrader design, & transcriptional control.
Event-driven pharmacology: catalytic MLLT1/3 degradation vs occupancy-based inhibition → sustained pathway suppression.
🖋️Target selection matters: non-enzymatic, scaffold proteins (MLLT1/3) inaccessible to classic inhibitors
🖋️Transcriptional reprogramming: disruption of leukemogenic gene networks → anti-leukemic activity
🖋️Resistance biology: degradation enables single-agent activity & rational combinations to extend remission durability
🖋️Platform relevance: expands small-molecule degradation into hematologic malignancies.
Amgen 🧪🔬🧬
@Amgen
Heading into 2026: Amgen bolsters its oncology pipeline.
Amgen will acquire UK-based Dark Blue Therapeutics Ltd. adding an investigational small molecule to treat acute myeloid leukemia (AML).
This builds on our commitment to patients with difficult to treat cancers.
🔗 Acquisition Details: amgen.ly/4pvTEY3
$AMGN -
soria
@jsoriamd
🧬 2025 FDA approvals: oncology still leads—but with a shifting mechanistic profile
• Oncology dominates approvals: 16/46 (35%) new FDA drugs in 2025 were cancer therapies—well above any other therapeutic area, reinforcing oncology as the primary engine of regulatory innovation.
• MoA trend in oncology: approvals cluster around precision modalities—ADCs (TROP2, c-MET), bispecific T-cell engagers (BCMA×CD3), immune checkpoints (PD-1), & highly selective kinase inhibitors.
• Contrast with non-oncology TAs: cardiology, inflammatory & metabolic drugs largely target physiologic pathway modulation (BTK, DPP1, PCSK9, Naᵥ1.8), with fewer cytotoxic or immune-redirecting mechanisms.
• Biology-driven cancer approvals: multiple first-in-class or mutation-defined indications (H3 K27M glioma, KRAS-mut ovarian cancer, HER2-mut NSCLC) highlight continued regulatory reliance on molecular stratification.
www.nature.com/articles/d41573-026-00001-z -
soria
@jsoriamd
Radio Ligand Therapies: how precision radiation is reshaping oncology
🌊 Tumor-targeting ligands deliver radioactive payloads systemically, irradiating cancer while trying to spare most normal tissue.
🔀 Radionuclide choice matters: β emitters enable crossfire in bulky/heterogeneous disease, α emitters do better in micrometastases.
🛡️ Efficacy depends on target stability, not oncogenic addiction (PSMA, SSTR2, FAP > RTKs)
🧬 Carrier design (small molecules vs antibodies, multimerization, pre-targeting) governs penetration, retention & toxicity.
🧪 Personal dosimetry + early-line use + rational combinations (ADT, PARPi, ICB) may expand the therapeutic window.
www.nature.com/articles/s41571-025-01069-z -
soria
@jsoriamd
mRNA vaccines as unplanned immunotherapy primers
⚡ SARS-CoV-2 mRNA vaccination triggers a type I IFN surge, activates APCs, and primes CD8⁺ T cells for tumor antigen recognition.
🧩 IFN-driven PD-L1 upregulation
🧭 Enhanced T-cell infiltration into “cold” tumors
🌐 Reprogrammed immune microenvironment enabling IO response
📈 Clinically: COVID mRNA vaccine <100 days before IO use increases OS in NSCLC & melanoma
#immunotherapy #cancer #mrna #targets25
www.nature.com/articles/s41586-025-09655-y -
soria
@jsoriamd
ADCs biology is shaped by antibody, linker stability, payload, & immune synergy
🌊 Systemic kinetics: DAR balance critical; high DAR → higher clearance/toxicity, low DAR → weak efficacy
🔀 Linker chemistry controls payload release: cleavable vs non-cleavable, stability/efficacy vs bystander effects
🛡️ Fc effector functions = ADCC, ADCP, TAM processing → can enhance efficacy but add toxicity
🧬 Immunogenic cell death (ICD): payloads trigger DAMP release → DC maturation & CD8⁺ T cell priming
🧪 Payload innovation: beyond chemo → degraders, immune activators, protein modulators
www.nature.com/articles/s41568-025-00869-w -
soria
@jsoriamd
ADCs are not just “guided missiles” — new biology is reshaping how we view them
🌊 Continuous payload exposure in circulation sustains cytotoxic thresholds
🔀 Antigen level ≠ response: extracellular cleavage enables efficacy in “HER2-null” tumors
🛡️ Fc functions & TME interactions may shape efficacy & toxicity (e.g., ILD, thrombocytopenia)
🧬 Cross-resistance across TOP1i ADCs → need for payload diversification
🧪 Future: dual-payload ADCs, tumor-selective linkers, ADC–ICI combinations ?
ascopubs.org/doi/10.1200/JCO-25-01235 -
soria
@jsoriamd
Mismatch Repair Deficiency: From DNA repair failure to immunotherapy sensitivity
🌊 Loss of MMR → microsatellite instability → hypermutation → abundant neoantigens
🛡️ Immune context: TIL-rich & inflamed, but immune checkpoints (PD-1, CTLA4, LAG3) and fibrotic stroma enable escape
🧬 Therapy: PD-1 ± CTLA4 blockade effective across cancers, but 25–40% show primary or acquired resistance
🧪 Future: neoadjuvant ICBs, WRN helicase inhibitors (synthetic lethality), frameshift peptide vaccines, aspirin prevention in Lynch
www.nature.com/articles/s41571-025-01054-6 -
soria
@jsoriamd
Circulating Tumor Cells: Mechanistic drivers of metastasis & biomarker promise
🌊 Intravasation via EMT/VEGF; clusters = 25–50× ↑ metastasis
🔀 Lineage plasticity (epithelial ↔ mesenchymal ↔ neuroendocrine)
🛡️ Platelets & neutrophils shield CTCs; PD-L1+ escape
🧬 Resistance: EGFR T790M, ESR1, AR-V7, CNV tracking
🧪 High-volume isolation → MRD, epitope monitoring, ex vivo drug tests
#ctcs #liquidbiopsy
www.cell.com/cancer-cell/fulltext/S1535-6108(25)00314-9 -
soria
@jsoriamd
Circulating Tumor Cells: Beyond ctDNA in Precision Oncology
🩸CTCs ≠ ctDNA: Beyond mutations, CTCs reveal real-time protein & RNA expression—useful for target discovery & resistance monitoring.
🔬 Liquid biopsy advantage: Noninvasive CTC analysis enables dynamic tracking of tumor evolution, therapy response & MRD.
📈 Prognostic power: High CTC counts in early disease predict relapse; in metastatic disease, counts stratify prognosis & guide treatment intensity.
🎯 Therapeutic targets: HER2, ER, AR, PSMA, PD-L1, EGFR, ALK—CTCs expose actionable biomarkers & resistance mechanisms in real time
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… -
soria
@jsoriamd
🩸 Platelets can carry tumor DNA.
🔹 Platelets – smallest yet 2nd most abundant blood cell type.
🔹New study: tumor-derived DNA found in platelets of advanced cancer patients.
🔹This cfDNA reservoir could complement plasma cfDNA, boosting detection sensitivity in low–tumor burden disease.
🔹Platelets’ ubiquity, rapid turnover & vascular contact make them ideal biosensors for cancer & genetic alterations.
🔹Findings carry broad implications for #liquidbiopsies & precision oncology. www.science.org/doi/10.1126/science.adp3971 -
soria
@jsoriamd
Cancer cachexia = an underdiagnosed, lethal syndrome.
· Affects up to 80% in pancreatic CA, 40% in lung.
· It’s not just weight loss—think systemic inflammation, altered metabolism, fat/muscle wasting.
· GDF-15, IL-6, activin A are key molecular drivers.
· A major unmet need in cancer patients
aacrjournals.org/cancerdiscovery/article/15/8/1543/763851… -
soria
@jsoriamd
Liquid biopsies in #crc
🩸 Serial MRD monitoring:
✔️Detects recurrence 8–11 months earlier than imaging
✔️Improves sensitivity from 40–50% to 80–90%
✔️Helps monitor ACT response
Liquid tumor-agnostic assays are evolving: now integrating
✅Methylation
✅Fragmentomics
✅Mutations
www.annalsofoncology.org/article/S0923-7534(24)04981-0/fu… -
soria
@jsoriamd
Humoral Immunity in CheckPoint Inhibitors Response
CPI response isn't just T cell-driven.
In a 374-patient CPI cohort, @Nature study shows:
✅ Broad, stable anti-exoproteome autoantibody signatures
✅Some AAbs enhance CPI efficacy (e.g., by blocking IL-6, IFN-I, TL1A)
✅Others impair it (e.g., anti-BMPR1A/2)
📌 Implication: Humoral immunity could serve as potential predictive biomarker and therapeutic target in IO.
www.nature.com/articles/s41586-025-09188-4 -
soria
@jsoriamd
Esteban Cvitkovic (“Steve”, “El Gordo”) died on June 20, 2025. Inventor of hyperhydrated cisplatin, developer of oxaliplatin, pioneer in head and neck cancers.He had the rare gift of seeing the truth behind appearances and asking:
“Is this practice truly useful to the patient?” -
soria
@jsoriamd
ctDNA/CTC-based liquid biopsies are redefining clinical oncology: enabling population screening, early relapse flagging, pharmacodynamic monitoring, and molecular profiling of resistance—all from peripheral blood. #liquidbiopsies
www.cell.com/cancer-cell/fulltext/S1535-6108(24)00444-6 -
soria
@jsoriamd
As of Jan 1, 2025, 18.6 million people in the U.S. are living with a history of cancer. By 2035, this is projected to exceed 22 million. Prostate, breast, & colorectal cancers lead prevalence. #oncology #cancersurvivorship
acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70011 -
soria
@jsoriamd
#asco25 Development of acquired therapeutic resistance limits the efficacy of cancer treatments. How resistance arises, varies across cancer types & differs depending on therapeutic modalities. www.nature.com/articles/s41568-025-00824-9
-
soria
@jsoriamd
Radioligand therapies harness the cytotoxic force of radiotherapy with molecular precision—emerging as a new strategy for cancers. Clinical-stage radioligand therapies landscape overview #asco25
www.nature.com/articles/d41573-025-00096-w -
soria
@jsoriamd
#asco25: We will present Phase Ill data, also published in @NEJM, for metastatic SCLC, offering a new option for this aggressive cancer, leveraging the use of T-cell engagers.
www.nejm.org/doi/full/10.1056/NEJMoa2502099
NEJM
@NEJM
Presented at #asco25:
Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. Full DeLLphi-304 phase 3 trial results: www.nejm.org/doi/full/10.1056/NEJMoa2502099
@ASCO -
soria reposted
Amgen Oncology
@AmgenOncology
🚀#dll3 innovation brought us to new frontiers in small cell lung cancer care.
@Amgen’s T-cell engager technology is designed to activate the immune system to find & attack cancer cells that express DLL3.
Discover how ⬇️
#asco25 -
soria
@jsoriamd
mRNA pre-drugs: a new path in oncology drug design, with clear trade-offs.
✅ Lower production costs
✅ Extended antibody half-life
⚠️ New toxicities
⚠️ Reduced control over pharmacokinetics
#asco25
#oncology #drugdevelopment #mrnatherapeutics -
soria
@jsoriamd
Bi-specifics: not all created equal.
🧬 Tumor-targeted
🛡️ Immune-redirecting
🔥 Immune-enhancing
Solid visual from #asco25 #tce
#cancertreatment -
soria
@jsoriamd
Algorithmic approach to TOP1i ADCs maps tumor types & cross-resistance to optimize payload decisions. Unique opportunities in hard-to-treat cancers like GBM, HNSCC, PDAC? . #adc #precisiononcology #asco25
-
soria
@jsoriamd
Carcinoma of Unknown Primary: Cancer without a past
🧬 Early dissemination
🛡️Immune editing of the primary
🧪CK20+, CDX2+, SATB2+ → treat colon-like
🧭Let biology, not anatomy, guide therapy
Not a diagnostic failure — a metastatic strategy.
www.nejm.org/doi/full/10.1056/NEJMcp2402691
#asco25 #cup #cancerbiology -
soria
@jsoriamd
🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency.
🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response
2️⃣ PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC & endometrial.
#msi #immunotherapy #biomarkers
🔗 www.nature.com/articles/s41571-025-01015-z -
soria
@jsoriamd
Cancer-associated Cachexia is a lethal metabolic syndrome marked by systemic inflammation, CNS appetite dysregulation, & muscle/fat loss—better characterized with imaging. Prevalent in cancers like pancreatic/lung, it's linked to IL-6, GDF-15, & tumor-driven energy drain. Trials targeting CNS and inflammation (e.g., Ghrelin receptor agonist, anti-GDF15 Ab) show promise. #aacr25 #cancer #cachexia aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
-
soria
@jsoriamd
CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic clones in blood—especially TET2 mutant ones—migrate into tumors, reshape immunity, drive progression, and promote recurrence. The ability of a somatic clonal expansion in the hematopoietic compartment, to regulate malignant progression in another tissue represents a new perspective in cancer biology. #chip #lcms #cancer #biology #aacr25 www.nejm.org/doi/full/10.1056/NEJMoa2413361
-
soria
@jsoriamd
ADC’s Bystander Effect may be crucial for efficacy!
In a provocative recent paper, HER2 ADC’s payload may not need ADC internalization for efficacy ! Activity may rely on extracellular proteases, such as cathepsin L (CTSL). This extracellular release in the TME appears to kill nearby HER2-low/negative cancer cells. #cancer #adc #tumormicroenvironment #aacr25 www.nature.com/articles/s41467-025-58266-8 -
soria
@jsoriamd
The 2025 Annual Report on the Status of Cancer confirms a continued decline in overall cancer mortality (Cancer death rates decreased by 1.7%/ year for men & 1.3%/ year for women from 2018 to 2022) yet the pace of improvement has slowed during the COVID-19 pandemic. Lung cancer mortality declines at a faster rate than incidence, likely due to improved treatments, early detection, & tobacco control, but screening rates remain under 20% of eligible adults. acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr…
-
soria
@jsoriamd
From resisting death to spreading across the body, #cancer evolves through sequential stages. Understanding this roadmap is key to designing better therapies. The Hallmarks of Cancer, reimagined as a 5-stage evolution wheel encompass:
1. Initiation
2. Evolvability
3. Niche Construction
4. Survival Adaptations
5. Emergence
aacrjournals.org/cancerdiscovery/article/15/4/685/754377/… -
soria
@jsoriamd
Detailed maps of #mutations in both healthy and cancerous gastric tissue provide insights into how #gastric #cancer develops and may help guide early detection efforts. www.nature.com/articles/d41586-025-00803-y
www.nature.com/articles/s41586-025-08708-6 -
soria
@jsoriamd
Do you remember when you joined twitter/X? I do! I have learned so much and connected with many over those years.
-
soria
@jsoriamd
The oncology dealmaking landscape is shifting! Pharma is moving beyond niche drugs to focus on ADCs, bispecifics & radioligand therapies. Low interest in narrow biomarker drugs, pharma is chasing pan-cancer blockbusters! #oncologydeals #pharma www.nature.com/articles/d43747-025-00006-4
-
soria
@jsoriamd
Can baseline routine blood tests & clinical characteristics predict if #cancer patients will benefit from #immunotherapy? 🤔Meet SCORPIO—an #ai model that appears to outperform existing FDA-approved biomarkers (TMB, PD-L1) in predicting treatment response. doi.org/10.1038/s41591-024-03398-5
-
soria
@jsoriamd
Seeing the unseen! FAP-PET unlocks TME visualization, allowing the imaging of cancer-associated fibroblasts (CAFs), notably in tumors with low metabolic activity. aacrjournals.org/cancerdiscovery/article/15/2/264/751329/…
-
soria
@jsoriamd
I agree, Breakthrough is a great read for anyone who wishes to understand how new & transformative therapeutics are created and developed
Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD
New book out, by William Pao. Great stories about developing drugs. Definitely covers EGFR, but other important medicines as well. It is a great read.
-
soria
@jsoriamd
FDA approved 57 new therapeutic drugs (NTDs) in 2024. This is above the average of 53 NTDs per year for the last decade, & below the 71 approvals in 2023. The total projected annual peak sales for these NTDs is US$60 billion, which is considerably below the average since 2014 of $88 billion. www.nature.com/articles/d41573-025-00014-0
-
soria
@jsoriamd
Today’s @US_FDA approval is a milestone moment for patients with chemorefractory KRAS G12C-mutated #mcrc.
Our team continues to push cancer care forward – this is the oncology team’s 4th FDA approval in the past 12 months. #mycompany
Amgen 🧪🔬🧬
@Amgen
The @US_FDA approved Amgen’s targeted combination therapy for the treatment of adult patients with chemorefractory KRAS G12C-mutated #mcrc.
🔗 Press release: amgen.ly/3DSN5fR
$AMGN -
soria
@jsoriamd
Cancer death rates in the U.S. have dropped 34% since 1991, averting over 4.5M deaths. However incidence continues to increase for breast, prostate, melanoma, uterine corpus, pancreas, & CRC (<65 years). The cancer burden is shifting from older to younger adults & from men to women. Middle‐aged women have higher cancer risk than their male counterparts, and young women are almost twice as likely to be diagnosed as young men. acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac…
-
soria
@jsoriamd
Reported associations between tumor-infiltrating lymphocyte subsets, including cytotoxic CD8+ T cells, CD4+ T helper cells, T reg cells & B cells in pretreatment tumor samples, and sensitivity or resistance to #immunotherapy in patients with various solid tumor types. www.nature.com/articles/s41571-024-00984-x
-
soria
@jsoriamd
Genomic instability in NMIBC: Whole-genome doubling (WGD) in 15% of non-muscle-invasive bladder cancers (NMIBCs) is linked to poor outcomes. This is driven by alterations in TP53, cell-cycle genes, high neutrophil infiltration &T cell exhaustion markers, suggesting immune evasion mechanisms. In the USA there are 61,000–66,000 new cases of NMIBC annually #bladdercancer #genomics
www.nature.com/articles/s41588-024-02030-z -
soria
@jsoriamd
2024 FDA approvals show that #cancer remains the dominant focus of drug developers, with 15 (30%) novel approvals in 2024. Dermatology & non-malignant hematology were second, with 6 (12%) approvals each. A total of 32 (64%) of the new approvals are small molecules, in line with the 5-year average for this leading modality.
www.nature.com/articles/d41573-025-00001-5 -
soria
@jsoriamd
FcγR engagement influences antibody efficacy, toxicity & pharmacokinetics:
1) Effector Functions: Critical for anti-CTLA4 to deplete Tregs via ADCC/ADCP; unnecessary for anti-PD(L)1.
2) Toxicity: Increases immune-related adverse events (irAEs) & infusion reactions
3) Pharmacokinetics: FcγR engagement influences antibody clearance & shortens half-life
4) Hyperprogression: FcγRIIb engagement may trigger immunosuppression or PD-1+ T-cell depletion.
5) Polymorphisms: FcγR variants affect efficacy #immunotherapy onlinelibrary.wiley.com/doi/10.1111/imr.13427 -
soria
@jsoriamd
Liquid biopsies offer 2 paths for MRD detection in colorectal cancer:
1) Tumor-Informed: High sensitivity via personalized tumor profiles. Requires tissue sampling.
2) Tumor-Agnostic: Broader use with plasma-only analysis. Lower sensitivity but evolving tech bridges the gap.
#cancerresearch #liquidbiopsy #precisiononcology
www.annalsofoncology.org/article/S0923-7534(24)04981-0/fu… -
soria
@jsoriamd
Fructose consumption has increased considerably over the past five decades, due to the widespread use of high-fructose corn syrup as a sweetener. A recent publication shows that fructose supplementation enhances tumor growth in various animal models. The liver converts dietary fructose to lipids that enter the blood, & cancer cells use the lipids to make membranes for proliferation.
www.nature.com/articles/d41586-024-03653-2
www.nature.com/articles/s41586-024-08258-3 -
soria
@jsoriamd
Spatially exploring RNA biology in archival formalin fixed paraffin-embedded tissues holds the potential to revolutionize the analysis of human pathology by revealing vulnerabilities in the structural supports of tumors.
doi.org/10.1016/j.cell.2024.09.001 -
soria
@jsoriamd
Tumor fraction (TF) at liquid biopsy is a potential marker for tumor burden. In this study of 1065 patients, tumor fraction (TF) at liquid biopsy was weakly associated with total tumor volume (TTV) measured by contrast-enhanced CT. Although not sufficiently correlated, TF and TTV may provide complementary information regarding tumor evolution and survival.
pubs.rsna.org/doi/10.1148/radiol.232674 -
soria
@jsoriamd
ecDNA fuels cancer progression: large, mobile circles of DNA in tumors drive high oncogene copies & rapid genetic changes. Their random spread during cell division increases treatment resistance & tumor evolution. Determining therapeutic vulnerabilities & identifying target compounds to limit ecDNA evolution could open impactful new therapeutic horizons.
www.nature.com/articles/s41586-024-08107-3 -
soria
@jsoriamd
Biomarker discovery through highly multiplexed tissue imaging is a critical step for precision oncology. It identifies complex patterns in tumors, paving the way for novel predictive biomarkers & treatment approaches. #cancerbiomarkers #precisionmedicine aacrjournals.org/cancerdiscovery/article/14/11/2071/74919…
-
soria
@jsoriamd
Researchers at @Columbia used synthetic biology to reprogram intratumoral bacteria, boosting immune responses to control tumors. In a bladder cancer model, these engineered bacteria helped produce tumor-specific antibodies, enhancing PD-1 blockade effectiveness & spotlighting humoral immunity in cancer therapy. #sitc24 www.biorxiv.org/content/10.1101/2024.10.24.620122v1
-
soria
@jsoriamd
The tumor microenvironment of SCLC is often "immune cold" (due to low T cell infiltration & high immune suppression), & frequently shows high levels of DNA damage response. Despite these complexities, new clinical targets are now demonstrating promising activity: DLL3, B7H3, FucGM1& others. aacrjournals.org/clincancerres/article/30/14/2872/746334/…
-
soria
@jsoriamd
Non-oral drug delivery options are key to deliver the full promise of protein degraders in #cancer. Nanoparticle-based delivery systems, peptide-based degraders, ADC-degraders, & long-acting injectables are some of the potential solutions www.nature.com/articles/s41573-023-00652-2
-
soria
@jsoriamd
ADCs represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs FDA-approved & more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development remains challenging as evident from the clinical discontinuation of more than 150 ADCs to date. This review discussed key insights into the toxicity, efficacy, stability, distribution, & fate of ADCs. aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
-
soria
@jsoriamd
Global data & research on different types of #cancer available across regions & countries @OurWorldInData.
Risk factors for cancer, modulation of risk across the lifespan, worldwide differences & projections over time: all at your fingertips with great graphics.
ourworldindata.org/cancer -
soria
@jsoriamd
From targeting cancer cell receptors to activating T-cells & delivering cytotoxic drugs with ADCs, antibodies offer multiple ways to combat cancer. www.nature.com/articles/s41568-024-00690-x
-
soria
@jsoriamd
Cancer immune evasion is a multifaceted process—tumors employ a mix of antigen hiding, immune cell reprogramming, & metabolic control to escape detection. Understanding the interplay of these mechanisms is key to advancing therapies. linkinghub.elsevier.com/retrieve/pii/S1535610824003581
-
soria
@jsoriamd
FIH dose selection is a critical step in drug development. This dose should be optimized to avoid exposing patients to subtherapeutic doses while avoiding doses with unacceptable toxicity. A higher FIH starting dose can improve the efficiency but also reduce the cost of a FIH trial. Selecting the initial dose for T-Cell Engagers has been historically challenging. Here a modified MABEL approach to FIH dosing for TCE boosts efficiency by enabling a 10x higher starting dose while maintaining safety. ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3431
-
soria
@jsoriamd
The integration of #cancer #biomarkers has revolutionized cancer treatment, allowing remarkable advancements in cancer therapeutics & the prognosis of cancer patients. This review paints the road ahead. www.sciencedirect.com/science/article/pii/S00928674240024…
-
soria
@jsoriamd
Recent research highlights extrachromosomal DNA role in cancer progression. By increasing oncogene copy numbers, enhancing transcription via 'ecDNA hubs,' & promoting genetic diversity, ecDNA drives rapid tumor evolution & treatment resistance. www.nature.com/articles/s41568-024-00669-8
-
soria
@jsoriamd
Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer & 3 for non-oncology indications. This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell & checkpoint inhibitors.www.nature.com/articles/s41573-024-00896-6
-
soria
@jsoriamd
Our cells detect foreign DNA to initiate immune responses to DNA viruses. These immune responses involve the production & secretion of type I interferons. Responses to DNA are now known to play central roles in many diseases, including autoimmune diseases & cancer. How DNA Sensing Drives Inflammation is related to a DNA-activated enzyme called cyclic GMP–AMP synthase (cGAS), which binds DNA & initiates inflammation. www.nejm.org/doi/full/10.1056/NEJMcibr2410049
-
soria
@jsoriamd
The global cancer burden is staggering: 20 million new cases and over 9.7 million deaths worldwide in 2022. Those numbers will be in 2050 : 35.3 million new cases & 18.5 million deaths. Urgent action and research are needed to reduce this toll. Read the superb @AACR Cancer Progress Report from 2024. #cancerresearch cancerprogressreport.aacr.org/progress/
-
soria
@jsoriamd
There is a rising incidence of early-onset (EO) cancers. Traditionally observed in adults over the age of 65, some solid tumors are now increasingly diagnosed in younger individuals under the age of 50 (annual percentage increase of 2.5% for pancreas, 5% for oropharynx, 8% for biliary…). Identifying the causes of EO cancers is mandatory to protect the next generations from this unprecedented epidemic. #esmo24 www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24…
-
soria
@jsoriamd
Just before #esmo24 entered full swing, @Amgen Partners of choice scientific summit took place in @VHIO campus. We thank our partners @GustaveRoussy @PeterMacCC, @pmcancercentre, @MSKCancerCenter, @AsanMedicalCtr,
@DanaFarber, @VHIO, & University Hospital Essen for their robust contribution -
soria
@jsoriamd
Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication.
www.nature.com/articles/s41571-024-00924-9 -
soria
@jsoriamd
Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients per tumour type were assessed for developing a screening tool for tumour-agnostic potential (i.e., the ESMO Tumour-Agnostic Classifier). #esmo #tumouragnostic #precisionmedicine, @Annals_Oncology
www.annalsofoncology.org/article/S0923-7534(24)01519-9/fu… -
soria
@jsoriamd
New study reveals the complexity of tumor-infiltrating B cells across 19 cancer types. Tumor-Associated Atypical B Cells may predict patient response to immunotherapy, opening doors to personalized cancer treatments. #immunotherapy #personalizedmedicine #bcells
-
soria
@jsoriamd
Colorectal cancer is not a single disease but a complex collection of subtypes with unique genomic landscapes. Whole-genome sequencing of 2,023 samples sheds light on the molecular diversity of CRC. Researchers identify 4 new subgroups of microsatellite-stable CRCs with distinct genomic features & prognostic associations #genomics #precisionmedicine www.nature.com/articles/s41586-024-07747-9
-
soria
@jsoriamd
Delighted to visit @GustaveRoussy and meet with it’s General Director @barlesi A new metro station, new research buildings & much more to come in Paris Saclay Cancer Cluster
-
soria
@jsoriamd
Leptomeningeal metastasis occurs in 5-10% of patients with solid tumors & have a bleak prognosis. The pathways essential for leptomeningeal colonization remain unknown. Applying modern molecular systems biology & computational oncology approaches to leptomeningeal disease holds the potential to unravel the molecular &neuroanatomic basis for this complex disease process, enabling rational therapeutic targeting & improved clinical outcomes.
www.nature.com/articles/s41568-024-00700-y -
soria
@jsoriamd
Two provocative manuscripts suggest the therapeutic potential of #jak inhibition in combination with #immunotherapy in #cancer. In one paper, JAKi significantly reduced neutrophil-to-lymphocyte ratios & percentages of myeloid suppressor cells & rescued the function of exhausted T cells. In the other paper, JAKi enhanced CD8 T cell plasticity by decreasing the inflammatory & IFN-I signals that drive terminal differentiation of CD8 T cells. In patients this combination is suggestive of #pd1 activity enhancement in both NSCLC & Hodgkin lymphoma. www.science.org/doi/10.1126/science.ade8520
www.science.org/doi/10.1126/science.adf1329 -
soria
@jsoriamd
Biological approaches have led to numerous advances in #cancer but integrating fields across #engineering & the #physical sciences may accelerate cancer discovery & therapy. www.cell.com/cancer-cell/abstract/S1535-6108(24)00185-5
-
soria
@jsoriamd
Today, years of research & development have come to fruition in a new treatment option for small cell lung cancer, one of the most aggressive types of cancer. @Amgen ‘s T-cell engagers empowers the body’s immune system to specifically seek out and attack selective cancer cells. Tarlatamab is the second FDA approved BiTE® molecule. #mycompany
Amgen 🧪🔬🧬
@Amgen
The @US_FDA has approved Amgen’s treatment for adults with extensive-stage small cell lung cancer (ES-SCLC).
This option is the first BiTE ® therapy for ES-SCLC.
🔗 Press release: amgen.ly/4blqtR1
$AMGN -
soria
@jsoriamd
The potential role of AI in clinical practice for oncology is anchored around improving detection, diagnosis, and treatment. aacrjournals.org/cancerdiscovery/article/14/5/711/745040/…
-
soria
@jsoriamd
A great overview of the clinical ADC landscape with a focus on target, payload mechanism of action, antibody, linker & conjugation method. www.nature.com/articles/d41573-024-00064-w
-
soria
@jsoriamd
EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #aacr24 @marinagarassino
-
soria
@jsoriamd
Waun Ki Hong Award for Outstanding Achievement in Translational & Clinical Cancer Research bestowed to @skopetz
The legacy of Dr Hong in cancer care and research is partially grasped by the caliber of many clinician scientists that he mentored @DrFadloKhuri @DrRoyHerbstYale @VivekSubbiah #aacr24
soria
@jsoriamd
Waun Ki Hong vision for cancer research : let’s do great things for patients
-
soria
@jsoriamd
The hallmarks of cancer framework provide an exceptional synthesis of carcinogenesis, but does not address complexities of cancer as a systemic disease, including tumor initiation & promotion, tumor micro- & immune macro-environments, aging, metabolism & obesity, cancer cachexia, circadian rhythms, nervous system interactions, tumor related thrombosis, & the microbiome. www.cell.com/cell/fulltext/S0092-8674(24)00175-2
-
soria
@jsoriamd
Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as adenocarcinomas and most commonly in women & individuals of Asian ancestry. www.nature.com/articles/s41571-023-00844-0
-
soria
@jsoriamd
Thank you to my @AACR colleagues for this humbling vote of confidence. I am honored to serve among respected leaders across the oncology space as we work to accelerate #research and further the Association’s legacy as the leading cancer research organization. #mycompany
Amgen Oncology
@AmgenOncology
Congratulations to Amgen’s @jsoriamd on his election to the @AACR Board of Directors! 👏
Jean-Charles will lend his expertise in precision medicine and immuno-oncology to help guide Association policy and advance cancer research. Click to learn more 🔗 amgen.ly/4cmnlFA -
soria
@jsoriamd
Plastics have enabled extraordinary advances in virtually every area of medicine & have made our lives more convenient. However plastics may be neither as safe nor as inexpensive as they seem. The benefits of plastics come at great & increasingly visible costs to human health: carcinogens, neurotoxicants, endocrine disruptors, disruptors of lipid metabolism & increased risk of diabetes, cardiovascular disease, & stroke
www.nejm.org/doi/full/10.1056/NEJMra2300476; www.nejm.org/doi/full/10.1056/NEJMe2400683
soria
@jsoriamd
Patients with carotid artery plaque in which microplastics & nanoplastics (MNP) were detected had a higher risk of a composite of myocardial infarction, stroke, or death from any cause vs those in whom MNPs were not detected
www.nejm.org/doi/full/10.1056/NEJMoa2309822 -
soria
@jsoriamd
In-depth genomic analysis of SCLC demonstrates that treatment-naive tumors show clonal homogeneity, but chemotherapy triggers significant genetic diversity. Effective first-line treatment is crucial in SCLC, as it shapes the genomic landscape of relapse & resistance www.nature.com/articles/s41586-024-07177-7
-
soria
@jsoriamd
A noninvasive assay of cell-free DNA in plasma used to screen for colorectal cancer appears at least as effective as fecal immunochemical testing which detects human hemoglobin in stool. This liquid biopsy showed 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, & 13% sensitivity for advanced precancerous lesions.
www.nejm.org/doi/full/10.1056/NEJMoa2304714 -
soria
@jsoriamd
Cancer is not a uniform disease, & neither is its treatment. I share how #mycompany pairs our biology-first approach with the latest technology to investigate targeted options for patients who need them most in this #amgensponsored article: www.washingtonpost.com/creativegroup/amgen/are-we-enterin…
Amgen Oncology
@AmgenOncology
Discover how our transformative research is shaping new possibilities for people with the toughest-to-treat cancers. SVP & Oncology Area Therapeutic Head @jsoriamd explains in this @Amgen-sponsored @washingtonpost article: www.washingtonpost.com/creativegroup/amgen/are-we-enterin…
-
soria
@jsoriamd
New research introduces a noninvasive method using cfDNA methylation signatures to accurately detect #neuroendocrine #prostate #cancer, highlighting the potential of methylation profiling in personalized medicine. #precisionmedicine #cancertherapy #nepc #genomics.
-
soria
@jsoriamd
WHO Global #cancer Observatory just released it’s latest update. Explore incidence, mortality, & prevalence for 36 cancer types in 185 countries. You can also discover trends until 2050!. It is a fascinating website to explore. gco.iarc.fr/today/en
-
soria
@jsoriamd
Delving into the future of #cancer treatment with new #adc formats: Bispecific ADCs targeting multiple antigens, Dual-drug ADCs combining different cytotoxins, Probody-drug conjugates for enhanced tumor specificity, Immune-stimulating ADCs, Protein-degrader ADCs & other formats pushing the frontiers of oncology. doi.org/10.1038/s41571-023-00850-2
-
soria
@jsoriamd
New study uncovers that ≈ a third of NSCLC patients develop specific mutations as acquired resistance to #immunotherapy, including alterations in STK11, B2M, APC,MTOR, KEAP1, & JAK1/2. ascopubs.org/doi/10.1200/JCO.23.00580
soria
@jsoriamd
This paper also reveals significant immunophenotypic changes in NSCLC with acquired resistance to #immunotherapy, highlighting decreased intratumoral lymphocytes and altered T-cell engagement. ascopubs.org/doi/10.1200/JCO.23.00580
soria
@jsoriamd
This innovative study that combined genomic profiling, machine learning, & multiplexed immunofluorescence to map out resistance mechanisms to #immunotherapy, also shows a decrease in HLA class I expression in NSCLC patients at the time of acquired resistance. ascopubs.org/doi/10.1200/JCO.23.00580
-
soria
@jsoriamd
Recent trends show an increase in incidence rates for 6 of the top 10 #cancers, including breast, prostate, pancreas, as well as cervical and colorectal cancer in young adults. acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac…
-
soria
@jsoriamd
From glioblastomas to sarcomas: genomic insights from 13,880 tumors showcases how specific genomic alterations could guide tailored #cancer treatments. #cancergenomics #precisionmedicine #wgs www.nature.com/articles/s41591-023-02682-0
-
soria
@jsoriamd
Antibodies targeting tumors & immunomodulatory receptors are key anti #cancer tools. #fcγRs play a role in the mechanism of action of these therapeutics, but meaningful gaps remain in our understanding, as evidenced by antibodies targeting the same receptors using different IgG subclasses. A systematic evaluation of FcγR biology, polymorphisms & FcγR-expressing innate immune cells are needed to optimize clinical success. www.nature.com/articles/s41568-023-00637-8
-
soria
@jsoriamd
FDA approvals by modality in 2023: Small molecules, including peptides of up to 40 AA in length, & oligonucleotides are approved as new molecular entities (NMEs) and represent the dominant modality. Protein-based candidates are approved through biologics license applications (BLAs): mAb, monoclonal antibody; siRNA, small interfering RNA. On the antibody front, 4 T-cell engaging bispecifics were approved. . www.nature.com/articles/d41573-024-00001-x
-
soria
@jsoriamd
The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years. By TA, oncology continues to accumulate the most approvals with 13 (24%) new cancer therapies in 2023. Neurology came in second, with 9 (16%) while ID & haematology tied for third, with 5 (9%) a piece. www.nature.com/articles/d41573-024-00001-x
-
soria
@jsoriamd
#radioligands or radiotheranostics is a rapidly developing field in #cancer therapy, that has impacted thyroid, neuroendocrine, & prostate tumors. This review provides a good landscape view of this class of agents.
www.annalsofoncology.org/article/S0923-7534(23)00113-8/fu… -
soria
@jsoriamd
If you ever wondered what is: the total mass, number, & distribution of immune cells in the human body, this is a must read. Lymphocytes & neutrophils account each for 40% of all immune cells, while macrophages account for 10%. www.pnas.org/doi/full/10.1073/pnas.2308511120
-
soria
@jsoriamd
Machine & deep learning (#artificialintelligence techniques) will be crucial to interpret large multi-dimensional datasets encompassing pathomic, radiomic, genomic, proteomic data, etc. This review focus on #immunotherapy biomarkers. www.annalsofoncology.org/article/S0923-7534(23)04331-4/fu…
-
soria
@jsoriamd
After a prolific #esmo23, ADC gained yet extra-visibility. But one of the key questions for the future of #adc is what is their best partner of choice? doi.org/10.1016/j.trecan.2023.01.003
-
soria
@jsoriamd
Patients with #ctdna clearance post PD1 #immunotherapy have better PFS & OS in this prospective study. Liquid biopsies may be used to rapidly & accurately determine clinical response, especially in the metastatic setting. www.nature.com/articles/s41591-023-02598-9
-
soria
@jsoriamd
The cancer #immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. Check out this revised review that helps better understand the successes & failures of cancer #immunotherapy doi.org/10.1016/j.immuni.2023.09.011
-
soria
@jsoriamd
Through our biology-first approach, @Amgen is advancing first-in-class medicines in oncology. Learn more on Friday regarding the initial phase 1 results of our investigational MTA-cooperative PRMT5 inhibitor w/ @AACR at the 2023 AACR-NCI-EORTC International Conference. #mycompany #targets23
-
soria
@jsoriamd
Designing Best-in-Class Small Molecules needs to integrate advances in Chemistry, Cancer Biology, & Data Science. Responses rates and prevalence across actionable targets is nicely summarized in this paper.
doi.org/10.1158/2159-8290.CD-23-0280 -
soria
@jsoriamd
#precisionmedicine in oncology is evolving towards high-throughput genomics use. This approach may provide vast molecular information in tumors, revealing an average of 4-5 drivers per tumor. Actionable alterations should be prioritized by using validated rankings for treatment tailoring. However, the advent of abundant complex biological data will make #artificialintelligence algorithms indispensable for thorough analysis & appropriate treatment decisions doi.org/10.1016/j.esmoop.2023.101642
-
soria
@jsoriamd
Cancer targeted therapies are based on inhibition of critical pathways. In this manuscript, conditional activation of signaling pathways allows to leverage activation lethality to create a new class of cancer medicines. www.nature.com/articles/s41588-023-01515-7
-
soria
@jsoriamd
Our goal is to make profound differences in improving the standard of cancer care – and we are committed to doing that through collaboration with cutting edge academic centers.
Amgen 🧪🔬🧬
@Amgen
We are proud to share that we’ve launched the Amgen Partners of Choice (APoC) network, bringing together our oncology experts and world-renowned clinical leaders from eight research centers from across the world.
➡️ Learn more: amgen.ly/3Pv3dGH
$AMGN -
soria
@jsoriamd
Modulating the #innate #immune system in #cancer has being disappointing. This review presents a framework where distinct innate immune signaling pathways activate 5 key dendritic cell activities that are important for T cell-mediated immunity. Most approaches in the clinic have modulated a single pathway, which cannot agonize all activities needed for durable immunity. doi.org/10.1016/j.immuni.2023.07.018
-
soria
@jsoriamd
Increased #adiposity is linked to 13 #cancers, notably colorectal & endometrial. The mediators of the obesity–cancer link is an unraveling puzzle. doi.org/10.1210/endrev/bnad015
-
soria
@jsoriamd
3D #pathology is coming our way. This will have a deep impact in the #cancer field. 3D pathology could enhance disease understanding, accuracy of diagnosis & will unlock a world that interrogates orders-of-magnitude more tissue & provides a feature-rich volumetric context for complex tissue morphologies.
www.biorxiv.org/content/biorxiv/early/2023/08/06/2023.08.… -
soria
@jsoriamd
Ageing tissues ‘walk a tightrope’, retaining adequate levels of cell plasticity to generate & maintain tissues while avoiding overstepping into transformation. Rather than viewing cancer as ‘bad luck’, understanding the complex choreography of cell intrinsic & extrinsic factors that characterize transformation can help discover effective new ways to prevent & detect cancer before it becomes incurable. www.nature.com/articles/s41568-023-00602-5
-
soria
@jsoriamd
Oncology is a demanding profession, asking a great amount of those practicing in the field. Oncology clinicians can set boundaries while still meeting ethical practice standards. Setting boundaries may ultimately allow clinicians to be more present & engaged while working, have more satisfaction with their work, & maintain personal well-being. Some great suggestions in this table & article ascopubs.org/doi/full/10.1200/EDBK_390598
-
soria
@jsoriamd
The peripheral & central nervous systems appear to support tumorigenesis & metastasis. Tumors can build local autonomic & sensory nerve networks & can develop a long-distance relationship with the brain through circulating adipokines, inflammatory cytokines, neurotrophic factors, or afferent nerve inputs. This points to innovative approaches against #cancer. doi.org/10.1038/s41568-023-00556-8
-
soria
@jsoriamd
Immune-checkpoint inhibition for resectable non-small-cell lung cancer : opportunities & challenges. doi.org/10.1038/s41571-023-00794-7
-
soria
@jsoriamd
FDA oncology approvals by disease site since 2000 illustrates ❶ the high number of approvals obtained in the last 5 years ❷ the very rich landscape of lung, breast, GU & lymphoma ❸ the scarcity of approvals in brain & head & neck. doi.org/10.1038/s41573-023-00723-4
-
soria
@jsoriamd
Protein kinase inhibitors reached the clinic over 20 years ago, starting with cancer but now impacting autoimmune, allergic & even infectious diseases including COVID-19. Check out this overview of small molecule inhibitors specifically generated to target protein kinases relevant to immune cell function.
www.nature.com/articles/s41577-023-00877-7 -
soria
@jsoriamd
The #cancer treatment landscape has changed dramatically since 2000. This Review summarizes trends in the approval of oncology #therapeutic products by #fda from 2000 to 2022, based on their mechanism of action & primary target. A must read. www.nature.com/articles/s41573-023-00723-4
-
soria
@jsoriamd
Technological advances have enhanced our ability to measure biologic processes at scale. The resulting volume of data is dealt with #machinelearning methods that are increasingly tuned for the analysis of multidimensional biologic data sets. The outcome is a progressively detailed understanding of the molecular trajectory of disease that is now finding application in clinical medicine. www.nejm.org/doi/full/10.1056/NEJMra2204787
-
soria
@jsoriamd
Metabolic rewiring of tumor cells is essential for cancer progression. Historically the genomic landscape & cell signaling, were considered drivers of cancer cell metabolism but recent data show the unique role of the niche formed by the TME in shaping the metabolic landscape. Many distinct cell types contribute to the metabolite composition of the TME. doi.org/10.1038/s42255-020-00317-z
-
soria
@jsoriamd
The efficacy of #immunotherapy is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators of CD8+ cytolytic T cells. CD4+ T cells were shown preclinically capable of eradicating tumour cells that do not express MHC-II by mobilizing myeloid cells. www.nature.com/articles/s41586-023-06199-x
-
soria
@jsoriamd
A broad overview of the growing field of #adc development for #cancer treatment. With a focus on the diversification of antigenic targets & bioactive payloads that are rapidly broadening the scope of tumor indications for ADC. A must-read.
www.nature.com/articles/s41573-023-00709-2 -
soria
@jsoriamd
Last week we launched @AmgenOncology Partners of choice initiative. The excitement & energy was fueled by this unique moment in drug development where science, biotechnology, drug design & disease biology understanding are quickly advancing in multiple #cancer fronts.
-
soria
@jsoriamd
As #asco23 ends, this is great @JCO_ASCO read on #adc
soria
@jsoriamd
ADC are one of the fastest-growing oncology therapeutics. Acquired #resistance mechanisms to #adc can be categorized according to the 3 major steps of ADC functioning: target binding, intracellular trafficking of the mAb-payload complex, & payload activity. #asco23 pre-read.
ascopubs.org/doi/10.1200/JCO.23.00013 -
soria
@jsoriamd
Data in over 8000 patients confirms the value of TMB as a predictor of #immunotherapy efficacy (as monotherapy). Wide range of TMB distribution by tumor type is remarkable. #asco23
-
soria
@jsoriamd
ADC are one of the fastest-growing oncology therapeutics. Acquired #resistance mechanisms to #adc can be categorized according to the 3 major steps of ADC functioning: target binding, intracellular trafficking of the mAb-payload complex, & payload activity. #asco23 pre-read.
ascopubs.org/doi/10.1200/JCO.23.00013 -
soria
@jsoriamd
Does epigenetic silencing of antigen presentation explain lack of broad activity of #immunotherapy in SCLC?
www.jto.org/article/S1556-0864(23)00554-3/fulltext -
soria
@jsoriamd
An analysis of biopharma #pipelines shows that the average number of assets per target investigated has more than doubled: 3 assets/target in 2000 to 7 today. The number of assets in clinical development is outpacing the number of biological approaches, particularly in oncology.
-
soria
@jsoriamd
New exciting kid in the block of degraders: proteolysis-targeting antibodies. These bispecific molecules allow ‘on-demand’ receptor degradation by using E3 ubiquitin ligases with exposed extracellular domains. #cancer #degraders
www.nature.com/articles/s41586-022-05235-6 -
soria
@jsoriamd
Genomic analysis of 3,600 SCLC cases demonstrates frequent alterations in the PTEN pathway in brain metastases, a rare subgroup of TP53/RB1 WT tumors (5.5%), & ultra-rare cases HPV+. 4q12 amp has increased OS , while CCNE1 amp has decreased OS.
doi.org/10.1158/2159-8290.CD-22-0620 -
soria
@jsoriamd
A cohort of 1,031 tumors resistant to SOC were analyzed by WES & RNAseq. Mutational signatures were observed in platinum treated pts. MSI & high TMB found in 3% & 13% of refractory metastatic cancer patients, what is #imunotherapy value for such patients?
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… -
soria
@jsoriamd
#artificialintelligence models built through self-supervision on large, diverse datasets, will interpret combinations of medical modalities, including data from imaging, electronic health records, laboratory results, genomics, graphs, or medical text.
www.nature.com/articles/s41586-023-05881-4 -
soria
@jsoriamd
A comprehensive review on #pancreatic #cancer pathogenesis, progression & therapeutic perspectives.
www.sciencedirect.com/science/article/pii/S00928674230014… -
soria
@jsoriamd
A fascinating paper suggesting that aneuploidy can be measured in ctDNA #liquidbiopsy in #pancreatic #cancer patients.
genomemedicine.biomedcentral.com/articles/10.1186/s13073-… -
soria reposted
Elizabeth McKenna
@ElizSMcKenna
Attending the #aacr23 educational session on Evolution of Drug Resistance? For a primer read this @CD_AACR review by @jsoriamd and colleagues: Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies aacrjournals.org/cancerdiscovery/article/11/4/874/665864/…
-
soria
@jsoriamd
Cancer-associated cachexia increases morbidity & mortality in cancer. NSCLC with cachexia have inflammatory signaling & EMT pathways, upregulated MAGEA6 & ADAMTS3. Proteomic analysis supports the l therapeutic relevance of targeting GDF15 in cachexia.
www.nature.com/articles/s41591-023-02232-8 -
soria
@jsoriamd
A must read: @CharleSwanton last paper. Packed with exceptional & actionable data. E.g. (1) histological spread through airspace = risk of intra-thoracic recurrence, (2) pre-operative ctDNA detection is associated with extra-thoracic recurrence.
www.nature.com/articles/s41591-023-02230-w -
soria
@jsoriamd
Multiplexed antibody-based imaging technologies can quantify 2 to 60+ proteins while preserving spatial information. These approaches might be applied to sections of FFPE patient’s biopsies to guide #immunotherapy, #bispecifics & others.
aacrjournals.org/cancerdiscovery/article/13/4/824/725006/… -
soria
@jsoriamd
Tumor-infiltrating lymphocytes, #tils, can encompass T cells but also B cells & plasma cells. TIL-Bs can contribute to antigen presentation & antibody production, focusing immune responses on cognate antigen & innate mechanisms.
doi.org/10.1016/j.ccell.2023.02.017 -
soria
@jsoriamd
Cancer-associated fibroblasts have functions ranging from collagen deposition to immunosuppression. They can be promote tumor genesis & therapeutic resistance.
doi.org/10.1016/j.ccell.2023.02.015 -
soria
@jsoriamd
EMT has been associated with #resistance to therapy in #cancer cells. RHOJ, a small GTPase expressed in #emt cancer cells, controls resistance to therapy by enhancing the response to replicative stress and activating the DNA-damage response. www.nature.com/articles/s41586-023-05838-7
-
soria
@jsoriamd
Bacterial ‘syringes’ could inject drugs directly into human cells. Discover a programmable system for protein delivery, derived from a molecular injection device found in bacteria, that represents a new biotechnological tool for drug delivery. #elcc23 www.nature.com/articles/s41586-023-05870-7
-
soria
@jsoriamd
Cancer relies on oncogenic events-bearing cells & a complex trait incorporating parameters from tissue & whole organism system. The tumor being a ‘neo-organ’, #cancer #therapies should explore targets in the non-tumor components of the system.
www.sciencedirect.com/science/article/pii/S2589004222004874 -
soria
@jsoriamd
Myeloid cells, comprised of macrophages, DC, monocytes, & granulocytes, represent a major
component of the tumor microenvironment & are involved in regulation of tumor progression. A better understand of this compartment is key for cancer #immunotherapy.
doi.org/10.1016/j.ccell.2023.02.009 -
soria
@jsoriamd
A holistic, systems biology-oriented understanding of the tumor cell & its interactions with proximal & distal cells within the organism, is an essential new frontier to improve cancer understanding & therapy. Check out this whole issue on this topic.
www.cell.com/cancer-cell/current -
soria
@jsoriamd
The cellular composition & functional state of the tumor-micro-environment is crucial at each stage of #cancer progression, from tumor initiation, progression, invasion, & intravasation to metastatic dissemination.
doi.org/10.1016/j.ccell.2023.02.016 -
soria
@jsoriamd
Optimal #antibody effectiveness depends on the level of affinity binding. For blocking antibodies, a high affinity may be most effective. However, for agonist antibodies, recent results suggest that intermediate affinity works best, for #immunotherapy.
www.nature.com/articles/d41586-023-00244-5 -
soria
@jsoriamd
CRC cases among those < 55 years increased from 11% in 1995 to 20%. Despite mortality declines, CRC is shifting to diagnosis at a younger age, more advanced stage, & left-sided. Uncovering the etiology of rising incidence in younger patients is needed.
doi.org/10.3322/caac.21772 -
soria
@jsoriamd
Antibodies are an important class of cancer therapeutics. Advances in antibody-based engineering will continue to expand their potential in oncology. doi.org/10.1038/s43018-023-00516-z
-
soria
@jsoriamd
It is assumed that metastasis is a property exclusive to cells that have acquired oncogenic mutations. A study shows that non-transformed epithelial cells that lack oncogenic mutations can be shed from organs, disseminate & colonize distant organ
www.nejm.org/doi/pdf/10.1056/NEJMcibr2213497?articleTools… -
soria
@jsoriamd
Not all TMB-high are created equal & predict for #immunotherapy efficacy. In GI cancers with MSS & TMB-high, mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, & RASA1 were associated with suppressed tumor immune environment. www.sciencedirect.com/science/article/pii/S14702045220078…
-
soria
@jsoriamd
The potential for biological discovery at the interface of #immunology and matrix biology are significant. Extra Cellular Matrix structures determine immune cell localization & function.
doi.org/10.1126/science.abp8964 -
soria
@jsoriamd
Can single & multiple human organ #chip systems model complex diseases & reproduce human responses to #drugs, #radiation & toxins. Organ-on-a-chip microfluidic culture devices can recapitulate organ-level functions.
doi.org/10.1038/s41576-022-00466-9 -
soria
@jsoriamd
Protein degraders harnesses the cell’s natural protein-degradation machinery (ubiquitin–proteasome system) to target proteins involved in #cancer. 18 protein degraders are under clinical evaluation in patients with solid tumors & hematological cancers.
www.nature.com/articles/s41571-023-00736-3 -
soria
@jsoriamd
Spatial profiling & single-cell RNA sequencing has demonstrated that tumor-associated microbiota coalesce in micro-niches where they may mediate immune & epithelial oncogenic roles.
www.cell.com/immunity/fulltext/S1074-7613(22)00652-5
doi.org/10.1038/s41586-022-05435-0 -
soria
@jsoriamd
Autoimmunity arises from loss of T cell tolerance , while in cancer, poor immunity against transformed self is present. Knowledge from the treatment of autoimmunity can help treat iAE in cancer patients. This Janus nexus is crucial to exploit.
www.cell.com/immunity/fulltext/S1074-7613(23)00034-1 -
soria
@jsoriamd
A subset of pts experiences paradoxical rapid cancer progression during #immunotherapy (hyperprogressive disease (HPD)). A triple-high (IFNγ/FGF/β-catenin) gene signature is associated with HPD. This may serve as a surrogate marker for HPD
www.cell.com/cancer-cell/fulltext/S1535-6108(22)00594-3 -
soria
@jsoriamd
Metastasis can arise years after tumor cells migrate from the primary tumor. The local microenvironment controls the formation of metastases. Harnessing tissue immunity will be essential for #immunotherapy to prevent the establishment of #metastases.
www.nature.com/articles/s41577-023-00836-2 -
soria
@jsoriamd
SCLC is an aggressive tumor. #myc amplification is a driver of #sclc heterogeneity. Extra-chromosomal DNAs bring to proximity enhancers & oncogenes, creating transcription-amplifying units, driving high MYC gene dosage. This can be seen in #liquidbiopsies
doi.org/10.1158/2159-8290.CD-22-0796 -
soria
@jsoriamd
Mechanism driving the composition & functional state of the immune landscape of cancer cells. How cancer cell-intrinsic parameters & their immunoregulatory pathways impact the tumor immune milieu & #immunotherapy activity.
www.nature.com/articles/s41568-022-00544-4 -
soria
@jsoriamd
γδ T cells have unique features: 1) tissue tropisms (mucosa for γδ1+, blood &LN for γδ2+), 2) activity independent of neoantigen burden, 3) activity independent of MHC-dependent antigen presentation. Potential therapeutic paths are discussed in this review
www.nature.com/articles/s41571-022-00722-1 -
soria
@jsoriamd
All #cancers combined relative 5-year overall #survival in USA has improved from 49% (mid 70s) to 68%.
This has saved close to 4 million people from 1991 to 2020.
doi.org/10.3322/caac.21763
soria
@jsoriamd
The top cancer killers in men, have all shown a survival improvement over that period except #pancreas acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21763
soria
@jsoriamd
Same is true for the 4 most lethal cancer tumor types in women. No progress in #pancreas acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21763
-
soria
@jsoriamd
Deep & integrative multi-omics analysis provides new insights into the basis of CRC. Several of the new genes & pathways identified are potential targets for #cancer treatment or #chemoprevention.
www.nature.com/articles/s41588-022-01222-9 -
soria
@jsoriamd
KMT2D is mutated in >20% of lung SCC. Kmt2d loss increases activation of RTKs, EGFR & ERBB2, driving a robust elevation in the oncogenic RTK-RAS signaling. Multiple therapeutic possibilities emerge from this finding. #lcsm #precisionmedicine
doi.org/10.1016/j.ccell.2022.11.015 -
soria
@jsoriamd
An increase in the incidence of #early-onset forms of several cancer types is clear. Multigenerational changes in the #exposome have occurred ( diet, lifestyle, obesity) but effect of individual exposures are unknown. Prospective cohorts are needed.
www.nature.com/articles/s41571-022-00672-8 -
soria
@jsoriamd
Rational drug #combinations based on understanding of the underlying molecular mechanisms associated with #cancer therapy #resistance are key to define effective drug combinations to combat resistance.
doi.org/10.1038/s41573-022-00615-z -
soria
@jsoriamd
Blockbuster origin by TA in the 2011-2020 period: oncology had the highest cumulative number of drugs. However, CV & ID were more successful in terms of relative number of blockbusters launches.
doi.org/10.1038/d41573-022-00213-z -
soria
@jsoriamd
A liquid biopsy to early cancer diagnosis leveraging cancer metabolism rather than genomics or proteomics shows 62% sensitivity to stage I disease at 95% specificity with any cancer type (area under ROC curve 0.83-0.93).
www.pnas.org/doi/suppl/10.1073/pnas.2115328119 -
soria
@jsoriamd
A guide to antigen processing & presentation via MHC class I & class II molecules: a must-read for #immunotherapy & #celltherapy aficionados.
www.nature.com/articles/s41577-022-00707-2 -
soria
@jsoriamd
Macrophages’ plasticity & heterogeneity captured in a conceptual framework that clarifies roles in health and disease status (highly relevant for #cancer & #immunotherapy).
doi.org/10.1016/j.cell.2022.10.007 -
soria
@jsoriamd
The complex genomic landscape of #ras-mutant tumors is described in this paper. Co-mutations with RAS are cancer lineage–specific & context-dependent manner. Enrichment in KRAS G12C mutations is seen in white females with NSCLC & colorectal carcinoma.
doi.org/10.1158/0008-5472.CAN-22-1731 -
soria
@jsoriamd
Membrane-less organelles or ‘biomolecular condensates’ are transient droplets in cells that may offer new biological & therapeutic insights in #cancer & neurological diseases.
www.nature.com/articles/d41586-022-03477-y -
soria
@jsoriamd
It is only in the past decade that #immunotherapy has made a broad impact on patient survival in multiple high-incidence #cancer indications. This review summarizes that journey.
www.nature.com/articles/s41573-021-00345-8 -
soria
@jsoriamd
Cancer-associated #fibroblasts are integral to the TME. CAFs were thought a uniform population, but single-cell RNA sequencing has revealed 3 CAF phenotypes: steady state-like, mechanoresponsive &immuno-modulatory CAFs. These have therapeutic implications.
www.sciencedirect.com/science/article/pii/S15356108220044… -
soria
@jsoriamd
There are 12 approved #adc & >140 in clinical trial. Better understanding the MoA of active ADCs (Ab-targeted delivery, free drug concentration, albumin transfer) & the relationship between ADC structure & PK/PD is key for the next generation of ADCs.
linkinghub.elsevier.com/retrieve/pii/S1535610822004457 -
soria reposted
FabriceAndre
@FAndreMD
8th MAP conference. co-created with @jsoriamd & @CharlesSwanton as a small workshop format with the aim to have basic scientists and clinicians in the same place & train young colleagues. It’s incredible the nb of ideas that circulate between attendees drg the 2 days💡
ESMO - Eur. Oncology
@myESMO
#map2022 it's a wrap! Thanks to all participants, Chairs @FAndreMD, @HaanenJohn & @CharlesSwanton, Speakers, the Scientific Committee, @CRUKresearch, @GroupeUnicancer, & staff. Looks like preparations are already underway for #map2023 👇
www.esmo.org/meetings/map-2023
#precisiononcology -
soria
@jsoriamd
LDH: not just a marker of tumor burden in #cancer. LDH isoenzymes have roles in cancer progression through metabolic pathway plasticity & #immune evasion. LDH could be an appealing cancer target. www.nature.com/articles/s41571-022-00686-2
-
soria
@jsoriamd
AI algorithms reveal diverse histological patterns indicative of a broad range of molecular & genomic alterations. #ai analysis of standard histopathology slides can predict MSI status with accuracy comparable to molecular #cancer tests. www.nature.com/articles/s43018-022-00436-4
-
soria
@jsoriamd
Antibodies are being leveraged with enormous success as therapeutic drugs. Biotherapeutic drug design is leveraging affinity & avidity tuning of engineered antibody formats to develop differentiated Ab drugs with tailored properties & novel functions. www.nature.com/articles/s41573-022-00501-8
-
soria
@jsoriamd
Liquid biopsy: unlocking actionable alternatives for #cancer patients. Two publications highlight the value of NGS of ctDNA in 1) metastatic solid tumors 2) biliary cancer.
doi.org/10.1016/j.annonc.2022.08.089
doi.org/10.1016/j.annonc.2022.09.157 -
soria
@jsoriamd
Discover the #cancer #mycobiome. Fungi were detected in 35 cancer types. Intratumoral fungi stratified clinical outcomes, including #immunotherapy response. Cell-free fungal DNA diagnosed healthy & cancer patients in early-stage disease.
doi.org/10.1016/j.cell.2022.09.005 -
soria
@jsoriamd
Computational analysis of 40,000 pts describes the association between 458 mutations & clinical outcomes & targeted therapies & #immunotherapy effect. APC mutation defined IO benefit in bladder cancer
www.nature.com/articles/s41591-022-01873-5
www.precision-cancer.org -
soria
@jsoriamd
Deeply grateful for the invitation to @GustaveRoussy Alumni : it was moving to reconnect with so many brillant students & fellows that I had the privilege to train #esmo22
-
soria
@jsoriamd
Resistance to targeted therapies is often due to mutations, but the lineage transition from adenocarcinoma to neuroendocrine histology is another escape route. Lineage plasticity in #prostate cancer depends on JAK/STAT & FGFR signaling. #esmo22
www.science.org/doi/10.1126/science.abn0478 -
soria
@jsoriamd
The promise & power of liquid biopsies is particularly well suited for #colorectal cancer since there is a great deal of shedding of circulating tumor fragments (cells, DNA, methylation markers...) in this tumor type.
ascopubs.org/doi/full/10.1200/JCO.21.02615 -
soria
@jsoriamd
Recently, we have seen many innovations in treating lung cancer, yet significant unmet need remains. Join us next week on Twitter Spaces, as we discuss how we’re leveraging research breakthroughs to provide better care for more patients with cancer. #mycompany #esmo22
Amgen Oncology
@AmgenOncology
SAVE THE DATE! Learn how @Amgen is advancing innovative targeted treatments for lung cancer.
🗓 Thursday, Sept. 1
⏰ 9:15am PT
🎙 @JSoriaMD, @IFenChang1, @DavidRaben & special guest @KashyapPatelMD
👉Use #scienceinfocus to send your questions: twitter.com/i/spaces/1DXGyDWaqmEKM/peek #esmo22 -
soria
@jsoriamd
γδ T-cells recognize & kill transformed cells independently of HLA-antigen presentation, but they represent only 1 to 10% of total CD3+ T-cells. What is the potential promise of γδ T-cell-based therapeutic strategies?
www.frontiersin.org/articles/10.3389/fimmu.2022.915837/full -
soria
@jsoriamd
Deep learning leveraging pathology whole-slide images & molecular profile data from 14 cancer types predicts poor & favorable outcomes.
www.cell.com/cancer-cell/fulltext/S1535-6108(22)00317-8 -
soria reposted
Amgen 🧪🔬🧬
@Amgen
Our Summer of Science series continues as @jsoriamd, SVP of Global Development - Oncology, discusses Amgen’s pipeline & its potential in delivering transformative medicines for patients with cancer.
Read his story during #wclc22: amgen.ly/3JBW3Nr -
soria
@jsoriamd
The metastatic spread of cancer is achieved by dissemination of circulating tumor cells. The temporal dynamics of CTC generation are uncharacterized. Here authors demonstrate higher generation of metastatic-prone CTC during sleep of cancer patients.
www.nature.com/articles/s41586-022-04875-y -
soria
@jsoriamd
Age & the molecular landscape of tumors. Breast cancer in younger patients is more aggressive with poorer survival, while older ovarian cancer patients have worst prognosis. Somatic mutations in cancer genes are not uniformly distributed across age.
www.cell.com/trends/cancer/fulltext/S2405-8033(22)00135-2 -
soria
@jsoriamd
Comprehensive overview of the PD(L)1 clinical trial landscape
www.nature.com/articles/d41573-022-00030-4 -
soria
@jsoriamd
Examining multidimensional molecular alterations (genomic, epigenomic, proteomic) in #liquidbiopsies & integrating the datasets can elucidate cancer-specific mechanisms, new therapeutic targets, & uncover novel combinations for early #cancer #detection.
www.nature.com/articles/s41571-022-00645-x -
soria
@jsoriamd
Image analysis unveils distinct TIL patterns in #lcsm. In adenocarcinoma, the prognostic TIL signature was comprised of CD4+ T & CD8+ T cells, whereas in SCC, the immune patterns were comprised of CD4+ T, CD8+ T, &CD20+ B cells.
www.nature.com/articles/s41698-022-00277-5 -
soria
@jsoriamd
A new sophisticated & multi-dimensional tools unlocks identification of driver elements & #mutations throughout the #genome
doi.org/10.1038/s41587-022-01353-8 -
soria
@jsoriamd
So why have I moved from academia to industry? 3 drivers are behind this decision: making science actionable, increasing the magnitude of the impact of science, & leveraging a historic moment at the intersection of science, technology, & reverse translation.
Amgen 🧪🔬🧬
@Amgen
Recently, @jsoriamd, SVP of Oncology, opened up to the @IASLC community about how cancer has affected his family and what sparked his move to industry, after nearly two decades as a physician-scientist in academia.
Read Dr. Soria's interview here: amgen.ly/3N6LJ0a -
soria
@jsoriamd
Can PDL1 expression in exosomes (extra cellular vesicles) help guide #immunotherapy choice? jeccr.biomedcentral.com/articles/10.1186/s13046-022-02379-1
-
soria
@jsoriamd
Mucin are densely O-glycosylated modular protein domains that play important roles in cancer. Mucins analysis remained challenging until recently. Checkout a new approach revealing the #mucinome landscape & its potential therapeutic value.
www.nature.com/articles/s41467-022-31062-4 -
soria
@jsoriamd
Pancreatic cancer response to T cells that recognize #kras G12C, a hot-spot mutation commonly found in that cancer. #celltherapy
www.nejm.org/doi/full/10.1056/NEJMoa2119662
soria
@jsoriamd
G12D, apologies
-
soria
@jsoriamd
Moving #precisionmedicine forward via clinical implementation of whole genome & transcriptome sequencing. Integrating RNA expression illuminated treatment options that resulted in 46% of treated patients experiencing positive clinical benefit.
www.annalsofoncology.org/article/S0923-7534(22)01723-9/fu… -
soria
@jsoriamd
To test loss-of-function mutations actionability, the synthetic lethal approach is crucial. A surge of synthetic lethal candidates is in & approaching the clinic — taking on POLQ, USP1, PKMYT1, PRMT5, MAT2A & WRN
www.nature.com/articles/d41573-022-00107-0 -
soria
@jsoriamd
Very robust overview of systemic management of #brain #metastases
ascopubs.org/doi/full/10.1200/EDBK_352320?cid=DM10795&bid… -
soria
@jsoriamd
New #cancer #therapies are approved earlier in the USA vs Europe. The median delay in market authorization for new oncology therapies in Europe was 241 (150-370) days compared with the US.
jamanetwork.com/journals/jamanetworkopen/fullarticle/2793227 -
soria
@jsoriamd
Interrogating #cancer #genomes has unveiled #mutational signatures that associate with specific etiologies & mutagenic mechanisms. A computational framework is now available.
www.sciencedirect.com/science/article/pii/S15356108220022…
www.science.org/doi/10.1126/science.abl9283 -
soria
@jsoriamd
T cell immune responses deciphered : an #ai approach reveals antigen encoding that predicts T cell responses.
www.science.org/doi/full/10.1126/science.abl5311 -
soria
@jsoriamd
Landscape of #cancer cell therapies: as of 15 April 2022, there are 2,756 active cell therapy agents in clinical development.
www.nature.com/articles/d41573-022-00095-1 -
soria
@jsoriamd
Using #liquidbiopsy (negative ctDNA) in decision-making about post-surgical chemotherapy, could reduce the number of patients treated with chemotherapy without compromising relapse risk. #asco22
www.nejm.org/doi/full/10.1056/NEJMe2204625 -
soria
@jsoriamd
Thanks to my colleague @DavidRaben for joining me on #twitterspaces to discuss the future of precision medicine. Missed the live event? Listen here: twitter.com/i/spaces/1mnxedvPRWZJX/peek #asco22 #mycompany
Amgen Oncology
@AmgenOncology
We are LIVE with Amgen’s @JSoriaMD & @DavidRaben, talking about opportunities to expand precision medicine into more types of cancer with new drug targets. Join us now 👉 twitter.com/i/spaces/1mnxedvPRWZJX/peek #asco22
-
soria
@jsoriamd
Looking forward to this upcoming #twitterspaces conversation with my colleague @DavidRaben. We’ll discuss @Amgen’s work to propel precision medicine forward and how we are targeting oncogenes once considered “undruggable.” #mycompany
Amgen Oncology
@AmgenOncology
What are the next targets in precision medicine? How can targeted therapies reach more patients with cancer? Amgen oncology experts @JSoriaMD & @DavidRaben will explore these topics & more ahead of #asco22.
-
soria
@jsoriamd
We are today at moment where scientific advancements, technological breakthroughs &patient identification strategies come together to allow undruggable targets to become druggable. This provides a unique window in time to change the way cancer is treated with systemic approaches.
-
soria
@jsoriamd
A retrospective analyses suggests that #cancer patients who take antihistamines during #immunotherapy have improved survival. Histamine & histamine receptor H1 are increased in the TME & induce T cell dysfunction.
www.sciencedirect.com/science/article/abs/pii/S1535610821… -
soria
@jsoriamd
Digital molecular pathology unlocks data present in a simple slide by leveraging proteomic mapping in a single cell or tissue. This allows to discover protein signatures & provides molecular insights into proteome variation in health and disease states.
www.nature.com/articles/s41587-022-01302-5 -
soria
@jsoriamd
Androgen receptor inhibits CD8+ T cell function & mediates resistance to #immunotherapy, has this contributed to lack of benefit of IO in prostate cancer ?
www.nature.com/articles/s41586-022-04522-6
www.sciencedirect.com/science/article/pii/S15356108220016… -
soria
@jsoriamd
10 years of cancer cellular immunotherapy, key challenges facing the field & strategies that are emerging to overcome these obstacles
www.nature.com/articles/s41591-022-01765-8 -
soria
@jsoriamd
A review on the development of 3rd G EGFR & ALK inhibitors, predominant mechanisms of resistance, & approaches to tackling resistance in the clinic.
www.nature.com/articles/s41571-022-00639-9 -
soria
@jsoriamd
High-risk non muscle-invasive bladder cancer is treated by resection & BCG therapy. Half of such patients can relapse. This paper demonstrates that BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
www.jci.org/articles/view/145666 -
soria
@jsoriamd
Why have I moved from academia to industry? Three main drivers are behind this decision: 1) making science actionable, 2) increasing the magnitude of the impact of science, & 3) leveraging a historic moment at the intersection of science, technology, & reverse translation.
IASLC
@IASLC
The opportunity to make science actionable and increase its impact inspired @jsoriamd to move from academia to industry. He shares his story in ILCN: www.ilcn.org/valuable-intersections-maximizing-career-opp… #lcsm
-
soria
@jsoriamd
Can PET help translate the hallmarks of #cancer in #imaging representations facilitating in vivo cancer phenotyping ?
acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34228 -
soria
@jsoriamd
Breast cancer tumor cells that resist T cell attack are quiescent. Quiescent cancer cells form clusters with reduced immune infiltration, superior tumorigenic capacity & higher expression of chemotherapy resistance & stemness genes.
www.sciencedirect.com/science/article/pii/S0092867422003439 -
soria
@jsoriamd
#theranostics target unique properties of #cancer cells using different radionuclides for diagnosis & treatment
www.nature.com/articles/s41591-022-01759-6 -
soria
@jsoriamd
Early #cancer #detection: advances in sensors, contrast agents, molecular methods, & artificial intelligence helping detect cancer-specific signals in real time.
www.nature.com/articles/s41591-022-01746-x -
soria
@jsoriamd
Precision medicine unlocks new therapeutic opportunities in #cancer but if patients cannot access advanced #diagnostics in daily clinical settings, we may be developing drugs that will reach fewer patients.
www.nature.com/articles/s41591-022-01717-2 -
soria
@jsoriamd
#kras mutant subtypes can be classified into functional subtypes with potential therapeutic implications.
aacrjournals.org/cancerdiscovery/article/12/4/913/689610/… -
soria
@jsoriamd
Increased understanding of the unique immunobiologic principles that govern response to #immunotherapy in the #cns is critical for identifying targets in the tumor microenvironment that may potentiate antitumor immunity.
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… -
soria
@jsoriamd
Pre-treatment serum Albumin & TMB as predictors of #immunotherapy efficacy in #cancer
www.nature.com/articles/s41698-022-00267-7 -
soria
@jsoriamd
Can preventive personalized vaccines help avoid #cancer in healthy people at high risk for disease?
www.science.org/content/article/new-generation-cancer-pre… -
soria
@jsoriamd
Perspective on how to progress towards #precision #immunotherapy in #cancer: understand for each individual patient at which level(s) the antitumor immune response failed & how it can be therapeutically restored.
www.esmoiotech.org/article/S2590-0188(22)00002-8/fulltext -
soria
@jsoriamd
Amazing to see #ai impact on #pathology: deep-learning models can assist pathologists in the detection of NSCLC subtypes & specific gene #mutations (STK11, EGFR, FAT1, SETBP1, KRAS & TP53).
www.nature.com/articles/s41591-018-0177-5 -
soria
@jsoriamd
Really looking forward to taking part in this #twitterspaces discussion with @acoxon_coxon on how early research & scientific innovation can help overcome the complexity of cancer to help more patients. #mycompany
Amgen Oncology
@AmgenOncology
Looking forward to #aacr22? Us too. Join @jsoriamd and @acoxon_coxon on April 6 at 12:30pm PT to hear their unique perspectives on decoding the complexity of cancer, the latest advances in precision medicine, multispecifics, and more. Set that reminder 👇
twitter.com/i/spaces/1MYxNnAYoEvxw/peek -
soria
@jsoriamd
Cells express lineage-specific & position-specific genes. Oncogenic alterations to DNA are not transforming in all cellular contexts. Anatomic position is a major determinant of why cells respond to specific oncogenes, in this #melanoma model.
www.nature.com/articles/s41586-022-04584-6 -
soria
@jsoriamd
The interaction of tumor-associated macrophages with cancer cells & stromal cells in the tumor microenvironment sustains most of the hallmarks of #cancer. TAM populations are dynamic & could be targeted.
www.nature.com/articles/s41571-022-00620-6 -
soria
@jsoriamd
Overview of recent advances in targeted therapy & #immunotherapy for pancreatic cancer.
www.nature.com/articles/s43018-022-00349-2 -
soria
@jsoriamd
Circular RNAs are primarily non-coding RNA molecules, that can have key roles in #cancer. CircRNAs can be detected in liquid biopsy samples (plasma, saliva & urine). CircRNAs have potential as #biomarkers, therapeutic agents & drug targets in cancer. www.nature.com/articles/s41571-021-00585-y
-
soria
@jsoriamd
Patients who have exceptionally favorable responses to treatment may be a key to better understanding MoA of anti #cancer therapies.
www.nature.com/articles/s41568-019-0145-5 -
soria
@jsoriamd
The number of possible drug combinations is huge. Using 2,025 2-drug combinations & molecularly characterized breast, colon & pancreatic cancer cell lines, shows that drugs-synergy is rare, & targeted agents are most likely to be synergistic.
www.nature.com/articles/s41586-022-04437-2 -
soria
@jsoriamd
A comprehensive transcriptional atlas of the cellular architecture of #breastcancer. Using single-cell signatures breast cancer cohorts were stratified into nine clusters with unique cellular compositions & clinical outcomes.
www.nature.com/articles/s41588-021-00911-1 -
soria
@jsoriamd
Human biology discoveries have shown that we are all genetic mosaics. Strong targeted therapy can select for resistant mutations not only in malignant populations but also in normal tissue clonal mosaicism.
ashpublications.org/blood/article/139/8/1124/484077/A-BAX….
ashpublications.org/blood/article-abstract/139/8/1198/476… -
soria
@jsoriamd
The landscape of PD1/PDL1 clinical trials: 5,683 clinical trials ongoing — as monotherapy or in combination #immunotherapy
www.nature.com/articles/d41573-022-00030-4 -
soria
@jsoriamd
Identifying nodes shared in #metastasis & therapy resistance signaling networks should offer new opportunities to improve #cancer therapy
www.nature.com/articles/s41568-021-00427-0 -
soria
@jsoriamd
Synthetic monoclonal antibodies are a new tool to stabilize unique protein conformations & enable the discovery of conformational sensors against #kras, caspases & GPCR.
www.nature.com/articles/s41587-021-01126-9 -
soria
@jsoriamd
Acute clinical toxicities of #immunotherapy are known, chronic effects less so. Fatal toxicities occur in 0.4–1.2% of patients. The effects on immune processes, such as atherosclerosis, heart failure, neuroinflammation, obesity are unclear.
www.nature.com/articles/s41571-022-00600-w -
soria
@jsoriamd
In high-lactic-acid conditions, the effect of PD-1 blockade switches from a CD8+ T cell-one to a Treg-one. This lactic switch converts PD-1 blockade from an immunostimulatory effect on CD8+ T cells to an immunosuppressive effect via Tregs ! #immunotherapy
www.cell.com/cancer-cell/fulltext/S1535-6108(22)00003-4 -
soria
@jsoriamd
#cancer triggered tissue damage releases cfDNA from injured cells of the host tissue. That specific cfDNA can be identified (unique methylation profile) & provide information on the existence & location of cancer. #liquidbiopsy
insight.jci.org/articles/view/153559 -
soria
@jsoriamd
Liquid biopsies will deeply impact #cancer #care & early #screening. Amazing work by @landau_lab that developed an ultrasensitive plasma tumor burden monitoring technique. This approach allows to detect colon adenomas in the blood !
www.biorxiv.org/content/10.1101/2022.01.17.476508v1.full.pdf -
soria
@jsoriamd
Enzymatic, small- molecule, DNA-based, cell-based sensors can enhance early #cancer #detection. Each technology senses dysregulated activity associated with TME. These approaches lower the limit of detection below clinical thresholds
www.nature.com/articles/s41568-021-00389-3 -
soria
@jsoriamd
In #cancer, the extracellular matrix is altered at multiple levels. Matrix changes modulate intracellular signaling in cancer & impact drug bio-distribution. Directly targeting the tumor matrix is a new frontier in drug development.
www.nature.com/articles/s41568-020-00329-7 -
soria
@jsoriamd
#ras: a 40-year recalcitrant #cancer target & the RAS pathway 2.0 cancerdiscovery.aacrjournals.org/content/early/2022/01/20…
-
soria
@jsoriamd
MEK inhibitor & chemotherapy combination synergizes with PD(L)1 blockade in lung tumor models by inducing CXCL10 in cancer cells. #immunotherapy
www.sciencedirect.com/science/article/pii/S15356108210066… -
soria
@jsoriamd
#artificialintelligence is poised to reshape medicine, potentially improving the experiences of both clinicians & patients, making healthcare more accurate, efficient & accessible for patients worldwide.
www.nature.com/articles/s41591-021-01614-0 -
soria
@jsoriamd
Towards pan #kras inhibition to expand the reach of #precisiononcology
cancerdiscovery.aacrjournals.org/content/early/2022/01/15… -
soria
@jsoriamd
Extracellular magnesium may impact cellular immunity. LFA-1 requires magnesium to adopt its active conformation on CD8+ T cells & augment specific cytotoxicity. Low serum magnesium levels are associated with worse outcomes in #cancer #immunotherapy .
www.sciencedirect.com/science/article/pii/S00928674210156… -
soria
@jsoriamd
Targeted protein degradation is a therapeutic modality with the potential to tackle #cancer targets considered undruggable.
www.nature.com/articles/s41573-021-00371-6 -
soria
@jsoriamd
The landscape of #immunooncology & the challenge of preclinical models
jitc.bmj.com/content/10/1/e003231.long -
soria
@jsoriamd
Functional #precisionmedicine is a strategy where live tumor cells from #cancer patients are directly perturbed with drugs to provide immediately translatable, personalized information to guide therapy. Check out this review #organoids #microdevices
www.sciencedirect.com/science/article/pii/S15356108210061… -
soria
@jsoriamd
Neutrophils are abundant innate immune cells in human circulation. Their derived exosomes have been rarely studied. They clearly induce tumor cell apoptosis by delivering cytotoxic proteins & activating caspase signaling pathway in #cancer cells.
www.science.org/doi/10.1126/sciadv.abj8207 -
soria
@jsoriamd
US #cancer statistics is out. Survival progress has stagnated for breast & prostate cancers but strengthened for lung cancer, coinciding with cancer screening implementation and/or new treatment opportunities.
acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21708 -
soria
@jsoriamd
The hallmarks of cancer updated concept is an important tool for distilling the vast complexity of #cancer phenotypes & genotypes into a provisional set of underlying principles.
cancerdiscovery.aacrjournals.org/content/12/1/31 -
soria
@jsoriamd
Autopsy program demonstrates pleiotropic mechanisms of resistance to #krasg12c inhibition: 1) KRAS G12C allele and CN frequency change, 2) MAPK pathway activation & EMT, 3) complement activation, coagulation & tumor angiogenesis, 4) immunologic evasion
www.jci.org/articles/view/155523 -
soria reposted
Endpoints News
@endpts
We're kicking off our #jpm22 events today with a discussion on the year ahead in oncology R&D, featuring @susanmgalbraith @AstraZeneca, @jsoriamd @Amgen, @CKadoch @harvardmed, and @Arie_Belldegrun @AllogeneTx. Join us at 11 am ET.
jpm22.endpts.com -
soria
@jsoriamd
Oncology still dominates the list of new FDA approvals in 2021.
www.nature.com/articles/d41573-022-00001-9 -
soria
@jsoriamd
Discover a novel class of CAR-T cells engineered to express an enzyme that activates a small-molecule prodrug at a tumor site. These synthetic enzyme-armed killer cells exhibit enhanced anticancer activity both in vitro & in vivo in mouse tumor models.
www.nature.com/articles/s41589-021-00932-1 -
soria
@jsoriamd
Cancer risk across mammals is not only related to size & longevity but also with diet, with carnivorous mammals (especially mammal-consuming ones) facing the highest cancer-related mortality.
www.nature.com/articles/s41586-021-04224-5 -
soria
@jsoriamd
How can we expand cancer #immunotherapy efficacy beyond PD(L)1 & CTLA4?
www.nature.com/articles/s41571-021-00552-7 -
soria
@jsoriamd
Tumors differ among them because of their tissue of origin, mutational landscape... Understanding cancer immunity as a collection of dominant patterns of immune organization is another key feature to account for #cancer #immunotherapy
www.sciencedirect.com/science/article/pii/S0092867421014264 -
soria
@jsoriamd
Protein degraders & molecular glues: promises & challenges www.nature.com/articles/s41587-021-01173-2
-
soria
@jsoriamd
Multimodal integration of advanced molecular diagnostics, radiological & histological imaging, & codified clinical data sets is key to advance precision oncology to the next level.
www.nature.com/articles/s41568-021-00408-3 -
soria
@jsoriamd
The end of 2021 is an opportunity to reflect on the year and its challenges & learnings. This video sums up the ways we at @Amgen continue to transform what is possible, as we plan to do in the years to come. #ash21 #mycompany #allanglesofcare
Amgen Oncology
@AmgenOncology
Every cancer experience is full of challenges from many angles. At @Amgen, we aim to change the expectations of treatment outcomes by targeting the toughest cancers with high unmet needs to ultimately improve the lives of those living with the disease.
#ash21 #allanglesofcare -
soria
@jsoriamd
Pancreatic cancer already among the deadliest epithelial malignancies, is rising in both incidence & contribution to overall cancer deaths. Decades of research have improved our understanding of PDAC carcinogenesis, check out this review.
www.nature.com/articles/s41568-021-00418-1 -
soria
@jsoriamd
ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payload targets mediate polyclonal acquired clinical resistance to #adc
cancerdiscovery.aacrjournals.org/content/11/10/2436 -
soria
@jsoriamd
Growing datasets clearly suggest that ctDNA MRD following treatment for solid tumors predicts relapse. These results also suggest that ctDNA MRD could identify candidates for adjuvant therapy & measure response to such treatment #liquidbiopsy
cancerdiscovery.aacrjournals.org/content/11/12/2968 -
soria
@jsoriamd
Biology has enabled the use of engineered cells, instead of small molecules or biologics, as novel therapeutics. Cells with synthetic gene circuits can control localization, timing & dosage of therapeutic activities in response to specific biomarkers
www.nature.com/articles/s41573-021-00285-3 -
soria
@jsoriamd
A thoughtful review on key challenges of #precisionmedicine & tumor-agnostic trials. Maximizing outcomes with targeted therapies requires acknowledging the criticality of the genomic, transcriptional & immunological context on which the target lies.
www.sciencedirect.com/science/article/pii/S0923753421047852 -
soria
@jsoriamd
The genomic landscape of lung adenocarcinomas in never-smokers shows oncogenic driver alterations (78-92%) & immune clusters depleted of various types of immune cells. 6% of NS samples have smoking-related mutagen signatures (passive smoking)
ascopubs.org/doi/pdf/10.1200/JCO.21.01691 -
soria
@jsoriamd
#artificialintelligence in radiology is a promising tool to identify new predictive & prognostic biomarkers for use in clinical decision-making. Original datasets are expanding in oncology for #immunotherapy #targetedtherapies & chemotherapy.
www.nature.com/articles/s41571-021-00560-7 -
soria
@jsoriamd
Looking forward to listening to the latest episode of Undruggable with my colleagues Ray Deshaies and Dave Reese. This will be a great podcast on ways to overcome rebellious targets #mycompany
-
soria
@jsoriamd
Trends in kinase inhibition design (allosteric & covalent inhibitors, bifunctional inhibitors & chemical degrader). Approved inhibitors represent about 30% of the human kinome, substantial unexplored opportunities in drug development remain.
www.nature.com/articles/s41573-021-00252-y -
soria
@jsoriamd
It’s an honor to accept this award on behalf of @Amgen with the utmost gratitude for @GO2Foundation’s continued partnership. People with cancer undoubtedly deserve “simply the best” in cancer care, & our partnership works towards providing exactly that. #mycompany #amgensponsored
Amgen Oncology
@AmgenOncology
.@Amgen is thrilled to receive the Simply the Best Honoree Award of @GO2Foundation’s annual fundraising event. Congratulations to all of the night's winners as we work together to rewrite the future of lung cancer treatment. #amgensponsored
-
soria
@jsoriamd
resistance to KRAS G12C inhibition includes alterations in KRAS, NRAS, BRAF, EGFR, FGFR2... . Low AF mutations in KRAS(G12V or G13D), NRAS(Q61K or G13R), MRAS(Q71R), BRAF(G596R) are observed in the cells with KRAS(G12C).
www.nature.com/articles/s41586-021-04065-2 -
soria
@jsoriamd
#liquidbiopsies can detect mutations but not always kinase fusions. This manuscript describes the pan-tumor landscape of targetable kinase fusions detected in circulating tumor DNA. Reliable detection rates are achieved when enough ctDNA is shed.
clincancerres.aacrjournals.org/content/early/2021/11/09/1… -
soria
@jsoriamd
The interplay between chemotherapy/inflammation & the immune system is complex. Chemo can induce inflammation & stimulate anti-cancer immune responses. IL6 produced by the tumor micro-environment suppresses that immune-stimulatory inflammation.
www.nature.com/articles/s41467-021-26407-4 -
soria
@jsoriamd
Anyone can get lung cancer and the signs should not be overlooked. At @Amgen, we aim to make a mark for #lunglives by elevating the voices of those impacted by lung cancer. Join our commitment to improve outcomes for people & families impacted by the disease. #mycompany
Amgen Oncology
@AmgenOncology
Lung cancer is personal & every person with cancer is on a unique journey. As #lcam begins, we’re making a mark across the skylines of several major U.S. cities. Join us in raising awareness for lung cancer & the importance of biomarker testing by using #lunglives.
-
soria
@jsoriamd
#immunotherapy is entering the adjuvant setting . Distinct TIL landscapes are associated with clinical outcomes in localized NSCLC. IM1 phenotype is associated with good prognosis, increased CD8+ T cells, B cell infiltrates & TLS. www.annalsofoncology.org/article/S0923-7534(21)04519-1/fu…
-
soria
@jsoriamd
Response to #immunotherapy in metastatic renal cancer is not correlated with tumor molecular features (single mutation, SCNA, TMB & INDEL load) whereas human endogenous retrovirus expression reflects tumor purity & indirectly correlates with response.
www.cell.com/cancer-cell/fulltext/S1535-6108(21)00543-2 -
soria
@jsoriamd
3D cell structure by my 8th grader son for his science project…homework can be fun
-
soria
@jsoriamd
Red blood cells are not simply immunologically inert hemoglobin bags, they are also immune sentinels. RBCs can bind cell-free DNA leading to phagocytosis of RBCs & innate immune activation in pathological settings. #immunology
www.nature.com/articles/s41577-021-00648-2
www.science.org/doi/10.1126/scitranslmed.abj1008 -
soria
@jsoriamd
Patients with NSCLC #lcsm are experiencing with increased incidence leptomeningeal involvement. Understanding drivers of leptomeningeal involvement is key for new therapies. Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in NSCLC migration.
www.nature.com/articles/s41698-021-00228-6 -
soria
@jsoriamd
Forecasting how a tumor will evolve is important because the dominance or scarcity of a particular clone might guide our treatment choice. New techniques allow for a much better evaluation of clonal fitness. #resistance #cancer
www.sciencedirect.com/science/article/pii/S1535610821004918
www.nature.com/articles/s41586-021-03648-3 -
soria
@jsoriamd
As tumours progress, TGFβ drives strong wound-healing programme in CAF & suppress the adaptive & innate immune system, thus facilitating #immunotherapy insensitivity.Overcoming TGFβ-mediated immune evasion in cancer is a difficult but important challenge.
www.nature.com/articles/s41568-021-00413-6 -
soria
@jsoriamd
The identification of tumor antigens (TA) is key to develop new #immunotherapies. TA are considered canonical if they derive from protein-coding regions of the genome. Mass-spectrometry-based #immunopeptidomics allows the discovery of noncanonical antigens
www.nature.com/articles/s41587-021-01038-8 -
soria reposted
-
soria
@jsoriamd
SCLC has various subtypes defined by differential expression of ASCL1, NEUROD1 & POU2F3 (SCLC-A, -N, & -P). A new PLCG2-high SCLC phenotype with poor survival appears to be profibrotic & associated with immunosuppressive monocyte/macrophages.
www.cell.com/cancer-cell/fulltext/S1535-6108(21)00497-9 -
soria
@jsoriamd
Fascinating preclinical model suggesting that #mutant clones in normal epithelium outcompete & eliminate emerging tumours. These mutant clones may have an unexpected anti-tumorigenic role in purging early tumours & preserving tissue integrity.
www.nature.com/articles/s41586-021-03965-7 -
soria
@jsoriamd
#personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biopsies was tested in 143 pts with hematologic cancers. 39% of the pts were treated according to this approach with promising results.
cancerdiscovery.aacrjournals.org/content/early/2021/09/29… -
soria
@jsoriamd
Tumour burden can be assessed using imaging (CT or PET-CT scan), liquid biopsy, or LDH measurement. Is tumor burden predictive of #immunotherapy efficacy ? @NatRevClinOncol
www.nature.com/articles/s41571-021-00564-3 -
soria
@jsoriamd
9p21 loss occurs in ~13% of all cancers. 9p21 loss confers “cold” tumor-immune phenotype, with low TILs prevalence, , diminished immune cell trafficking, decreased rate of PD-L1 +, & activation of immunosuppressive signaling #immunotherapy #biomarker
www.nature.com/articles/s41467-021-25894-9 -
soria
@jsoriamd
#immunotherapy has improved cancer outcomes across various tumor types, but activity is not universal & toxicity is not trivial. This review on hallmarks of response, resistance & toxicity to #immunotherapy is a must read. @CellPressNews
www.sciencedirect.com/science/article/pii/S0092867421011016 -
soria
@jsoriamd
Tumors from patients with MSS colorectal cancer express clonal predicted neoantigens despite low TMB. However low neoantigen expression & poor T-cell priming underlie early immune escape in CRC #immunotherapy
www.nature.com/articles/s43018-021-00247-z -
soria
@jsoriamd
The MYC oncogene : the grand orchestrator of cancer growth & immune evasion and a long lasting rebellious target
www.nature.com/articles/s41571-021-00549-2 -
soria
@jsoriamd
I look forward to our upcoming #twitterspaces conversation with my @AmgenOncology colleague, @IFenChang1, where we’ll discuss how advancements in precision medicine can address unmet medical needs. We hope that you’ll join us: twitter.com/i/spaces/1OwGWVenoBZKQ/peek #mycompany
-
soria reposted
ESMO - Eur. Oncology
@myESMO
#esmo21: Keynote lecture w/ @jsoriamd #drugdevelopment: How can academia and industry work together 👇Today (19/9) 12:45—13:15 Channel 1 esmocongress.esmo.org/home/esmo/esmo2021/en-GB/
ESMO - Eur. Oncology
@myESMO
#esmo21: @jsoriamd on how to bridge the gap between academia & industry. Shared interests, mutual gain, flexibility & trust key to building win–win partnerships in #drugdevelopment.
ESMO Daily Reporter 👉 www.esmo.org/insights-by-esmo
#clinicaltrial #cancerresearch #innovation -
soria
@jsoriamd
Throughout my career, I've worked in both academia & industry. The ways in which they collaborate build a crucial stage in addressing the needs of people with cancer. I expand on this concept in my presentation at #esmo21 #mycompany
Amgen Oncology
@AmgenOncology
Pursuing cancer breakthroughs is core to our mission. 🔬🧪 Join us on #twitterspaces to hear from @jsoriamd and @IFenChang1 on what’s next in oncology research at @Amgen. #esmo21
-
soria
@jsoriamd
The incidence of PDAC increases by 1 % /year & it will become the 2nd leading cause of cancer-related death by 2030. #pancreaticcancer is a hard to treat disease but many new approaches are being developed and summarized in this review.
jamanetwork.com/journals/jama/fullarticle/2783817 -
soria
@jsoriamd
Detection of cancer at an early stage improves outcome Biomarkers shed from early lesions are limited by fundamental biological & transport barriers. Synthetic biomarkers deploy bioengineered sensors inside the body & amplify disease signals
www.nature.com/articles/s41568-021-00389-3?WT.mc_id=TWT_N… -
soria
@jsoriamd
Tumor analyses have shown that mutations can transform cells in some situations but not in others. This paper shows that oncogenic competence is mediated by oncogenes (BRAFV600E), transcription factors (such as SOX10), & chromatin factors (ATAD2).
doi.org/10.1126/science.abc1048 -
soria reposted
ESMO - Eur. Oncology
@myESMO
#esmo21: @jsoriamd on how to bridge the gap between academia & industry. Shared interests, mutual gain, flexibility & trust key to building win–win partnerships in #drugdevelopment.
ESMO Daily Reporter 👉 www.esmo.org/insights-by-esmo
#clinicaltrial #cancerresearch #innovation -
soria
@jsoriamd
Acquired resistance to #immunotherapy is frequent in NSCLC, occurring in a majority of initial responders. A clear clinical definition of acquired resistance to IO in patients with metastatic NSCLC is provided in this review @Annals_Oncology #lcms
www.sciencedirect.com/science/article/abs/pii/S0923753421… -
soria
@jsoriamd
Resistance to targeted therapies is a major challenge in #cancer care. In melanoma exposure to BRAF & MEK shows that resistance occurs via genetic & non-genetic mechanisms that differ among patients
www.cell.com/cancer-cell/fulltext/S1535-6108(21)00281-6
www.sciencedirect.com/science/article/pii/S15356108210039… -
soria reposted
Amgen 🧪🔬🧬
@Amgen
First episode of DNA Unlocked is live now! Congratulations to our Amgen team and @TheScientistLLC on this collaboration.
The Scientist
@TheScientistLLC
DNA Unlocked - Ep.1: The Promise and the Potential 🎧 viewonline.the-scientist.com/dna-unlocked-pre-signup?hss_…
In this episode, Ray Deshaies talks to Richard Scheller about why scientists are so enamored with genetics, and the challenges and potential of using genetics in target and drug discovery. -
soria reposted
Nature Reviews Cancer
@NatureRevCancer
NEW Review! Sophie Postel-Vinay @sophiepostelvi1 & co discuss the dynamic interplay betw the #dnadamage response & anticancer #immunity & how we can move towards harnessing this interplay for therapeutic benefit.
go.nature.com/3y35huU
@natrescancer @jsoriamd @GustaveRoussy -
soria
@jsoriamd
Understanding the blood-tumor barrier is key to develop optimal new therapeutic approaches in #cancer. This review provides current knowledge of BTB structure & function with a focus on how this knowledge can be translated into clinical advances
www.nature.com/articles/s41571-021-00529-6 -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Le Professeur Fabrice @Barlesi est nommé Directeur Général de Gustave Roussy pour une durée de 5 ans.
Il prendra ses fonctions le 1er août 2021.
Pour plus d’informations, lire le communiqué ⬇️
www.gustaveroussy.fr/fr/le-pr-fabrice-barlesi-est-nomme-d… -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Bientôt un #timbre à l'effigie de Gustave Roussy !
A l'occasion des 100 ans de la 1re consultation de cancérologie ouverte en France par le Pr Gustave Roussy, La Poste lancera un timbre à l'image de notre fondateur et de notre Institut. 👏 -
soria
@jsoriamd
My academic career summarized by a partial collection of badges. Thank you @GustaveRoussy @CEAParisSaclay for all what I have received
-
soria reposted
LARVOL
@Larvol
LARVOL VIEW ranked #oncologists worldwide 🗺️ based on their activity and influence on Twitter.
Take a look at the top 🔟 doctors ranked in Europe.
See the full list: tlg123llc.sharepoint.com/_layouts/15/doc2.aspx?sourcedoc=… -
soria reposted
Gustave Roussy
@GustaveRoussy
#emploi 📢Vous êtes infirmier(e)s ? Rejoignez @GustaveRoussy, leader européen de la #cancérologie !
Intégrez un environnement innovant, faites le choix d’un parcours professionnel encadré & varié et bénéficiez de nombreux avantages.
👉Intéressé(e) ? Rdv gustaveroussy.fr/ide -
soria
@jsoriamd
The diversity of the TCR repertoire of tumor infiltrating T lymphocytes at baseline is prognostic in various cancers, & predictive for efficacy of PD1 blockade #immunotherapy in #melanoma
www.nature.com/articles/s41467-021-24343-x -
soria
@jsoriamd
The ambitious bet of President @EmmanuelMacron to push France as the European leader in health innovation with 7 billion € investment & a new political & administrative software eager to facilitate innovation. Proud of the collective work achieved with colleagues #csis2020
-
soria
@jsoriamd
Nous rendons hommage à un homme d’une très grande force intérieure, capable de repousser les frontières et de créer des synthèses improbables au service des patients atteints du #cancer
Gustave Roussy
@GustaveRoussy
C'est avec une profonde tristesse que nous apprenons le décès du Pr Axel Kahn. Les équipes de @GustaveRoussy saluent ce grand médecin et chercheur, humaniste et engagé, notamment dans la lutte contre le cancer. Toutes nos pensées à sa famille, à ses proches et à @laliguecancer.
-
soria
@jsoriamd
Serving as the CEO of @GustaveRoussy these last 18 months has been an immense privilege & the crown of my academic career. @GustaveRoussy is an exceptional philharmonic orchestra. It remains a world-class philharmonic even if the maestro changes end of July 2021
-
soria
@jsoriamd
What an exceptional trajectory for @Annals_Oncology just 8 years ago IF was barely around 6 Chapeau bad @FAndreMD & all the editorial team 👏@myESMO
FabriceAndre
@FAndreMD
The new Impact Factor @annals_oncology is 32. It means the papers we publish are highly cited and, given our Editorial scope, probably impact patient's outcome. Remember that all articles are free for @myesmo members ! Thank you all for your contributions !
-
soria reposted
Gustave Roussy
@GustaveRoussy
📣 @SanofiFR @GustaveRoussy @Inserm @IP__Paris @UnivParisSaclay s’engagent pour que la France occupe une place stratégique dans la médecine personnalisée contre le #cancer à travers un #biocluster centré sur le #patient : le Paris Saclay Cancer Cluster.
👉www.gustaveroussy.fr/fr/creation-dun-biocluster-en-oncolo… -
soria reposted
Gustave Roussy
@GustaveRoussy
📣 .@jsoriamd, DG de @GustaveRoussy, présente les conclusions du rapport du #csis, remis au Président @EmmanuelMacron :
Élysée
@Elysee
EN DIRECT | Présentation de la stratégie innovation santé 2030 par le Président @EmmanuelMacron.
x.com/i/broadcasts/1jMJgpprQokxL -
soria reposted
Gustave Roussy
@GustaveRoussy
[#recrutement] Comme Astride, infirmière en pédiatrie, engagez-vous dans la lutte contre les cancers de l’enfant au sein d’une équipe en or. 🤩 Rejoignez Gustave Roussy !
Pour postuler, rendez-vous sur gustaveroussy.fr/rh
#ide #emploiThis media couldn't be displayed. See it on the original post. -
soria
@jsoriamd
The potential of liquid biopsy to detect #cancer at earlier stages with methylation-based detection test. In this validation study, at cancer diagnosis: 99.5% Sp, 51% Se, 88% prediction of organ origin. This has the potential to reduce cancer mortality.
www.annalsofoncology.org/article/S0923-7534(21)02046-9/fu… -
soria
@jsoriamd
A very comprehensive review of the #immunotherapy space in #lcsm without oncogene-addiction. A nice read, thank you @NatRevClinOncol
www.nature.com/articles/s41571-021-00520-1 -
soria reposted
Gustave Roussy
@GustaveRoussy
Merci infiniment à Mme #brigittemacron, venue à la rencontre de nos patients et de nos professionnels à @GustaveRoussy. La première dame a pu faire le point avec nos équipes sur les dernières avancées et l'avenir de la cancérologie, déjà en cours de mise en oeuvre à l'Institut.
-
soria
@jsoriamd
In 124 #kras G12C NSCLC pts 2L/3L, sotorasib ORR 37.1% , CR 3.2%, median DOR 11.1 months. DCR 80.6%, median PFS 6.8 months, median OS 12.5 months .TRAE 69.8% pts, grade 3 in 19.8%; only 7.1% of patients discontinuing treatment.
www.nejm.org/doi/full/10.1056/NEJMoa2103695 -
soria
@jsoriamd
#kras is an actionable target. Mechanisms of resistance to adagrasib include 1)KRAS alterations 2) amplification of KRASG12C 3) bypass mechanisms (MET amplif; mut in NRAS, BRAF, MAP2K1 & RET), 4) fusions ALK RET BRAF RAF1 & FGFR3 5) mutations in NF1 & PTEN www.nejm.org/doi/full/10.1056/NEJMoa2105281
-
soria reposted
Elizabeth McKenna
@ElizSMcKenna
For a comprehensive review on resistance to targeted therapy, don't miss this review by @jsoriamd, @FAndreMD, and colleagues @gustaveroussy in the #cdturns10 special issue: cancerdiscovery.aacrjournals.org/content/11/4/874
-
soria
@jsoriamd
CTLA4-PD1 combination strategy has improved the outcome of a selected number of tumors. In parallel #immunotherapy combination with #antiangiogenics or #chemotherapy has demonstrated broader activity. Discover a comprehensive review on this topic.
cancerdiscovery.aacrjournals.org/content/11/6/1368 -
soria
@jsoriamd
Modern delivery of chemotherapies via #adc is a growing & promising anti #cancer approach @NatRevClinOncol
www.nature.com/articles/s41571-021-00470-8 -
soria
@jsoriamd
The potential of combining #immunotherapy & #adc probably underline this alliance investors.bms.com/iframes/press-releases/press-release-de…
-
soria reposted
Gustave Roussy
@GustaveRoussy
🔴 LIVE
La conférence « L’#asco21 décrypté par Gustave Roussy » est en cours, retrouvez-nous en direct sur YouTube : youtu.be/uise--KB0YY -
soria
@jsoriamd
Development of therapeutic PI3K inhibitors has known its lows and highs. Check out this comprehensive review on the topic @FAndreMD @NatRevDrugDisc
www.nature.com/articles/s41573-021-00209-1 -
soria
@jsoriamd
where will the wave of innovation take #cancer #care? #esmoperspectives @myESMO perspectives.esmo.org/latest-edition/promoted-content/mom…
-
soria
@jsoriamd
Le Centre International des Cancers Thoraciques est une alliance d'experts internationaux pour les #cancers du #thorax permettant de rassembler toutes les compétences d'hôpitaux partenaires de réputation mondiale @GustaveRoussy @GHPSJ @HMLannelongue www.cict-paris.com
-
soria reposted
Gustave Roussy
@GustaveRoussy
🚨Que faut-il retenir de l'#asco21 ?
Nos experts décrypteront pour vous les actualités marquantes du congrès lors d'une conférence live le mercredi 16 juin à 17h sur la chaîne YouTube de
@GustaveRoussy.
➡️ Voir le programme : www.gustaveroussy.fr/fr/lasco-2021-decrypte-par-les-exper… -
soria
@jsoriamd
Fascinating original paper suggesting that real-time monitoring of #targeted #cancer therapy is achievable by measuring changes in drug occupancy & protein composition in molecular subpopulations of circulating extracellular vesicles #liquidbiopsy.
www.nature.com/articles/s41565-021-00872-w -
soria
@jsoriamd
The biology of breast cancer response to neoadjuvant therapy is underdescribed. Mutational heterogeneity, subclonal architecture, the improvement of immune microenvironment along with remodelling of hypoxia & EMTinfluence the response to neoadjuvant tt
www.nature.com/articles/s41523-021-00282-0 -
soria reposted
LARVOL
@Larvol
Tonight we are celebrating the final night of #asco21 with a virtual reality gallery opening and the announcement of the LARVOL VIEW Top 100 Most Influential Oncologists. Here is a look at our top 10 of 2021! Get the full list: www.larvol.com/blog/larvol-view-top-100-most-influential-…
-
soria reposted
Gustave Roussy
@GustaveRoussy
🗞️ A lire dans @Le_Figaro :
Les résultats de l'étude PEACE-1 présentée à l'#asco21 par le Pr Fizazi @GustaveRoussy, source d'espoir contre le #cancerdelaprostate métastatique ⬇️
www.lefigaro.fr/sciences/de-nouveaux-espoirs-dans-le-trai… -
soria
@jsoriamd
Pancreatic cancer remains a dramatic disease. #asco21 highlighted the targetability of NRG1 translocations, BRCA mutations, KRAS mutations. This is an interesting review on the genomic landscape of #pancreaticcancer
www.nature.com/articles/s41575-021-00463-z -
soria reposted
Benjamin Besse
@BenjaminBesseMD
Sotorasib #asco21 update in pts with KRAS G12C NSCLC. I hear a lot of "enough to be better than CT-IO in first line?" Look at the 13 pts that did not receive any chemo : ORR is 69.2%, mOS 17.7 mo... Intrigued to see more data in untreated pts.
-
soria
@jsoriamd
FabriceAndre
@FAndreMD
Big emotion to see LAG3 validated as a target. LAG3 was discovered & characterized as a target by @GustaveRoussy Research Division. A real achievement for the Institution & its supporters (public agencies, government & donors). Incredible rupress.org/jem/article/171/5/1393/24421/LAG-3-a-novel-ly…
-
soria
@jsoriamd
Magnitude of #immunotherapy efficay with atezolizumab in resected NSCLC is greatest in patients with the highest levels of PDL1 #asco21 @HwakeleeMD @ZPiotrowskaMD
-
soria
@jsoriamd
Impower010 adjuvant #immunotherapy in resected NSCLC. Safety profile is overall acceptable & shows 50% irAE, 8% grade 3-4, but 4 fatalities noted & 18% discontinued atezolizumab because of AE
-
soria
@jsoriamd
Impower010 is the first phase 3 adjuvant #immunotherapy trial in resected lung cancer. Atezo improves DFS in stage II-IIIA PDL1+ patients (HR 0.66), but no benefit in PDL1 neg patients. Stage IB-IIIA benefit is 0.81. Use of MRI or PET not discussed #asco21
-
soria
@jsoriamd
Adjuvant vs neoadjuvant #immunotherapy in resected lung cancer #asco21
-
soria
@jsoriamd
Adjuvant therapy conceptual framework @ZPiotrowskaMD #asco21
-
soria
@jsoriamd
Durvalumab survival benefit after CTRT in NSCLC confirmed at 5 years. HR for OS 0.72 with Survival @60m of 43% vs 33% #immunotherapy #asco21
-
soria reposted
Gustave Roussy
@GustaveRoussy
#asco21
📢 A @GustaveRoussy @BERGONIE33 study shows promising results of a new #immunotherapy in metastatic or recurrent cervical cancer.
Press release ⬇️
www.gustaveroussy.fr/en/asco-2021-metastatic-or-recurrent… #cervicalcancer -
soria reposted
Gustave Roussy
@GustaveRoussy
#asco21
Le Pr Antoine Italiano de @GustaveRoussy @Bergonie33 explique en vidéo les résultats d'une étude présentée à l'@ASCO 2021, portant sur une nouvelle #immunothérapie prometteuse contre le cancer du col de l'utérus : -
soria
@jsoriamd
Le périmètre foncier de @GustaveRoussy est de 100 000 m2 sur son site de Vïllejuif explique Frédéric Lemos à @EmmWargon & @LauStmartin @saidahamada en visite sur le site @pardouxstephane
-
soria
@jsoriamd
Adjuvant treatment value in resected high-risk muscle-invasive urothelial carcinoma is unclear. In a phase 3 randomized, controlled trial,#immunotherapy (nivolumab) demonstrated an HR for disease recurrence or death, of 0.70 (HR was 0.55 for PDL1 >1%)
www.nejm.org/doi/full/10.1056/NEJMoa2034442 -
soria
@jsoriamd
Signature d’un accord de collaboration entre @GustaveRoussy & @chudelareunion @LionelCalenge au service des patients atteints du #cancer à la Réunion
-
soria
@jsoriamd
Fascinating review in @NEJM demonstrating that healthy cells in all tissues bear mutational burdens. Cancer-gene mutations in healthy organs blurs the genomic border between cancer & healthy tissues.Some “benign” diseases undergo malignant transformation.
www.nejm.org/doi/full/10.1056/NEJMra2101920 -
soria
@jsoriamd
Check out the data that allowed sotorasib to become the first #kras approved targeted therapy : ORR of 32% out 59 #lcsm patients, & median PFS of 6.3 months. Lower responses also in colorectal, pancreatic, endometrial, appendiceal cancers & melanoma.
www.nejm.org/doi/full/10.1056/NEJMoa1917239 -
soria
@jsoriamd
Sotorasib gets approval for #kras G12C+ NSCLC www.cancernetwork.com/view/sotorasib-earns-accelerated-ap…
-
soria
@jsoriamd
Tumor microenvironment subtypes predict response to #immunotherapy: four TME subtypes, conserved across diverse cancers, correlate with immunotherapy response in melanoma, bladder & gastric cancers.
www.cell.com/cancer-cell/fulltext/S1535-6108(21)00222-1 -
soria
@jsoriamd
Check out the interview of multiple healthcare workers who were unsure about #covid19 vaccination but finally accepted it: long covid, ICU stay & other potential sequels are discussed
Gustave Roussy
@GustaveRoussy
#vaccination #covid19
Ils sont médecin, infirmière, brancardier, aide-soignante : le personnel de @GustaveRoussy témoigne de l'importance de la vaccination contre la Covid-19, pour eux, pour leurs proches, pour les patients, pour tous.
🎥youtu.be/o8LOU_N8c68 -
soria
@jsoriamd
Le directeur général de @GustaveRoussy Roussy explique comment la pandémie #covid19 a bouleversé la prise en charge des patients atteints du #cancer et sa vision d’avenir pour la cancerologie www.lefigaro.fr/sciences/jean-charles-soria-le-diagnostic…
-
soria
@jsoriamd
The journey of #kinase inhibition in #cancer. Over the past 20 years small-molecule inhibitors of protein & lipid kinases, resulted in the approval of more than 70 new drugs.
www.nature.com/articles/s41573-021-00195-4 -
soria
@jsoriamd
Expanding the conquest of #kras as an actionable anti #cancer target : a monobody able to target the active form of KRAS G12V & G12C : preclinical but fascinating (G12V accounts for up to 30% of RAS mutations in certain tumor types)
www.nature.com/articles/s41467-021-22969-5 -
soria
@jsoriamd
Finalisation du projet stratégique institutionnel de @GustaveRoussy : notamment étendre le recours à tous les stades du #cancer @barlesi
-
soria
@jsoriamd
Interesting position paper reflecting on how understanding drug #resistance mechanisms can enable innovative treatment regimens that deliver longer-lasting benefit to #cancer patients @CD_AACR
cancerdiscovery.aacrjournals.org/content/11/5/1016 -
soria
@jsoriamd
Colorectal cancer metastasizes mainly to the liver. In preclinical models, it was demonstrated that the premetastatic niche in the liver is induced by bacteria dissemination from primary CRC. Clinical datasets intriguingly may support this hypothesis.
www.sciencedirect.com/science/article/pii/S15356108210016… -
soria
@jsoriamd
Décès Pr Alain Laugier, une des figures emblématiques de la cancérologie française. PUPH visionnaire, à l’éloquence inégalée, Alain Laugier fut un modernisateur toujours en avance & à l’humour mordant. La médecine perd un de ses très grands patrons. @APHP
aaa-aphp.fr/deces-de-notre-ami-le-professeur-alain-laugie… -
soria
@jsoriamd
Bacteria, #cancer & #immunotherapy efficacy: a window for new therapeutic opportunities. Intra-tumoral bacteria can directly modulate antitumor immune responses; this represents a new class of therapeutically relevant, non-human tumor antigens.
www.sciencedirect.com/science/article/pii/S15356108210021… -
soria
@jsoriamd
The tissue microenvironment controls how local immune cells behave, with tissue-resident fibroblasts emerging as a key cell type in regulating activation or suppression of an immune response in #cancer
www.nature.com/articles/s41577-021-00540-z -
soria
@jsoriamd
Fascinating pre-clinical paper demonstrating that SETDB1 is an #epigenetic checkpoint that suppresses tumour-intrinsic immunogenicity, and thus represents a candidate target for #immunotherapy.
www.nature.com/articles/s41586-021-03520-4 -
soria reposted
Gustave Roussy
@GustaveRoussy
📣 Vous êtes étudiant(e) en soins infirmiers ? @GustaveRoussy finance votre 3e année en #ifsi ! Engagez-vous à nos côtés dans la lutte contre le #cancer, rejoignez-nous 🤝
Plus d’informations :
➡️ www.gustaveroussy.fr/fr/allocation-pour-etudiants-infirmiers #recrutement #ide -
soria
@jsoriamd
Nous accueillons avec joie 115 Internes à @GustaveRoussy pour ce semestre d’été. Nous veillerons à ce que votre intégration et votre organisation de travail soient de qualité et nous resterons à votre écoute en cette période difficile de #covid19
-
soria
@jsoriamd
Excellent review on the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as efforts to define treatment strategies to overcome resistance @NatureCancer
www.nature.com/articles/s43018-021-00195-8 -
soria
@jsoriamd
Fascinating pre-clinical paper showing that glioblastoma escape immune clearance by establishing an enhanced immunosuppressive tumor microenvironment via epigenetic immune-editing
twww.cell.com/cell/fulltext/S0092-8674(21)00351-2?rss=yes -
soria reposted
EIN Presswire: Press Releases
@EINPresswirePR
@GustaveRoussy and @WIN_Consortium join forces to advance innovative cancer research s.einnews.com/3Ohtvb1XaG
-
soria
@jsoriamd
Check out a great review summarizing the growth and clinical benefit of anti-cancer compounds in lung cancer @NatRevClinOncol
www.nature.com/articles/s41571-021-00501-4 -
soria
@jsoriamd
Aujourd’hui la Direction et les chefs de département ont tenu à remercier chaleureusement la centaine d’Internes qui vient de passer un semestre @GustaveRoussy: les Internes sont la cheville ouvrière de l’Hopital @ISNItwit @SIHParis @AssoAERIO
-
soria
@jsoriamd
Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options
www.nature.com/articles/s41571-019-0262-9 -
soria
@jsoriamd
The incidence of early-onset CRC(<50 years), has increased worldwide. Early-onset CRCs have differential clinical, pathological & molecular features . This perspective discusses how can we improve its prevention & clinical management. @NatRevClinOncol
www.nature.com/articles/s41571-020-00445-1 -
soria
@jsoriamd
Jose Baselga—a visionary leader , a drug developer involved in the approval of 12 anti-cancer compounds, and one who also transformed institutions & professional societies every¬where he went. Orbituary by @TaberneroJosep @DHymanMD
cancerdiscovery.aacrjournals.org/content/early/2021/04/12… -
soria
@jsoriamd
Can anti-cancer drugs help manage #covid19 ? Check out this manuscript initiated by the @AACR COVID19 task force under Toni Ribas #aacr21 @mihaela_aldea @MichotJM
cancerdiscovery.aacrjournals.org/content/early/2021/04/12… -
soria reposted
Elizabeth McKenna
@ElizSMcKenna
Just out in @CD_AACR by members of the @AACR #covid19andcancer Task Force: #repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in #covid19 @jsoriamd @GustaveRoussy #aacr21 cancerdiscovery.aacrjournals.org/content/early/2021/04/12…
-
soria
@jsoriamd
Interception is frequently discussed during #aacr21, liquid biopsy is a key tool to help intercept cancer before it is clinically or radiologically established @CD_AACR
cancerdiscovery.aacrjournals.org/content/10/11/1635 -
soria
@jsoriamd
Developing personalized cancer vaccines. A great review in @NatRevClinOncol #personalized #immunotherapy
www.nature.com/articles/s41571-020-00460-2 -
soria
@jsoriamd
#liquid biopsies in #cancer allow for early detection of tumors, improved risk assessment & staging, as well as early detection of relapse & monitoring of tumor evolution in the context of therapeutic pressures. @CD_AACR
cancerdiscovery.aacrjournals.org/content/11/4/858 -
soria
@jsoriamd
#immunotherapy has deeply impacted #cancer care over the last 10 years. This review provides a great glimpse at this reality & its current challenges.
cancerdiscovery.aacrjournals.org/content/11/4/838 -
soria
@jsoriamd
#obesity is associated with diabetes and cardiovascular diseases. Obesity link to #cancer is also better documented (notably thyroid, uterine, and liver cance): obesity leads to increased chronic inflammation & changes in populations of #immune cells.
www.nejm.org/doi/full/10.1056/NEJMcibr2035081?af=R&rss=cu… -
soria
@jsoriamd
Fascinating paper of mechanisms of #resistance to KRASG12C inhibitors: 1) polyclonal RAS-MAPK reactivation 1 2) KRAS switch-II pocket mutation that impairs binding
cancerdiscovery.aacrjournals.org/content/early/2021/04/02… -
soria
@jsoriamd
As we grief Jose Baselga death, we celebrate the life of this visionary cancer researcher, gifted physician, transformer of institutions, dedicated mentor. We will seek to honor his legacy with urgency in our hearts & minds. @DHymanMD @TaberneroJosep
www.annalsofoncology.org/article/S0923-7534(21)01119-4/fu… -
soria
@jsoriamd
This review in @CD_AACR describes the most common mechanisms of resistance to targeted therapies & #immunotherapy & discusses challenges for overcoming #resistance #precisionmedicine @barlesi @FAndreMD @mihaela_aldea
cancerdiscovery.aacrjournals.org/content/11/4/874 -
soria
@jsoriamd
In this review, we provide a summary of recent therapeutic advances in SCLC in light of #immunotherapy, as well as current challenges of this strategy in patients who are elderly, have poor performance status or brain metastases.
www.sciencedirect.com/science/article/pii/S09237534210087… -
soria
@jsoriamd
Tous les jours des milliers de professionnels se mobilisent @GustaveRoussy pour traiter le #cancer et apporter de l’espoir, #covid19 ou pas nous sommes là pour vous
-
soria
@jsoriamd
Biology-guided therapy is well established in breast or lung cancer. New biomarkers are emerging for the management of gastric and GEJ cancers. @NatRevClinOncol
www.nature.com/articles/s41571-021-00492-2 -
soria reposted
Elizabeth McKenna
@ElizSMcKenna
@mihaela_aldea, @FAndreMD, Aurelien Marabelle, Semih Dogan, @barlesi, and @jsoriamd provide an overview on overcoming resistance to tumor-targeted and immune-targeted therapies @GustaveRoussy /12
cancerdiscovery.aacrjournals.org/content/11/4/874 -
soria
@jsoriamd
#immunotherapy has improved cancer care. It’s biggest impact could potential be in the (neo) adjuvant setting. Nivolumab in Resected stage II or III Esophageal or H+GEJ Cancer: DFS HR for disease recurrence or death, 0.69; 96.4% CI, 0.56 to 0.86; P<0.001.
www.nejm.org/doi/full/10.1056/NEJMoa2032125 -
soria
@jsoriamd
2 publications demonstrate how to build bispecific antibodies that recognise peptides derived from mutant p53 or RAS & engage antitumour T cell response. These two studies open up a new avenue for #cancer #immunotherapy
science.sciencemag.org/content/371/6533/eabc8697.full
immunology.sciencemag.org/content/6/57/eabd5515.abstract -
soria
@jsoriamd
Clinical applications of tumor sequencing include 1) identifying mutations or structural variants that are predictive biomarkers of drug response, 2) assist with cancer subtype diagnosis 3) or confer increased heritable cancer risk
www.nature.com/articles/s41576-021-00338-8 -
soria
@jsoriamd
Is #immunotherapy active in all tumors with high TMB ? This correspondence to @NEJM argues no. In #colorectalcancer only tumors with MMR–deficiency status or pathogenic mutations in polymerase ε or polymerase δ1 benefited.
www.nejm.org/doi/full/10.1056/NEJMc2031965
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria
@jsoriamd
Jose Baselga memorial event by zoom thank @AppleHelix
This media couldn't be displayed. See it on the original post. -
soria
@jsoriamd
Memorial for Jose Baselga, @LeviAGarraway : to some extent Jose life is like the Sagrada Familia: towering, singular and inspirational, tragically unfinished...but the finishing depends on those galvanized by him
-
soria reposted
Tatiana Prowell, MD
@tmprowell
So moving to hear all of these tributes to Dr. Jose #baselga at his memorial today. “You are part of a family,” says @jsoriamd. Even attending this memorial virtually, I think we all feel it. The #bcsm family is expansive, cozy, global, affectionate, remarkable. ❤️
-
soria
@jsoriamd
Great summary by @dplanchard on ADC activity in #lcsm #elcc21
-
soria
@jsoriamd
The Washington Post on José Baselga. Do not miss the zoom this Saturday March 27 3 pm EST to share on his legacy astrazeneca.zoom.us/webinar/register/WN_-mn4wVtjT9GvJdShi… www.washingtonpost.com/local/obituaries/jose-baselga-dead…
-
soria
@jsoriamd
I will participate in this event Saturday March 27 to honor José Baselga legacy
Jing Liang 🇺🇦
@AppleHelix
1/ Remembering Dr. José Baselga
Saturday March 27, 3pm EST, via @Zoom
Friends, colleagues, and patients will join his family to pay tribute to his humanity and legacy.
If you would like to attend, use the link below to register.
*Please retweet*
astrazeneca.zoom.us/webinar/register/WN_-mn4wVtjT9GvJdShi… -
soria reposted
ESMO - Eur. Oncology
@myESMO
ESMO pays tribute to Prof. José Baselga. 'Undoubtedly a giant of oncology, one of the most innovative scientists, an amazing mentor. He gave a lot to cancer research, cancer professionals and cancer patients: now we all must continue his legacy.' www.esmo.org/newsroom/esmo-society-news/esmo-pays-tribute…
-
soria
@jsoriamd
1st positive adjuvant #immunotheray trial in lung cancer Atezlizumab showed DFS bebefit after surgery & chemotherapy in Stage II-IIIA patients with NSCLC. The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population.
www.roche.com/media/releases/med-cor-2021-03-22.htm -
soria reposted
AstraZeneca
@AstraZeneca
We are deeply saddened by the news that José Baselga, EVP Oncology R&D, has passed away. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. We send our condolences to his family. know.az/3tMm6sd
-
soria
@jsoriamd
I am devastated by the death of José Baselga: one of the true giants in oncology, the most disruptive & brillant mind I ever met. He has shaped modern oncology and saved so many lives. I have lost a real friend & mentor. I pray for his beloved family & our cancer community.
-
soria
@jsoriamd
Current treatment and future challenges in ROS1-rearranged #lcsm
www.sciencedirect.com/science/article/pii/S03057372210002… -
soria
@jsoriamd
Fascinating paper describing the development of CAR-T that will target tumor cells with LOH. This approach, termed NASCAR (Neoplasm-targeting Allele-Sensing CAR), had its POC in models of HLA LOH in vitro and in vivo. #immunotherapy #cellulartherapy
www.pnas.org/content/118/12/e2022410118 -
soria
@jsoriamd
20 million people have received #astrazeneca #covid19 vaccine as of March 16 & EMA has found only 7 cases of blood clots in multiple blood vessels & 18 cases of CVST. A causal link with the vaccine is not proven, but is possible. Benefit >>> risk
EU Medicines Agency
@EMA_News
EMA’s safety committee (PRAC) concludes that the benefits of the #covid19vaccine AstraZeneca still outweigh its risks despite possible link to rare blood clots associated with low levels of blood platelets.
👉Read more: www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-be… -
soria
@jsoriamd
Patients with #cancer & under #immunotherapy should be vaccinated against #covid19, ideally before chemo. SThe seroconversion for influenza vaccine is 56% if given same day as chemotherapy, such data unknown for Sars-Cov2
www.ejcancer.com/article/S0959-8049(21)00069-1/fulltext
www.ncbi.nlm.nih.gov/pmc/articles/PMC3111157/ -
soria
@jsoriamd
Focal adhesion kinase (FAK) is a non- receptor tyrosine kinase & an adaptor protein that regulates adhesion signalling and cell migration, but FAK can also promote
cell survival in response to stress & be involved in resistance to anti-cancer therapies
www.nature.com/articles/s41568-021-00340-6 -
soria reposted
Gustave Roussy
@GustaveRoussy
🎙️ Invité de #lafrancebouge sur @Europe1, Pr Fabrice @Barlesi illustre l'innovation française en cancérologie en exposant les 10 grands programmes de recherche lancés par @GustaveRoussy, dont les champs s'étendent de la #prévention jusqu'à l'après-#cancer.
-
soria
@jsoriamd
Celebrating 9 years on Tweeter, & close to 10k followers. Thank you @JackWestMD & @charles_ferte for pushing me to join this community
-
soria
@jsoriamd
The #covid19 pandemic has stimulated intense efforts to find effective therapeutics for the disease. Unfortunately, worldwide clinical research activities on COVID19, reviewed by @US_FDA , appear as a disorganized “comic opera”… @NatRevDrugDisc
www.nature.com/articles/d41573-021-00037-3 -
soria
@jsoriamd
Various approaches to enhancing NK cell effector function and explore NK cell platform for #cancer #immunotherapy is nicely summarized in this @NatRevClinOncol paper
www.nature.com/articles/s41571-020-0426-7 -
soria
@jsoriamd
Somatic HLA Class I Loss Is a Mechanism of Immune evasion which helps refine TMB as a Biomarker of #immunotherapy response. This is particularly true for tumors with TMB < 30 mutations/mb.
cancerdiscovery.aacrjournals.org/content/11/2/282 -
soria
@jsoriamd
A very interesting review providing an overview of the expanded universe of cancer targets. The diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes.
www.cell.com/cell/fulltext/S0092-8674(21)00170-7 -
soria
@jsoriamd
Fascinating paper by @VHIO @seoanelab demonstrating that Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment, opening interesting perspectives for #immunotherapy
www.nature.com/articles/s41467-021-21789-x -
soria reposted
Gustave Roussy
@GustaveRoussy
| 10 ans d'avancées en médecine de précision |
🎯 En 2011, @GustaveRoussy signait une publication de référence ouvrant la voie à une décennie d’innovations en médecine de précision, axe stratégique majeur pour le développement de nouveaux traitements du #cancer :This media couldn't be displayed. See it on the original post. -
soria reposted
Gustave Roussy
@GustaveRoussy
📢Journée mondiale de sensibilisation aux #hpv
⚠️ Les papillomavirus humains sont responsables de différents #cancers (col de l'utérus, ORL, anus...). La vaccination HPV est recommandée et remboursée pour les filles et les garçons dès 11 ans.
Explications du Dr @GorphePhilippe : -
soria
@jsoriamd
#esmotat21 how to optimize the therapeutic index for CAR-T in solid tumors
-
soria
@jsoriamd
#esmotat21 Susan Guedan provides an overview of CAR-T cell trials in solid tumors
-
soria
@jsoriamd
#esmotat21 @Mark_Cobbold @AstraZeneca on optimizing CAR-T for solid tumors
-
soria
@jsoriamd
#esmotat21 @Mark_Cobbold Head of cell therapy @AstraZeneca delivering an overview of targets for CAR-T in solid tumors
-
soria
@jsoriamd
Check out the results of neoadjuvant nivo vs nivo- ipi operable NSCLC. Increased MRP at 38% in nivo+ Ipi vs nivo alone (22%) comes at a high cost of AE & importantly final resectabilty (21/23 pts on the nivo arm versus only 16/21 in the nivo-ipi arm)
www.nature.com/articles/s41591-020-01224-2 -
soria reposted
ESMO - Eur. Oncology
@myESMO
#esmotat21 Opening session and Keynote addresses starting now “The Home of Phase I in #oncology”. Registration 👉 Free for ESMO members www.esmo.org/meetings/esmo-targeted-anticancer-therapies-… Access the platform here 👉 cattendee.abstractsonline.com/meeting/10400 @plummer_ruth @lillian_siu @jsoriamd @LSeymourMD
-
soria reposted
Teresa Amaral, MD, PhD
@TeresaSAmaral
#esmotat2021
Check it out 👇
@myESMO
Annals of Oncology
@Annals_Oncology
The @myESMO targeted anticancer therapies 🎯 virtual congress 2021 #esmotat21 , a "must attend" congress for drug developers in oncology, starts on Monday.
You can find a special collection of articles here: www.elsevier.com/events/ESMO -
soria
@jsoriamd
1678 patients representing 16 tumor types & treated with #immunotherapy, present response rates that were higher with high TMB (>10 mutations per megabase). However, TMB & response rates varied widely across cancer types.
jamanetwork.com/journals/jamaoncology/article-abstract/27… -
soria
@jsoriamd
Pancreatic cancer is refractory to #immunotherapy. In this manuscript, authors describe a complex network of immune-suppressive cellular interactions with patient-specific immune changes to be taken into account for future development plans.
doi.org/10.1038/s43018-020-00121-4 -
soria reposted
Gustave Roussy
@GustaveRoussy
#journéeInternationaleDuCancerDeLEnfant
2 800 enfants et adolescents par an sont touchés par le #cancer, rien qu'en France.
Aidez les chercheurs de @GustaveRoussy à progresser plus vite pour #guerirlecancerdelenfantau21esiecle
➡️Faites un don sur www.guerirlecancerdelenfant.fr -
soria
@jsoriamd
Journée internationale des cancers de l’enfant. @GustaveRoussy nous mobilisons tous les talents pour bâtir des programmes ambitieux & novateurs au service des enfants #guerirlecancerdelenfantau21emesiecle Merci @EmmanuelMacron @NicolasSarkozy @Frederic_Lemos
-
soria reposted
Philippe Morlat
@PhilippeMorlat
Les étudiants en santé dont le cursus de formation comporte des stages à l’hôpital, en établissements médicaux sociaux ou en médecine ambulatoire sont naturellement éligibles à la @vaccination #covid ! Qu’on se le dise !
-
soria
@jsoriamd
If you want to understand #coronavirus variants & mutations & its implications, check out this superb article @nytimes
www.nytimes.com/interactive/2021/health/coronavirus-varia… -
soria
@jsoriamd
Antibody–drug conjugates (smart chemotherapies) are becoming key new players in #cancer therapy
doi.org/10.1038/s41571-021-00470-8 -
soria
@jsoriamd
Four "#cancer drugs in the top ten #drugs with the highest sales forecasts for 2021
www.nature.com/articles/d41573-020-00219-5 -
soria
@jsoriamd
Check out the links between infection, irritable bowel syndrome symptoms & food intake. Bacterial infection can trigger a break in oral tolerance & localized immune responses leading to meal-induced abdominal pain. True also for #cancer patients
www.nature.com/articles/s41586-020-03118-2 -
soria
@jsoriamd
Merci @aur_rousseau de votre soutien @GustaveRoussy et votre présence lors de la visite du Président @EmmanuelMacron Nous avons la chance de vous avoir comme timonier solide et expérimenté à la tête @ARS_IDF en ces temps si difficiles de #covid19
-
soria
@jsoriamd
#guérirLeCancerDeLenfantAu21eSiècle merci Président @EmmanuelMacron de votre visite au département de cancérologie pédiatrique @Frederic_Lemos @GustaveRoussy @GroupeUNICANCER
-
soria
@jsoriamd
Today #worldcancerday President @EmmanuelMacron visited the patients, clinicians & researchers of @GustaveRoussy while announcing a very ambitious national cancer strategy. This visit was a great sign of encouragement for all those involved in #cancer care & research
-
soria reposted
Gustave Roussy
@GustaveRoussy
En cette #journeemondialecontrelecancer, le Président @EmmanuelMacron a choisi @GustaveRoussy pour illustrer la nouvelle stratégie décennale contre le cancer et rencontrer soignants, chercheurs et patients. Une visite et une confiance qui nous honorent.
-
soria reposted
Nicolas Sarkozy
@NicolasSarkozy
Une reconnaissance méritée ! Bravo aux formidables équipes de @GustaveRoussy
Gustave Roussy
@GustaveRoussy
En cette #journeemondialecontrelecancer, le Président @EmmanuelMacron a choisi @GustaveRoussy pour illustrer la nouvelle stratégie décennale contre le cancer et rencontrer soignants, chercheurs et patients. Une visite et une confiance qui nous honorent.
-
soria reposted
Gustave Roussy
@GustaveRoussy
Merci à la Présidente de la Région @iledefrance @vpecresse pour cette rencontre avec les équipes de @GustaveRoussy et d’@OWKINscience (lauréat AI for Health Challenge 2019), et l'intérêt porté aux avancées de nos projets d'#ia.
Pour plus d'infos :
▶️www.gustaveroussy.fr/fr/valerie-pecresse-rencontre-les-eq… -
soria
@jsoriamd
We are grateful to @vpecresse @iledefrance for their visit & funding of part of our AI infrastructure @GustaveRoussy
-
soria
@jsoriamd
For those following #wclc20 read this great piece about TIGIT and all questions related to the current phase 2 dataset www.sugarconebiotech.com?p=1155
-
soria reposted
Kai
#wclc2020 Excellent graphics of Take Home Messages by @jsoriamd summarizing recent years changes in cancer therapies and clinical trials design @IASLC @OncoAlert @gecp_org @GustaveRoussy
2 media couldn't be displayed. See them on the original post. -
soria
@jsoriamd
Whole-genome doubling occurs early in tumorigenesis and generates genetically unstable tetraploid cells that fuel tumour development. KIF18A, is specifically required for the viability of WGD & is a key theoretical #cancer therapeutic target.
www.nature.com/articles/s41586-020-03133-3 -
soria
@jsoriamd
The cancer–NK cell immunity cycle: an important road to increase #immunotherapy efficacy
www.nature.com/articles/s41568-020-0272-z?WT.mc_id=TWT_Na… -
soria
@jsoriamd
#covid19 identifying predictors of disease severity is key. In this paper @GustaveRoussy & @OWKINscience investigators show that AI-analysis of CT-scans adds to the prognosis value of 5 variables: age, sex, oxygenation, urea & platelet.
www.nature.com/articles/s41467-020-20657-4 -
soria reposted
Gustave Roussy
@GustaveRoussy
🎥 #covid19 : Comment l'#ia développée par @GustaveRoussy @Hopital_Bicetre @Inria_Saclay @OWKINscience pour prédire l'évolution de la maladie a-t-elle été conçue ? En quoi consiste-t-elle ?
Réponses en vidéo :
➡️youtu.be/PdUPcx1ps4k -
soria
@jsoriamd
The next frontier of liquid biopsy in oncology is likely the systemic treatment of patients with ‘#ctdna relapse’, as well as #cancer #screening & diagnosis. A great review in @NatRevClinOncol
www.nature.com/articles/s41571-020-00457-x -
soria
@jsoriamd
FDA Opposée aux changements de schéma vaccinaux | FDA states suggesting changes to the FDA-authorized dosing or schedules of these vaccines is premature and not rooted solidly in the available evidence.#covid19 #vaccination www.fda.gov/news-events/press-announcements/fda-statement…
-
soria
@jsoriamd
Statement on 2021 Annual Meeting | ASCO Annual Meeting will be online only #asco21 meetings.asco.org/am/statement-2021-annual-meeting
-
soria
@jsoriamd
Delighted today to sign a scientific partnership between @GustaveRoussy & @IRSNFrance on radiobiology research topics @radioprotection
-
soria reposted
FabriceAndre
@FAndreMD
10 y ago, we reported in @ASCO_pubs w @jsoriamd one of the 1st papers about high throughput genomics for target identification. Lot of advances since then, but the key prob remains: how to interpret biol in each pt ? Modeling biology is the next step ascopubs.org/doi/pdf/10.1200/JCO.2010.31.6877
-
soria
@jsoriamd
Truly honored to be able to discuss France #cancer strategy with President @EmmanuelMacron , @VidalFrederique , @olivierveran & various colleagues including @INCa_veillePro president. Thank you for allowing #covid vaccination for cancer #patients
-
soria
@jsoriamd
Prof Gordon McVie 1945 - 2021
It is with tremendous sadness that I have seen on its LinkedIn account the death of Professor John Gordon. Gordon was a hugely loved and well recognised figure in the world of cancer care: a true giant in oncology -
soria
@jsoriamd
Data is growing to suggest that auto-immunity is an important player in severe #covid19 cases. #masks #vaccinationcovid
www.nature.com/articles/d41586-021-00149-1 -
soria reposted
FabriceAndre
@FAndreMD
.@GustaveRoussy launches its center for early cancer detection, led by S. Delaloge. For participants with high risk of cancer; individualized intervention + inclusion in a research cohort to discover methods of cancer detection (plasma, feces, imaging...). 1st step: n=10 000 pts
-
soria reposted
Eric Topol
@EricTopol
A new, very large #sarscov2 household transmission study (27K households, 30K cases, 58K contacts)
www.thelancet.com/journals/laninf/article/PIIS1473-3099(2…
—age ≥ 60 and infants most likely to get infected
—<age 20 most likely to infect others (1.6X)
@TheLancetInfDis -
soria reposted
Eric Topol
@EricTopol
Most are familiar with "liquid biopsy" for #cancer.
That for covid, not so much.
First report here using methylation of cell-free DNA to organ specific injury, level of cf-DNA correlates w/ disease progression
www.cell.com/med/fulltext/S2666-6340(21)00031-3 @MedCellPress @DeVlaminckLab @cfDNAlex -
soria reposted
Nathan A. Pennell MD, PhD, FASCO
@n8pennell
Important to show ctDNA MRD after surgery isn't only prognostic but may indicate high risk population who benefit from adjuvant treatment! Strong work! #gi21
Pashtoon Kasi MD, MS
@pashtoonkasi
#gi21 Here’s an interesting observation. Snapshot of 11 #ctdna #crcsm studies.
Where no Rx was given, 💯recur.🔴cuts x-axis~2 yrs.
Adjuvant #ctdna studies, 🟢they all plateau off👇🏾.
There’s a proportion who is getting cured.
🩸🧬➕➡️➖
A lot of the🪄serial data in supplements.📚 -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 @GustaveRoussy recommande aux patients atteints de #cancer de se faire vacciner contre la #covid19. Ces personnes sont prioritaires pour la vaccination généralisée en France à partir du 18 janvier.
Consultez nos recommandations détaillées sur :
▶️www.gustaveroussy.fr/fr/vaccin-covid-patients -
soria
@jsoriamd
Great news starting Monday cancer patients in France will have priority access to #covid19 vaccination. I encourage them to get vaccinated as Covid19 severity & fatality is increased among cancer patients www.lefigaro.fr/flash-actu/covid-19-ouverture-lundi-de-la…
-
soria
@jsoriamd
Very interesting correspondence in @NEJM showing that KRAS G12C mutation frequency varies according to ethnicity and sex even in the same tumor type, with frequencies between 3 to 14%!
www.nejm.org/doi/full/10.1056/NEJMc2030638 -
soria reposted
Gustave Roussy
@GustaveRoussy
Découvrez les temps forts qui ont marqué l’année 2020 à @GustaveRoussy, une année complexe mais riche en avancées médicales, scientifiques et humaines👇
#retrospective2020
www.gustaveroussy.fr/highlights-2020/ -
soria
@jsoriamd
FDA approved 53 novel therapeutics in 2020 (2nd highest number since 1996). Check out the share of oncology and the modality of the approved compounds (small molecules, proteins, etc)
www.nature.com/articles/d41573-021-00002-0 -
soria reposted
Gustave Roussy
@GustaveRoussy
💉 Coup d’envoi cette semaine à @GustaveRoussy de la #vaccination #covid19 du personnel prioritaire.
Protéger nos équipes, protéger nos patients et leur entourage pour contribuer au plus vite à la rupture des chaines de contamination et garantir la continuité de nos soins 🤝 -
soria
@jsoriamd
Toujours mobilisés pour construire et finaliser avec le personnel le nouveau projet stratégique institutionnel de @GustaveRoussy
-
soria
@jsoriamd
Patients with liver metastasis derive less benefit from #immunotherapy. In this paper, liver metastases siphon activated CD8+ T cells from systemic circulation & macrophages in the liver promote T cell elimination creating thus an immune desert.
www.nature.com/articles/s41591-020-1131-x -
soria
@jsoriamd
Monsieur le Ministre @olivierveran les patients atteints par le cancer devraient être vaccinés de façon prioritaire @axelkahn
soria
@jsoriamd
#cancer patients are at increased risk of #covid19 complications including death. They should be on the priority list of #vaccination @AACR @CD_AACR @AACRPres
cancerdiscovery.aacrjournals.org/content/early/2020/12/22… -
soria
@jsoriamd
#cancer patients are at increased risk of #covid19 complications including death. They should be on the priority list of #vaccination @AACR @CD_AACR @AACRPres
cancerdiscovery.aacrjournals.org/content/early/2020/12/22… -
soria reposted
Gustave Roussy
@GustaveRoussy
✨ Les équipes de @GustaveRoussy vous souhaitent une très belle année 2021 ! Cette nouvelle année nous rapproche un peu plus de l'objectif que nous poursuivons aux côtés de nos patients, mécènes, donateurs et partenaires : guérir le #cancer au 21e siècle ✨
-
soria reposted
-
soria reposted
Jordi Remon
@JordiRemon
Despite COVID outbreak, treatment opportunities for aNSCLC💊💉🧬 have increased ⬆️even moved to early stage. Reduce access inequalities FDA/EMA is pending. This figure (not exhaustive) summarizes 2020. Progress continues with all our effort and thanks to patients💪🏻💪🏻 #lungcancer
-
soria
@jsoriamd
Many great interactions happen via tweeter #chirptycircle @FAndreMD @barlesi @axelkahn @charles_ferte @GustaveRoussy @AACR @drgandara
-
soria reposted
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
@APassaroMD
🛎 a must-read just published on @CD_AACR on #covid19 vaccination for pts w/ #cancer
👉🏻Pts who r currently receiving treatment,or have an advanced-C in particular #lungcancer or hemat,should be prioritised & receive COVID19 vaccination
@AACRPres @jsoriamd
cancerdiscovery.aacrjournals.org/content/early/2020/12/19… -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Le @CLCCLeonBerard et @GustaveRoussy s’engagent dans un partenariat stratégique pour le rayonnement de l’excellence française en cancérologie.
Pour en savoir plus : www.gustaveroussy.fr/fr/leon-berard-et-gustave-roussy-par… -
soria
@jsoriamd
Our Institution @GustaveRoussy & @CLCCLeonBerard enter into a key strategic partnership to face the key challenges of modern oncology including molecular fragmentation of common tumors
Gustave Roussy
@GustaveRoussy
📢 Le @CLCCLeonBerard et @GustaveRoussy s’engagent dans un partenariat stratégique pour le rayonnement de l’excellence française en cancérologie.
Pour en savoir plus : www.gustaveroussy.fr/fr/leon-berard-et-gustave-roussy-par… -
soria
@jsoriamd
MET-aberrant NSCLC encompasses MET-amplified & METex14. METex14 patients do not seem to benefit from #immunotherapy in contrast to METamp patients
doi.org/10.1016/j.jtho.2020.11.017 -
soria
@jsoriamd
Myeloid derived suppressor cells have been shown to be induced by tumors and suppress anti-tumor immunity. In this paper gut #microbiome is shown to control accumulation of MDSC in the liver and promote #cholangiocarcinoma
cancerdiscovery.aacrjournals.org/content/early/2020/12/11… -
soria
@jsoriamd
ctDNA applications for colorectal cancer , excellent manuscript in @NatRevClinOncol
www.nature.com/articles/s41571-020-0392-0 -
soria
@jsoriamd
Liquid biopsies with ctDNA can detect smaller tumors or relapses before they are visible on standard imaging. In this paper, a mathematical model shows that ctDNA can detect a relapse 140 days earlier than with imaging-based approaches
advances.sciencemag.org/content/6/50/eabc4308.full -
soria
@jsoriamd
The online registration system for the ESMO Targeted Anticancer Therapies TAT Virtual Congress 2021 is now open at the following link: www.esmo.org/meetings/esmo-targeted-anticancer-therapies-…
This is a great meeting for early drug development for IO, targeted agents, cell therapy, etc -
soria
@jsoriamd
Fascinating report demonstrating in melanoma patients who progressed on #immunotherapy that fecal microbiota transplant allows for some of them, a new response to #immunotherapy
science.sciencemag.org/content/early/2020/12/09/science.a… -
soria reposted
Gustave Roussy
@GustaveRoussy
🧑🎓 Le célèbre Cours de chimiothérapie de @GustaveRoussy proposé par l'Ecole @SciencesCancer aura lieu en format 100% digital du 11 au 22 janvier 2021.
👉Consultez le programme : formation.gustaveroussy.fr/main/default_course_document/d…
👉Inscrivez-vous : formation.gustaveroussy.fr/shop/cours-de-chimiotherapie-a… (tarif préférentiel jusqu'au 31/12) -
soria
@jsoriamd
Notch signalling is involved in angiogenesis, tumour immunity & cancer stem-like state. Its targeting has been disappointing in the clinical setting despite strong preclinical datasets. Check out this promising review. @NatRevDrugDisc www.nature.com/articles/s41573-020-00091-3
-
soria
@jsoriamd
Targeting PAK4 could normalize tumor vasculature and increase the trafficking of CAR-T, thus potentially increasing the efficacy of #cellulartherapy in solid tumors
www.nature.com/articles/s43018-020-00147-8 -
soria reposted
Gustave Roussy
@GustaveRoussy
MDs, PharmDs, Engineers: how deep is your ambition?
🎓 Get a #phd in #oncology, apply for the 'Course of Excellence in Oncology - Fondation Philanthropia' @GustaveRoussy & the School of @SciencesCancer in Paris.
📨 Application by April 4 2021 👉phd-in-oncology.com/en/ -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 L'actualité scientifique en #cancérologie vue par @GustaveRoussy : c'est Good to Know !
🔎 Ne manquez pas le nouveau numéro de notre newsletter scientifique et inscrivez-vous pour recevoir directement ses prochaines éditions :
▶️gustaveroussy.fr/fr/good-know-02
#goodtoknow #oncoalert -
soria reposted
ESMO - Eur. Oncology
@myESMO
#esmotat21 Virtual (1-2 March 2021): Present your novel insights in #cancer science to worldwide experts in the field. 👉Deadline: 06 January 2021 www.esmo.org/meetings/esmo-targeted-anticancer-therapies-… @jsoriamd @curijoey @VriesElisabeth @TaberneroJosep
-
soria reposted
Gustave Roussy
@GustaveRoussy
Le 24 novembre 1874 naissait Pr Gustave Roussy. Pionnier de la lutte contre le #cancer, il fit de la cancérologie une spécialité à part entière.
Aujourd'hui plus d'1 cancer sur 2 peut être guéri et l'Institut qu'il a créé fait partie des 5 meilleurs centres spécialisés du monde. -
soria
@jsoriamd
Our mission @GustaveRoussy to fight #cancer on all fronts
www.universite-paris-saclay.fr/en/news/jean-charles-soria… -
soria reposted
Gustave Roussy
@GustaveRoussy
#lesaviezvous ?
Le #cancerdupoumon ne concerne pas seulement les fumeurs : il touche aussi les non-fumeurs dans environ 20% des cas, pour lesquels il comporte quelques spécificités.
#lcam #lungcancerawarenessmonth -
soria
@jsoriamd
Intriguing @Nature paper showing that inhibition of PCSK9 (cholesterol target) can boost the response of tumors to #immunotherapy. Mechanistically, PCSK9 can disrupt the recycling of MHC I to the cell surface.
www.nature.com/articles/s41586-020-2911-7 -
soria reposted
Gustave Roussy
@GustaveRoussy
🏆 12 médecins/chercheurs de @GustaveRoussy dans la liste des chercheurs les plus cités au monde #highlycited2020 @webofscience !
Nous sommes fiers de rassembler toutes ces expertises, reconnues mondialement, au service de la lutte contre le #cancer et de nos patients 👏 -
soria reposted
Université Paris-Saclay
@UnivParisSaclay
👤 [PORTRAIT]
Combattre le #cancer sur tous les fronts !
Jean-Charles Soria - chercheur 👨🔬 & professeur @UnivParisSaclay - dirige @GustaveRoussy depuis janvier 2020. #immunotherapie #oncologie #recherche #sante
Il a reçu de nombreuses distinctions.
👉 www.universite-paris-saclay.fr/actualites/jean-charles-so… -
soria reposted
Gustave Roussy
@GustaveRoussy
🎥 Quelle prise en charge pour le #cancerdupoumon ? Qui concerne-t-il ? Quelles sont les dernières avancées des traitements ?
Faites le point en 3 mn avec le Dr @dplanchard de @GustaveRoussy ▶️youtu.be/BTyV9h1arq0
#lcam #lungcancerawarenessmonth #moissanstabac -
soria
@jsoriamd
Persistent #cancer cells are the discrete & usually undetected cells that survive cancer drug treatment & constitute a major cause of treatment failure. Discover in this review the therapeutic challenges generated by these deadly survivors.
www.sciencedirect.com/science/article/pii/S00928674203139… -
soria reposted
Gustave Roussy
@GustaveRoussy
Parmi les cancers les plus fréquents et les plus meurtriers, le #cancerdupoumon a pour principal facteur aggravant le tabac. #moissanstabac : il n'est jamais trop tard pour arrêter 🚭
#lungcancerawarenessmonth #lcam #lcsm -
soria
@jsoriamd
Targeting the PD1 and PDL1 axis has paved the way for a new era of clinical care in #cancer. #immunotherapy trials remain the dominant force in oncology. IO trials have doubled in 2020 with a strong surge of combinations & growing challenges in recruitment
www.nature.com/articles/d41573-020-00204-y -
soria
@jsoriamd
Even with #covid19 mild-cases there are long-term symptoms. Here is a dataset of 488 patients who were hospitalized & survived the disease. At 60 days post-hospitalization: 32% still have symptoms, 23% are breathless walking stairs, etc, jaw-dropping...
www.acpjournals.org/doi/10.7326/M20-5661 -
soria
@jsoriamd
Oncogene-driven changes in tumor cell metabolism can impact the TME & present barriers to #cancer therapy & #immunotherapy. These changes also reveal potential opportunities to reshape the TME by targeting metabolic pathways
doi.org/10.1016/j.molcel.2020.05.034 -
soria reposted
Children's Cancer Cause
@childrenscause
“Congratulations to @GustaveRoussy's Dr. Vassal! On behalf of pediatric cancer survivors and patients worldwide, thank you for your dedication to fighting childhood cancer.”
- Ben Rosen, childhood cancer survivor and grandson of the award's namesake Leonard Rosen
EIN Presswire: Press Releases
@EINPresswirePR
Children's Cancer Cause Presents Rosen Research Award to ACCELERATE's Dr․ Gilles Vassal s.einnews.com/8GSTDOmU67
-
soria
@jsoriamd
The adenosine pathway is a broadly immunosuppresive pathway, inhibitors of this pathway may help enhance the activity of #immunotherapy in #cancer Check out this excellent review in @NatRevClinOncol
www.nature.com/articles/s41571-020-0382-2 -
soria
@jsoriamd
In #cancer, #celltherapy is a major new therapeutic avenue. Check out this review in @Annals_Oncology on the side-effect management of CART therapy
doi.org/10.1016/j.annonc.2020.10.478 -
soria
@jsoriamd
Great short TED talk by @AmyCEdmondson on how to lead during a crisis @HarvardHBS
1)Be Transparent
2)Communicate often
3)Admit what you do not know
4)Act with urgency
5)Follow your values
6)Share the power & ask for help
www.ted.com/talks/amy_c_edmondson_how_to_lead_in_a_crisis -
soria
@jsoriamd
When we face many challenges, it is important to reconnect with the simple beauty offered by nature
-
soria reposted
FabriceAndre
@FAndreMD
👇🏼 A patient association sending a letter to the government to advocate for cancer treatment access during covid 👏🏼👏🏼
RoseUp Association
@RoseUpAsso
Après avoir alerté @MinSoliSante & @Institut_cancer, notre association a envoyé un courrier aux ARS en rappelant qu'il est inconcevable qu'à nouveau les malades de #cancer voient leurs soins déprogrammées. Les pertes de chance, réelles, documentées se comptent en milliers de vies
-
soria
@jsoriamd
Does academic research in oncology need so much bureaucracy? Outstanding perspective by @FAndreMD perspectives.esmo.org/latest-edition/featured-content/doe…
-
soria reposted
Gustave Roussy
@GustaveRoussy
⚠ Malgré la #covid19, le #cancer n'attend pas !
Le diagnostic et la prise en charge du cancer restent indispensables.
@GustaveRoussy vous accueille dans les meilleures conditions de sécurité.
Pour prendre un 1er RDV :
📞 01 42 11 43 77
💻 RDV en ligne rdv.gustaveroussy.fr -
soria
@jsoriamd
AI-Driven quantification, staging & outcome prediction of #covid-19 pneumonia. Great collaboration between @GustaveRoussy @APHP @TheraPanacea @centralesupelec @ParisSaclay
doi.org/10.1016/j.media.2020.101860 -
soria reposted
NetCancer
@NetCancerFrance
[#vaccinationgrippe]
La saison de la #vaccination contre la #grippe a débuté. Faut-il se faire vacciner? Découvrez les recommandations du Dr Olivier Mir, oncologue médical
vimeo.com/472521528/0b277321c1
#prévention #patient #cancer #campagnegrippe #information #oncologie #interview -
soria
@jsoriamd
•Remarquable dataset from the KRYSTAL trial at #enasymp20. Adagrasib activity in #krasg12c: ORR in CRC 17%, a signal in PDAC & cholangio, ORR 45% in NSCLC, DCR 96%, no median duration of response reported but treatment ongoing >11 m for majority of patients with responses (4/6)
-
soria reposted
Roberto Ferrara
@RobertoFerrara_
Check the age of circulating NSCLC pts' T-cells! Immunosenescence occurs in ∼28% of NSCLC. It is a negative predictive factor for ICI and a biomarker of HPD. @navimacha @BenjaminBesseMD @JordiRemon @LauraMezquitaMD @marinagarassino @CCR_AACR @OncoAlert
doi.org/10.1158/1078-0432.ccr-20-1420 -
soria
@jsoriamd
The current trends suggest that we will face a truly severe second wave of #covid19 in the EU
www.wsj.com/articles/covid-rips-through-european-countrie… -
soria
@jsoriamd
The potential of #immunotherapy either alone or with chemotherapy in the neoadjuvant/adjuvant setting is huge. Check out this excellent review in @CCR_AACR by @JordiRemon @BessemD on NSCLC.
clincancerres.aacrjournals.org/content/26/19/5068 -
soria
@jsoriamd
The fall is just such a beautiful season
-
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Découvrez le 1er numéro de la newsletter Good to Know, l'actualité scientifique en #cancérologie vue et commentée par @GustaveRoussy, et inscrivez-vous pour recevoir les prochaines éditions !
▶️www.gustaveroussy.fr/fr/good-know-01
#goodtoknow #oncoalert -
soria
@jsoriamd
In the @NEJM paper reporting the DFS benefit of adjuvant Osimertinib in NSCLC, there is a KM curve hidden in the appendix It demonstrates the DFS benefit of Osimertinib in patients who never received adjuvant chemo (HR 0.23) vs those who did (HR 0.16)
www.nejm.org/doi/full/10.1056/NEJMoa2027071 -
soria
@jsoriamd
The phase 1 dataset of sotorasib in patients harboring the #kras p.G12C mutation is out in @NEJM. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response, the median PFS was 6.3 months. ORR was only 7.1% in CRC.
www.nejm.org/doi/full/10.1056/NEJMoa1917239 -
soria
@jsoriamd
Interesting neoadjuvant trial of chemo with #immunotherapy that enrolled 46 resectable stage IIIA NSCLC patients. At 24 months, PFS was 77·1% (95% CI 59·9–87·7). Approach was not associated with surgery delays
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria reposted
Gustave Roussy
@GustaveRoussy
⏳ J-1 avant la web conférence live "L"#esmo20 décrypté par les experts de @GustaveRoussy"
RDV mardi 13 octobre à 17h sur la chaine YouTube de Gustave Roussy.
Voir le programme 👉 www.gustaveroussy.fr/fr/lesmo-2020-decrypte-par-les-exper… -
soria reposted
FabriceAndre
@FAndreMD
Thanks to all speakers of #map2020 .The meeting has become exactly what the founders @jsoriamd @CharlesSwanton @HaanenJohn @CRUKresearch @myESMO @GroupeUNICANCER envisioned: precise, well illustrated talks by high level scientists, at the crossroad of basic and clinical sciences
-
soria
@jsoriamd
In #cancer #ras is the new frontier in making oncogene-addiction actionable in the clinic. A lot is yet imperfect but the path is clear & promising.
www.nature.com/articles/s41573-020-0068-6 -
soria
@jsoriamd
#liquidbiopsy is transforming #cancer care. Here ctDNA genotyping shortened screening duration (11 versus 33 days) improved matched-trial enrollment rate (9.5 versus 4.1%,) without compromising outcome compared to tissue genotyping, in GI cancer patients. doi.org/10.1038/s41591-020-1063-5
-
soria
@jsoriamd
This year #nobelprize in chemistry is awarded to Emmanuelle Charpentier (born 1968 in France) & Jennifer Doudna (born 1964 in the USA)– who proved that the CRISPR/Cas9 genetic scissors could be controlled to cut any DNA molecule at a predetermined site.@Nobelprize
-
soria
@jsoriamd
The 2020 #nobelprize in Medicine has been awarded jointly to Harvey J. Alter, Michael Houghton & Charles M. Rice for the discovery of Hepatitis C virus. @NobelPrize
-
soria
@jsoriamd
Very elegant work using #ctdna and circulating immune cell profiling to provide accurate, noninvasive, and early forecasting of therapeutic benefit for NSCLC patients receiving #immunotherapy
www.sciencedirect.com/science/article/pii/S00928674203114… -
soria reposted
Gustave Roussy
@GustaveRoussy
Parce que #toutnestpasrose face au cancer du sein, @GustaveRoussy multiplie les axes de recherche pour prévenir le #cancerdusein, améliorer les traitements et la qualité de vie des patientes.
www.toutnestpasrose.fr
#octobrerose
Explications en image 👇
youtu.be/GoENVBFhoT8 -
soria
@jsoriamd
The genomic landscape of MIBC is characterized by high mutational burden & genomic instability. Response to cisplatin include genomic instability & BRCA2 mutations. Immune cell infiltration and high PD-1 n are associated with treatment response
www.nature.com/articles/s41467-020-18640-0 -
soria reposted
Magali Lemos
@Maglemosgoud
Le magazine Newsweek a publié son classement des meilleurs hôpitaux spécialisés au monde.
En cancérologie, Gustave Roussy est à la 5e place derrière les 4 centres phares américains.
Bravo aux médecins, chercheurs et tout le personnel de @GustaveRoussy !
www.newsweek.com/worlds-best-specialized-hospitals-2021/o… -
soria
@jsoriamd
Understanding the precise immunological mechanisms that underlie the efficacy of chemotherapy has the potential to accelerate the development of synergistic combination regimens that enhance the clinical effectiveness of #immunotherapy
stm.sciencemag.org/content/10/459/eaat7807.full -
soria
@jsoriamd
The absence of lymphocytes in the tumour microenvironment defines cold tumours (no response to #immunotherapy). To turn cold tumours into hot , : increase local inflammation, neutrale immunosuppression, modify the tumour vasculature, and others
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria
@jsoriamd
Artificial intelligence applied to #pathology a great review in @NatRevClinOncol Many fascinating promises…including evaluation of oncogene mutational status, HRD, TMB from a single H&E slide… Thank you @FAndreMD for highligthing it
www.nature.com/articles/s41571-019-0252-y -
soria reposted
Cancer Core Europe (CCE)
@CancerCoreEU
One afternoon. Four outstanding speakers. Join the Cancer Core Europe (CCE) Virtual Keynote Session on Translational Cancer Research on October 13th, 2020. Register by October 6th, 2020@ www.cancersummerschool.eu
static1.squarespace.com/static/5c0e63148f5130b92375aa0f/t… -
soria
@jsoriamd
Pleinement mobilisés pour l’élaboration du nouveau projet stratégique institutionnel de @GustaveRoussy au service des patients atteints du #cancer @pardouxstephane @barlesi @FAndreMD
-
soria
@jsoriamd
Pour mieux traiter les patients porteurs de tumeurs thoraciques @GustaveRoussy & @GHPSJ joignent leurs forces au sein del’Institut d’Oncologie Thoracique
-
soria
@jsoriamd
#covid19 & #cancer @GustaveRoussy Age > 70, smoking status , metastatic disease, CT & ECOG of ≥2 increased risk of death. #immunotherapy, hormone therapy & targeted therapy did not increase death risk. CRP & LDH increased risk of clinical worsening,
doi.org/10.1038/s43018-020-00120-5 -
soria reposted
Fabrice Barlesi
@barlesi
The @GustaveRoussy experience with Covid19 in cancer patients finally out in @NatureCancer; administration of chemotherapy should be carefully discussed giving a possible negative impact on survival @AlbigesL @jsoriamd
-
soria reposted
Fabrice Barlesi
@barlesi
Durvalumab maintenance provides with superior OS in PDL1+ advanced NSCLC pts: 1st results from the SAFIR02lung trial, jointly designed with @jsoriamd @GroupeUNICANCER @IFCTlung and co-leaded with @BenjaminBesseMD presented #esmo2020 @myESMO
-
soria
@jsoriamd
#esmo20 @Barlesi heroic effort by PIONeeR investigators to understand sensitive & resistance to #immunotherapy in #lcsm: circulating T cells, activated T cells, serum IL6 &TNFa correlated with OS, PK of PD1 molecules may explain PD, PDL1 positive cell density may be > PDL1
-
soria
@jsoriamd
#esmo20 the combination of pembrolizumab & lenvatinib keeps delivering promising results across tumor types with ORR of 29% TNBC, 32% in ovarian and 28% in CRC non-MSI high, toxicity is high with G3-5 in 35-68%. Combing #immunotherapy & #antiangiogenics is a real opportunity
-
soria
@jsoriamd
#esmo20 LungART trial sponsored by @GustaveRoussy in collaboration with @IFCT SAKK UK NCRI @Institut_cancer is an academic effort with 501 patients, no statistical advantage of PORT in pN2 resected NSCLC with HR of 0.85 (0.61-1.07) with an excess of death (with more CV)
-
soria
@jsoriamd
#esmo20 activity of #immunotherapy (nivolumab) in POLE mutant cancers (exonucleasic domain mutations are the relevant ones leading to high TMB) showed ORR 38% and DCR 62%, mPFS 5.3 m (thank you @Institut_cancer and @GroupeUNICANCER for their support of the Acse program)
-
soria
@jsoriamd
#esmo20 in EGFR mutant #lcsm the role of VEGF inhibition appears as inconclusive according to the discussant @LeciaSequist
-
soria
@jsoriamd
#esmo20, even if I deeply miss the human experience & interaction with friends & colleagues, this publication from @CDCgov on SARS-Cov2 transmission during an international flight reminds us on why we do this virtually wwwnc.cdc.gov/eid/article/26/11/20-3299_article
-
soria
@jsoriamd
#esmo20, the combination of immune effectors and host markers (soluble PDL1, NLR, NK cells, CD8 +PDL1+ Ly) has very good predictive value for #immunotherapy efficacy with an AUC of 9
-
soria
@jsoriamd
#esmo20, the combination of TMB & CCL9 and some other TME components has better predictive value for #immunotherapy efficacy vs TMB alone in over 1000 tumors including some PDL1- and TMB low tumors
-
soria reposted
Giannis Mountzios
@g_mountzios
🚨#oncoalert #esmo20 STIMULI trial in SCLC-LD failed to show improvement in PFS or OS with Nivo1+IPI3 follows by Nivo240q2w consolidation after non-progressing ChemoRT.
➡️High G3-4 toxicity 51% due to NIVO/IPI
➡️ Early discont of NIVO/IPI impacted results
#lcsm #sclc @myESMO -
soria reposted
Arlindo R Ferreira
@ajrsferreira
1/3 of pts with #breastcancer are poorly adherent to tamoxifen at 3 years; serum assessment finds more pts. We must be vigilant to improve treatment tolerability; enough data for serum assessment?
Great work @BarbaraPistill2 and @inesvazluis!
#esmo20 #canto @GroupeUNICANCER -
soria
@jsoriamd
Neoadjuvant trials with IO #esmo20
@BenjaminBesseMD presented atezolizumab efficacy in PRINCEPS @GustaveRoussy trial with @GHPSJ : no safety signal (in contrast with IONESCO trial), with 14% MPR and 41% pathological response >50%, MPR not correlated with RECIST or PET but PDL1 -
soria
@jsoriamd
#esmo20 an excellent summary of #immunotherapy efficacy by Tony Ribas
-
soria reposted
ESMO - Eur. Oncology
@myESMO
ESMO members - as part of your member benefits you have free registration to #esmo20 and access to all the meeting resources. However you will still have to register to be able to access the platform - you can do so here 👉 www.esmo.org/meetings/esmo-virtual-congress-2020/registra…
-
soria
@jsoriamd
Let’s see what #esmo20 will bring in terms of liquid biopsy utility. Check out this review @NatRevClinOncol on ctDNA value in #lcms. Availability & convenience of blood sampling vs the challenges of scheduling & performing a tumour biopsy to be considered
doi.org/10.1038/s41571-020-0423-x -
soria
@jsoriamd
For all those attending #esmo20, check out the publication in @TheLancetOncol of the trial that lead to the approval of pembrolizumab in TMB high tumors. PI A Marabelle @GustaveRoussy
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria
@jsoriamd
Detailed modeling @GustaveRoussy presented #esmo20 suggests a 5% increase in cancer mortality due to #covid19 www.gustaveroussy.fr/fr/esmo-2020-covid-19-surmortalite-c…
-
soria reposted
Benjamin Besse
@BenjaminBesseMD
Maintenance Durvalumab after 4X platinum-based chemo: PFS (HR 0.29) and OS (HR 0.32) benefit restricted to pts with PD-L1≥1% NSCLC without targetable molecular alteration. First results of the phase II SAFIR02-LUNG trial! @GroupeUNICANCER @IFCTlung @barlesi @jsoriamd #esmo20
-
soria
@jsoriamd
La reconnaissance de @ParisSaclay dans le top 15 mondial reconnu en présence des Highly cited researchers et de ses composantes @GustaveRoussy
-
soria
@jsoriamd
Liquid biopsies potential for cancer detection, stratification, therapeutic monitoring and risk classification keeps growing
www.reuters.com/article/us-grail-m-a-illumina-idUSKBN2672S6 -
soria reposted
Jordi Remon
@JordiRemon
Before #esmo2020 current evidence of targeted txt for aNSCLC with EGFR ex20 ins, 2% of all NSCLC cases. Lots of drugs (table) however, activity of these agents remains lower than EGFR TKI in common EGFR mut authors.elsevier.com/sd/article/S0305-7372(20)30143-2 @BenjaminBesseMD @HendriksLizza @AndresFCardonaZ
-
soria
@jsoriamd
Targeted agents, immunotherapy, cellular therapy and smart chemotherapies with ADC are driving the change in oncology. New ADC are very promising: Gilead to acquire Immunomedics
www.businesswire.com/news/home/20200913005051/en/Gilead-S…
clincancerres.aacrjournals.org/content/25/18/5441 -
soria
@jsoriamd
The accuracy of ctDNA in advanced breast cancer & its ability to select patients for mutation-directed therapy (HER2 & AKT1) demonstrated in a 1051 patient’s platform trial #liquidbiosy
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria reposted
Zoé4life
@zoe44life
Prenez deux minutes pour écouter l'intervention de M. Nicolas Sarkozy dans l’émission « Quotidien » de hier soir.
Il est temps que les grands de ce monde prennent conscience de l’importance de soutenir la recherche sur le cancer pédiatrique.
Ensemble nous ferons la différence!This media couldn't be displayed. See it on the original post. -
soria
@jsoriamd
Understanding acquired resistance to targeted therapies and #immunotherapy is crucial for #cancer patients. On purpose biopsies for genomic analysis and PDX establishment are feasible, over 330 patients participated in that approach @GustaveRoussy
www.nature.com/articles/s41698-020-00130-7 -
soria
@jsoriamd
Translational analysis of the JAVELIN study. In the combination arm: patients with higher levels of UTS2 have extended PFS, robust responses if higher levels of tumor-infiltrating CD8+ T cells, no value for PDL1 IHC #immunotherapy @AlbigesL
www.nature.com/articles/s41591-020-1044-8 -
soria
@jsoriamd
Geographical access to IC beds varies across EU countries & low ICU accessibility is associated with higher proportion of #covid19 deaths to cases. The availability of ICU beds in Germany (9330 deaths) is mind-blowing vs France (30770 deaths). @EricTopol
doi.org/10.1007/s00134-020-06229-6 -
soria
@jsoriamd
#covid19 La situation en France se dégrade sérieusement www.lemonde.fr/planete/article/2020/09/06/covid-19-en-fra…
-
soria
@jsoriamd
Targeting #ret : a great review & great @NEJM papers. This is an important clinical reality not to overlook: thyroid, lung, colon, pancreas, spitzoid...#lcsm #cancer #precisionmedicine
ascopubs.org/doi/full/10.1200/JCO.19.02551
www.nejm.org/doi/full/10.1056/NEJMoa2005651
www.nejm.org/doi/full/10.1056/NEJMoa2005653 -
soria
@jsoriamd
precision medicine has been key in improving #cancer care. Optimal management of new promising drugs is key. (N)TRK inhibitors can cause Weight gain, dizziness/ataxia, paresthesias & withdrawal pain These side-effects are manageable but shall be known
www.sciencedirect.com/science/article/pii/S09237534203982… -
soria reposted
NetCancer
@NetCancerFrance
📅 [#savethedate]
NetCancer organise le 15/09 à @GustaveRoussy une séance de dédicace. Ce coffret vous sera offert !
#oncologie #cancer #immunothérapie #cellulescart #innovation #informationpatient #patient #livre #livrepatient #evenement #signature #paris -
soria reposted
Gustave Roussy
@GustaveRoussy
#septembreenor : lumière sur les cancers pédiatriques
🎗️
Un mois #orducommun pour se mobiliser plus que jamais contre ces cancers qui tuent 500 enfants /an en France et pour porter avec @GustaveRoussy l'ambition de #guérirLeCancerDelEnfantAu21eSiècle ✨
▶️www.gustaveroussy.fr/fr/septembre-en-or-lumiere-sur-les-c… -
soria
@jsoriamd
Poursuite de la définition du nouveau project strategique institutionnel @GustaveRoussy
-
soria reposted
Gustave Roussy
@GustaveRoussy
🔬 Publication dans @ScienceMagazine d'une étude @GustaveRoussy @Inserm @UnivParisSaclay montrant la capacité d'une bactérie intestinale à éduquer le système immunitaire pour détruire des cellules cancéreuses grâce aux similitudes de leurs antigènes ⤵️
science.sciencemag.org/content/369/6506/936 -
soria
@jsoriamd
#immunotherapy has transformed #cancer care. What is the probability of efficacy of PD(L)1 in patients that responded to it and were then off -therapy without PD? This is the largest series ever reported. In a nutshell 23% of patients will progress
jitc.bmj.com/content/8/2/e000650 -
soria
@jsoriamd
A @GustaveRoussy nous nous engageons avec force dans la lutte contre le tabac pour les patients et le personnel
-
soria reposted
Gustave Roussy
@GustaveRoussy
🔉 @GustaveRoussy devient le 1er établissement d'IdF à signer la charte Lieu de Santé Sans Tabac en présence de @GinotLuc @ARS_IDF, @Prabenyamina @Respadd et @GroupeUNICANCER. L'Institut illustre ainsi sur tout son campus sa mobilisation contre le 1er facteur de risque de #cancer
-
soria
@jsoriamd
EGFR exon 20 insertion driver mutations represent 4-12% of #egfr mutations. Insensitive to EGFR TKIs, they have poor prognosis. This is an unmet medical need #lcsm. TAK-788 & amivantamab (an EGFR–MET bispecific antibody) appear to have promising activity
cancerdiscovery.aacrjournals.org/content/10/8/1194 -
soria reposted
ESMO - Eur. Oncology
@myESMO
Delighted to announce the ESMO awards 2020 winners! ESMO Award 2020: Hans-Joachim Schmoll. ESMO Award for Translational Research 2020: Antoni Ribas. ESMO Women for Oncology Award 2020: Caroline Robert. ESMO Lifetime Achievement Award 2020: Nadia Harbeck
👉 www.esmo.org/newsroom/press-office/esmo-announces-winners… -
soria reposted
FabriceAndre
@FAndreMD
A molecular mimicry is observed between tumor Ag and phages. It could explain some of the associations between microbiota & anticancer immunity. A report in @ScienceMagazine from @GustaveRoussy . phages could be a new therapy and prevention for cancer ? science.sciencemag.org/content/369/6506/936
-
soria
@jsoriamd
Proteolysis-targeting chimeras (PROTACs) & related molecules that induce targeted protein degradation by the ubiquitin–proteasome system represent a new therapeutic modality in #cancer.
www.nature.com/articles/s41573-019-0047-y -
soria
@jsoriamd
If you are still not convinced about the need for #maksforall just check out this publication measuring SARVS-Cov-2 infection among healthcare workers in the Mass General Brigham system #covid19
jamanetwork.com/journals/jama/fullarticle/2768533 -
soria
@jsoriamd
Pembrolizumab + chemotherapy demonstrated improvement in OS and PFS compared with chemotherapy (cisplatin +5-FU), in locally advanced or metastatic esophageal cancer. This is good news for this tumor type and yet another advance for #immunotherapy
www.businesswire.com/news/home/20200819005205/en/Merck’s-… -
soria
@jsoriamd
Why female & younger patients don't respond as well to cancer #immunotherapy? Younger & female patients tend to accumulate more cancer-causing genetic mutations of the sort that MHCs can't present to the immune system as efficiently (immuno-editing).
www.nature.com/articles/s41467-020-17981-0 -
soria reposted
Gustave Roussy
@GustaveRoussy
⚠️ Le #masque est le 1er rempart contre la #covid19
Il doit être porté correctement, en couvrant le nez et la bouche, jusqu'au menton 😷 -
soria
@jsoriamd
A collaborative paper between @GustaveRoussy and @APHP shows a link between abnormal myeloid cell subsets, high calprotectin and severe #covid19 with new therapeutic opportunities
Cell
@CellCellPress
New Article online now at Cell: Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 www.cell.com/cell/fulltext/S0092-8674(20)30993-4?rss=yes
-
soria
@jsoriamd
Epigenetics in #cancer: targeting writers, erasers, readers & movers may offer real new therapeutic opportunities
www.nejm.org/doi/full/10.1056/NEJMra1805035?query=TOC -
soria
@jsoriamd
Lung cancer remains a major killer but significant improvements in care have been made these last 10 years which have led to improved survival
www.nejm.org/doi/full/10.1056/NEJMoa1916623?rss=searchAnd… -
soria
@jsoriamd
There is an unmet clinical need for improved #liquidbiopsy tools for cancer detection. Proteomic profiling of extracellular vesicles & particles of 426 human samples, shows that EVP proteins can serve as reliable biomarkers for cancer detection www.cell.com/cell/fulltext/S0092-8674(20)30874-6
-
soria reposted
Lapostolle Sylvie
@SyLapostolle
Coronavirus: le taux d'incidence grimpe vite à Paris: il a passé le seuil d'alerte hier (50,6 cas pour 100.000 habitants) et déjà 54,4 aujourd'hui! sortez masqués!
-
soria
@jsoriamd
CheckMate -649, a Phase 3 Trial Evaluating nivolumab & Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival & PFS in First-Line Treatment of Gastric and Esophageal Cancers | Business Wire www.businesswire.com/news/home/20200811005245/en/CheckMat…
-
soria
@jsoriamd
Controlling #covid19 is difficult but possible, the New Zealand example illustrates the need for national coordination & strong measures on multiple fronts
www.nejm.org/doi/full/10.1056/NEJMc2025203 -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Une étude @GustaveRoussy @APHP @Inserm @UnivParisSaclay @Univ_Paris révèle des spécificités chez les patients #covid19 sévères et ouvre la voie vers une approche thérapeutique inédite.
➕ d'infos :
www.gustaveroussy.fr/fr/identification-dune-nouvelle-cibl… -
soria reposted
ESMO - Eur. Oncology
@myESMO
Conducting phase I #clinicaltrials during the #covid19 pandemic: An experience by the @GustaveRoussy Drug Development Department
👉www.esmo.org/oncology-news/conducting-phase-i-clinical-tr…
#oncologynews #clinicalresearch @jsoriamd -
soria
@jsoriamd
COVID-19 outbreak and Phase 1 trials: should we consider a specific patient management? - @GustaveRoussy expérience www.ejcancer.com/article/S0959-8049(20)30392-0/fulltext?m…
-
soria reposted
FabriceAndre
@FAndreMD
Single cell analyses from @GustaveRoussy reported in @CellCellPress suggest an association between abnormal myeloid cell subsets, high calprotectin and severe COVID. Potential therapeutics: tasquinimod & others. On the other side; IFN associated with mild COVID19
Cell
@CellCellPress
New Article online now at Cell: Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 www.cell.com/cell/fulltext/S0092-8674(20)30993-4?rss=yes
-
soria reposted
Gustave Roussy
@GustaveRoussy
Immune-checkpoint inhibitors #immunotherapy revolutionized the oncology field in more than one way 💡
Find out how with Prof. Caroline Robert @GustaveRoussy, who summarizes 10 years of ICI immunotherapy in @NatureComms ▶️www.nature.com/articles/s41467-020-17670-y -
soria
@jsoriamd
After successful lockdown strategies, with the summer and vacation time, Europe battles now to contain surge in #covid19 cases
www.ft.com/content/bcddc297-b7f2-444d-908f-54e8ce6f4f98 -
soria
@jsoriamd
We @GustaveRoussy developed a surgical randomized trial (23 hospitals) to evaluate 2nd-look surgery + hyperthermic intraperitoneal chemo in pts with CRC risk of peritoneal metastases. Outcome is negative, let's avoid futile actions in patients at risk.
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria
@jsoriamd
#ai applied to histopathology continues to make progress. There are widespread associations between bulk gene expression levels, types of mutations & histopathology, which reflect tumor composition & enable the evaluation of TIL @NatureCancer www.nature.com/articles/s43018-020-0085-8
-
soria reposted
Matt O'Brien
@ObsoleteDogma
Israel had crushed coronavirus cases almost down to zero, but then it reopened its schools without taking proper precautions.
Now it has an even worse outbreak, in per capita terms, than we do. www.wsj.com/articles/israelis-fear-schools-reopened-too-s… -
soria reposted
Daiichi Sankyo US
@DaiichiSankyoUS
New research #collaboration with @GustaveRoussy to accelerate development of our #trop2 and #her3 directed therapies in #nsclc and metastatic #breastcancer. Learn more about the multi-year, multi-study program: daiichisankyo.us/press-releases/-/article/364091/11393917
-
soria
@jsoriamd
Smart Chemotherapies are changing the cancer landscape Daiichi Sankyo & @GustaveRoussy Enter Innovative Research Collaboration around 3 ADC www.businesswire.com/news/home/20200721005963/en/Daiichi-…
-
soria reposted
-
soria
@jsoriamd
Smart chemotherapies will impact #cancer care. Why is DS-8201 (trastuzumab deruxtecan) such a great #adc for HER2-positive tumors ?
www.annalsofoncology.org/article/S0923-7534(19)43225-0/pdf -
soria
@jsoriamd
Visite du site @GustaveRoussy a Chevilly-Larue par le bureau de @GroupeUNICANCER
-
soria
@jsoriamd
Liquid biopsies will transform #cancer care. Check out @Annals_Oncology demonstrating early detection of various cancers by analysing cfDNA; & this perspective by @ChristianRolfo on liquid biopsies in lung cancer #screening
www.sciencedirect.com/science/article/pii/S0923753420360580
www.nature.com/articles/s41571-020-0393-z?proof=trueMay%2… -
soria
@jsoriamd
I am afraid #covid19 is here to stay for a yet significant period and as oncologists we need to learn how to deal with it. Read this fascinating paper showing that Sars-Cov-2 relies on a trinity : inflammation, dysfunctional immunity and thrombosis
www.nature.com/articles/s41577-020-0311-8 -
soria
@jsoriamd
Face au cancer @GustaveRoussy a l’expertise et les structures nécessaires pour prendre en charge les symptômes complexes, anticiper les prises de décision et assurer un lien apaisé entre oncologie et soins palliatifs
-
soria reposted
ESMO - Eur. Oncology
@myESMO
Calling all ESMO members: Due to #covid19 the Ordinary Annual General Assembly will be held on 28 July without the physical presence of members. Your participation is VITAL: ESMO members eligible to vote can do so in writing by 20 July www.esmo.org/about-esmo/how-we-work/esmo-general-assembly…
-
soria
@jsoriamd
La santé est la condition essentielle qui sous-tend les multiples aspirations de la société (liberté, amour, bien-être...): cette réalité est devenue éclatante avec le #covid19 ! Merci @axelkahn pour ce rappel au cours du colloque @GroupeUNICANCER
-
soria
@jsoriamd
Le modèle de gouvernance @GroupeUNICANCER est singulier et a montré sa robustesse depuis près de 100 ans
-
soria
@jsoriamd
Assemblée générale @GroupeUNICANCER en format mixte: inventons la cancerologie de demain !
-
soria
@jsoriamd
Congratulations to @FAndreMD and its superb team of associate editors @CharlesSwanton @AndresC27622123 @TaberneroJosep @peters_solange @Thomas_Helleday @NickyMcGranahan @drcmassard @aftimosp
Annals of Oncology
@Annals_Oncology
The new impact factor has been released and we are happy to see that the Annals of Oncology IF has increased to an all-time high of 18.274! 📈
-
soria
@jsoriamd
The combination of PD(L)1 with anti-angiogenic agents (notably oral VEGFR TKI) keeps demonstrating strong & promising results across various tumor types (better than PD(L)1 with any new #immunotherapy). Here in gastric cancer
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
soria
@jsoriamd
NK Cells represent a great opportunity to open new possibilities in #immunotherapy. Check out all potential targets and the cancer-NK cell immunity cycle. @NatureRevCancer
www.nature.com/articles/s41568-020-0272-z -
soria
@jsoriamd
Using multi-region whole-exome and RNA sequencing of prospectively collected pre- and post-osimertinib-resistant tumors, authors demonstrate that MET amplification is the leading event and coexist with other subclonal alterations www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20…
-
soria
@jsoriamd
Check out this manuscript demonstrating the unique value of PDL1 expression in dendritic cells to define #immunotherapy efficacy @NatureCancer
www.nature.com/articles/s43018-020-0075-x -
soria
@jsoriamd
Anti-EGFR #car-T cells in pancreatic carcinoma: A phase I clinical trial with some signs of efficacy (modest) & clear on-target toxicity. Cellular therapy will deeply affect the management of solid tumors, technology & science will drive this change
www.sciencedirect.com/science/article/pii/S1465324920306174 -
soria
@jsoriamd
Extrachromosomal DNA (ecDNA) is a mechanism to accelerate intratumour heterogeneity & develop favourable epigenetic modifications. Tumours with ecDNA formation are more aggressive, have poorer survival outcomes & provide mechanisms of drug resistance.
www.sciencedirect.com/science/article/pii/S0923753420363924 -
soria
@jsoriamd
Targeting apoptosis in cancer therapy
www.nature.com/articles/s41571-020-0341-y -
soria
@jsoriamd
T cell-engaging therapies: BITE, CITE, DART, TRIK, SMITE,... a whole #immunotherapy world
www.nature.com/articles/s41571-020-0347-5 -
soria reposted
Gustave Roussy
@GustaveRoussy
En visite à @GustaveRoussy, Mme Brigitte Macron a pu rencontrer nos jeunes patients et l'équipe de pédiatrie, mais aussi découvrir notre nouveau scanner "in the box", généreusement financé par la @FondationHPHF, dont elle est présidente :
-
soria
@jsoriamd
Check out this review on the applicable strategies to improve patient selection and optimize therapeutic efficacy of PSMA radioligand therapy, in prostate cancer #pcsm
clincancerres.aacrjournals.org/content/early/2020/05/06/1… -
soria
@jsoriamd
Liquid biopsies with a sensitivity of1 mutant molecule per 100,000 , vs the classical 1 mutant molecule per 30,000. With this sensitivity, authors could even detect mutant ctDNA in #glioblastoma patients
stm.sciencemag.org/content/12/548/eaaz8084
jamanetwork.com/journals/jamaoncology/fullarticle/2763313 -
soria reposted
FabriceAndre
@FAndreMD
With the @FDAOncology approval of pembro in pts with TMB-High tumor, this topic is going to be hot. To get some background, you can read this review published by @GeneCollector @CharlesSwanton @peters_solange @squezadd in @Annals_Oncology www.annalsofoncology.org/article/S0923-7534(19)30997-4/fu…
-
soria
@jsoriamd
Ne ratez pas ce soir l’analyse de l’#asco20 par les experts de @GustaveRoussy
Gustave Roussy
@GustaveRoussy
L'#asco20 décrypté par @GustaveRoussy : un concentré d'expertise à ne pas manquer 📢
🎥 Retrouvez nos experts en direct sur YouTube jeudi 18 juin à 17H, qui analyseront et commenteront les actualités marquantes du congrès, par thématique.
▶️ youtu.be/Zpnt3fo6cvw -
soria reposted
Gustave Roussy
@GustaveRoussy
L'#asco20 décrypté par @GustaveRoussy : un concentré d'expertise à ne pas manquer 📢
🎥 Retrouvez nos experts en direct sur YouTube jeudi 18 juin à 17H, qui analyseront et commenteront les actualités marquantes du congrès, par thématique.
▶️ youtu.be/Zpnt3fo6cvw -
soria
@jsoriamd
Expanding therapeutic opportunities for #ras : from undruggable to allele-specific covalent inhibitors www.nature.com/articles/s41573-020-0068-6
-
soria
@jsoriamd
A Patient's Perspective on Adjuvant Therapy in Lung Cancer @EGFRResisters jfeldman48.wixsite.com/website/post/finding-hope-a-patien…
-
soria reposted
Université Paris-Saclay
@UnivParisSaclay
👤 [#portrait]
9 millions de décès dans le monde par an ! #cancer
Personnaliser les traitements 💊 du cancer grâce à la #modélisation !
Fabrice André - médecin 👨⚕️ #oncologie, professeur 👨🏫 @UnivParisSaclay et chercheur 👨🔬 PMNCO @GustaveRoussy @Inserm
👉 www.universite-paris-saclay.fr/actualites/fabrice-andre-p… -
soria
@jsoriamd
Réunion du GCS de l’Institut d’Oncologie Thoracique regroupant @GHPSJ et @GustaveRoussy avec @barlesi @BenjaminBesseMD @dplanchard
-
soria
@jsoriamd
Targeting excessive host inflammation with a BTK inhibitor may be a therapeutic strategy in severe #covid19. @AstraZeneca is launching a randomized trial
immunology.sciencemag.org/content/5/48/eabd0110.full -
soria
@jsoriamd
Many normal human tissues become a patchwork of mutant clones with time. What drives the war of clones? Colom et al suggest that is not mainly the genome of the clones but the genotype of its neighbors
www.nature.com/articles/s41588-020-0624-3
www.nature.com/articles/s41576-020-0256-6 -
soria
@jsoriamd
Histologic transformation & other off-target molecular alterations appear to be frequent early emerging resistance mechanisms to osimertinib and to be associated with poor clinical outcomes @CCR_AACR
clincancerres.aacrjournals.org/content/26/11/2654 -
soria
@jsoriamd
Les acteurs de @GustaveRoussy mobilisés pour imaginer les priorités medico-scientifiques de demain
-
soria
@jsoriamd
Merci @ARS_IDF @aur_rousseau pour votre visite de @GustaveRoussy et la discussion sur son projet d’avenir ainsi que le vécu de la crise #covid19
-
soria
@jsoriamd
Fascinating review on the hallmarks of cancer cell dormancy and how the dormant cancer cell life cycle offers opportunities to target not only the cancer but also its environment to achieve a durable cure for seemingly incurable cancers.
www.nature.com/articles/s41568-020-0263-0 -
soria
@jsoriamd
The search for the optimal liquid biopsy allowing to screen asymptomatic people for several types of cancer is nicely illustrated by the CCGA study & the DETECT-A trial. @Annals_Oncology
www.sciencedirect.com/science/article/pii/S09237534203605…
science.sciencemag.org/content/early/2020/04/27/science.a… -
soria reposted
Gustave Roussy
@GustaveRoussy
Merci à Sébastien Bazin @accor, fidèle soutien de @GustaveRoussy et sa fondation, pour ce coup de projecteur sur les besoins de la recherche contre le #cancer dans l'émission #valp @France2tv, interrogé sur notre montre "qui attire l'attention" ⏱#guérirlecancerau21esiècle
-
soria
@jsoriamd
Ultradeep sequencing opens new perspectives for liquid biopsies.Whole-genome sequencing of plasma circulating tumor DNA allows for dynamic monitoring of disease burden and ultra-sensitive detection of MRD. @landau_lab www.nature.com/articles/s41591-020-0915-3?sf234618951=1
-
soria
@jsoriamd
Less COVID19 in high altitude cities (>2500 m) because of a) hypoxia-mediated ACE2 downregulation, b) decreased virus survival in high environment with drastic changes in temperature between night & day, air dryness, & high levels of UV radiation ?
www.ncbi.nlm.nih.gov/pmc/articles/PMC7175867/ -
soria reposted
Gustave Roussy
@GustaveRoussy
Que faut-il retenir du congrès #asco20 ❓
Réponse des Professeurs Fabrice @barlesi et Karim Fizazi de @GustaveRoussy, qui vous résument l'essentiel du congrès en 3 mn !
🎥 Voir la vidéo : youtu.be/KMcbte1yHfY -
soria
@jsoriamd
In this provocative paper @Dr_R_Kuzrock shows that 25% of 1417 tumors had a deleterious gene mutation that was not expressed at the RNA level ! Analysis of samples by NGS and RNA-seq is of value
df6sxcketz7bb.cloudfront.net/manuscripts/134000/134824/ca… -
soria reposted
FabriceAndre
@FAndreMD
Rituximab for high risk B NHL in children: 3 y DFS move from 82 to 94% ! by V Minard Colin from @GustaveRoussy
www.nejm.org/doi/full/10.1056/NEJMoa1915315?query=feature… -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Publication @NEJM
Belle avancée dans le traitement de certains #lymphomes de l'enfant ! Une étude promue par @GustaveRoussy (Dr Minard-Colin) et @COGorg a montré d'excellents résultats qui vont modifier le standard de traitement 👏
🔎 Plus d'infos :
www.gustaveroussy.fr/fr/un-nouveau-traitement-dimmunother… -
soria
@jsoriamd
KRAS G12C inhibitors have shown very promising activity in NSCLC #lcsm but very modest activity in CRC. In this paper, authors @Albert0Bardelli show that EGFR signaling is the dominant mechanism of CRC resistance to KRAS G12C inhibitors
cancerdiscovery.aacrjournals.org/content/early/2020/05/12… -
soria
@jsoriamd
Check out this fascinating work by @NickyMcGranahan
Multiregion exome and RNA-seq data & spatial histology demonstrate that cancer subclones derived from immune cold regions are more closely related in mutation space, vs subclones from immune hot regions.
www.nature.com/articles/s41591-020-0900-x -
soria
@jsoriamd
Physical distancing, face masks and eye protection best approaches to avoid #covid19 www.thelancet.com/journals/lancet/article/PIIS0140-6736(2…
-
soria reposted
Gustave Roussy
@GustaveRoussy
| Nomination ]
Le Dr Jean-Michel Heard est nommé secrétaire général de la recherche de @GustaveRoussy.
Pour en savoir plus 🔽 www.gustaveroussy.fr/fr/le-docteur-heard-secretaire-gener… -
soria reposted
Collin Blakely MD, PhD
@collin_blakely
While I would love to be proven wrong, what would the possible mechanism for cure be? There is no context I am aware of (preclinical or clinical) in which osimertinib (or any EGFR TKI) kills all cancer cells.
-
soria
@jsoriamd
Less grade 3-4 toxicities & hospitalizations, & better patient
experience with a digital monitoring system : Olivier Mir, MD, PhD
@GustaveRoussy presents the results of the randomized phase 3 trial CAPRI. #asco20
Abstract: meetinglibrary.asco.org/record/185986/abstract -
soria
@jsoriamd
Let’s all push to reach this $1M goal. All donations are meaningful whatever the amount #asco20 Challenging @fandre @TonyMok9 @Tony_Calles
Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO
@ASCOPres
Let’s raise $1M during #asco20 for @ConquerCancerFd. I challenge @CliffordHudis, @BandVsCancer, & @tmprowell to:
1. Donate at www.conquer.org/Together
2. RT-comment this tweet & challenge 3 others to do the sameThis media couldn't be displayed. See it on the original post. -
soria reposted
Gustave Roussy
@GustaveRoussy
🗞 A lire dans @lemondefr : le système de suivi à distance CAPRI de @GustaveRoussy, dont les excellents résultats ont été présentés à l'#asco20 🔽
Le Monde Sciences
@lemonde_science
Science Cancer : un télé-suivi efficace www.lemonde.fr/sciences/article/2020/05/30/science-cancer…
-
soria reposted
FabriceAndre
@FAndreMD
CAPRI; a device created at @GustaveRoussy that mix a digital tool and nurse intervention, improves dose intensity (1ry endpoint) , de reases hospitalisation (2ry) in a phase III randomized trial. A key milestone in the Digital medicine era.
Gustave Roussy
@GustaveRoussy
#asco20
Better drug tolerance and patient experience, less severe adverse events: Dr. Olivier Mir @GustaveRoussy presents the nice results of the CAPRI system 📲, which may become a new standard for monitoring oral therapies in #oncology.
Abstract:
▶️meetinglibrary.asco.org/record/185986/abstract -
soria
@jsoriamd
DS8201 ADC opens unique perspectives in HER2 mutant NSCLC with 62% ORR and 14-months-PFS in patients pretreated by CT (90%) and IO for 50% of them #asco20 #lcsm @barlesi @dplanchard
-
soria reposted
FabriceAndre
@FAndreMD
The DFS curve is 😳. now we have better targeted therapies, evidence accumulate that oncogene de-addition work very well in early stage cancers .
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
@APassaroMD
💥 #asco20 #lcsm ADAURA
Clear improvement of DFS in favour OSI but many open questions are emerged.
DFS was highly significant, of course potentially practice changing but...
Would you feel safe to use Osi in adjuvant thinking about your patients/OS? -
soria
@jsoriamd
Promising results of a new ADC targeting CEACAM5 with 21% ORR in high expressors in non-squamous #nsclc. Data presented by Dr. @GazzahAnas @barlesi @GustaveRoussy #ditep at #asco20 an. A PhIII vs Docetaxel is ongoing!
-
soria
@jsoriamd
Elegant oral presentation by @FAndreMD @GustaveRoussy on potential biomarkers of ribociclib sensitivity identified in the blood in a pooled analysis on MONALEESA trials #asco20
-
soria reposted
d.planchard
@dplanchard
Type of major tumor response that can be observed with Trastuzumab Deruxtecan in pts with HER2 mutated NSCLC...@GustaveRoussy #asco2020
-
soria reposted
Gustave Roussy
@GustaveRoussy
#sarcoma
Dr. Patricia Pautier @GustaveRoussy presents at #asco20 the final results of the LMS-02 study (phase II): two chemotherapies given as 1st-line treatment to patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.
🔎 Abstract: meetinglibrary.asco.org/record/186849/abstract -
soria reposted
Gustave Roussy
@GustaveRoussy
#asco20
🎥 VIDEO DECRYPTAGE– Dr Geoerger @GustaveRoussy explique les résultats d’une étude portant sur l'association de 2 thérapies ciblées dans le traitement du #gliome chez l'enfant, association déjà indiquée pour certains #cancers chez l'adulte.
▶ youtu.be/kaAHD_7ZgKw -
soria reposted
Gustave Roussy
@GustaveRoussy
#asco20
🎥 VIDEO DECRYPTAGE – Dr @GazzahAnas @GustaveRoussy explique les résultats d’un essai de phase précoce portant sur le traitement de certains #cancers du poumon non à petites cellules #nsclc par un anticorps conjugué (anticorps + agent cytotoxique).This media couldn't be displayed. See it on the original post. -
soria reposted
Gustave Roussy
@GustaveRoussy
Dr Olivier Mir @GustaveRoussy présente à #asco20 la 1re étude démontrant l'efficacité clinique d’un dispositif alliant outil numérique et organisation humaine pour le suivi à distance de patients #cancer : le dispositif CAPRI 📲
Lire le communiqué ⤵️
www.gustaveroussy.fr/fr/asco-2020-le-dispositif-capri-pro… -
soria
@jsoriamd
Conseil d’administration de @GustaveRoussy en présence du @Prefet75_IDF Michel Cadot: un bilan de la crise covid19 et les premiers éléments du projet stratégique institutionnel, et un grand merci au personnel pour sa mobilisation
-
soria reposted
Gustave Roussy
@GustaveRoussy
.@GustaveRoussy recrute un médecin #réanimateur (H/F) et un médecin #anesthésiste réanimateur (H/F) 50% MAR/ 50% MIR.
▶️www.gustaveroussy.fr/fr/medecin-reanimateur
▶️www.gustaveroussy.fr/fr/medecin-anesthesiste-reanimateur-… -
soria
@jsoriamd
Immune-related adverse events of checkpoint inhibitors a new #immunotherapy review
www.nature.com/articles/s41572-020-0160-6 -
soria
@jsoriamd
Fascinating paper based on the analysis of paired paired primary tumors and metastases, indicating that metastasis-specific mutations are not drivers of cancer spread but instead associated with drug resistance
www.nature.com/articles/s41588-020-0628-z -
soria reposted
Gustave Roussy
@GustaveRoussy
Malgré la crise du #covid19, le #cancer n'attend pas ⚠️
Le diagnostic et la prise en charge du cancer restent indispensables. @GustaveRoussy vous accueille dans les meilleures conditions de sécurité.
☎️ Pour prendre un 1er RDV : 01 42 11 43 77 -
soria reposted
Pierre Blanchard, MD
@PBlanchardMD
For #radonc interested in LOW DOSE lung #radiotherapy for #covid19 - here a paper from @GustaveRoussy showing doses 0.5-1Gy increase nerve associated macrophages and decrease inflammation... www.biorxiv.org/content/10.1101/2020.05.11.077651v1.full.pdf
at least some rationale cc @rweichselbaum -
soria
@jsoriamd
Proinflammatory monocyte-derived #macrophages were abundant in the bronchoalveolar lavage fluid from patients with severe #covid-19
www.nature.com/articles/s41591-020-0901-9 -
soria
@jsoriamd
Check out this paper on the contributions of the innate & adaptive immune systems to both viral control as well as toxicity during #covid-19 infections
rupress.org/jem/article/217/6/e20200678/151725/The-many-f… -
soria
@jsoriamd
PD-1 blockade exposure was not associated with increased risk of severity of #covid-19 in cancer patients. PD-1 blockade (#immunotherapy) does not appear to impact the severity of COVID-19 in patients with lung cancers.
cancerdiscovery.aacrjournals.org/content/early/2020/05/12… -
soria
@jsoriamd
P53 and mdm2 represent a central hub in cancer. Check out this review
www.nature.com/articles/s41568-020-0262-1 -
soria
@jsoriamd
Single-cell genomics is essential to chart tumor ecosystems. single-nucleus RNA-Seq is needed to profile frozen or hard-to-dissociate tumors. Each requires customization to different tissue and tumor types. Check out this fascinating paper
www.nature.com/articles/s41591-020-0844-1 -
soria
@jsoriamd
This is an example that demonstrates the absolute need of #masks4all : one index case leads to 87% of choir practice members infected with just a 2 hour exposure
CDC
@CDCgov
After choir practice in Skagit County, #washington, 52 members became ill with #covid19 symptoms. COVID-19 spreads easily between people. Avoid groups, stay at least 6 feet apart, and wear cloth face coverings to reduce spread. Learn more from @CDCMMWR: www.cdc.gov/mmwr/volumes/69/wr/mm6919e6.htm.
-
soria
@jsoriamd
Pancreatic tumor environment is complex, singular and poses therapeutic challenges & opportunities @NatRevClinOncol
www.nature.com/articles/s41571-020-0363-5 -
soria reposted
Ishwaria Mohan Subbiah, MD MS FASCO
@IshwariaMD
Catching a part of @ASCO webinar on global #cancercare during #covid. @jsoriamd discusses @GustaveRoussy experience w #covid19:
✅The early “mask for all” mandate at @GustaveRoussy meant the % of #healthcareheroes who acquired #covid19 was <<<< than the regional rate.
ASCO
@ASCO
Register for Tuesday's 8 AM EST webinar on #cancercare around the 🌏 during #covid19 w our Pres-elect @UMRogelCancer Dr. Lori Pierce, @GustaveRoussy Dr. Jean-Charles Soria, @CUHKMedicine @StephenLChan1, & @alvarorogado @FundacionECO ➡️ asco3.webex.com/mw3300/mywebex/default.do?nomenu=true&sit…
-
soria reposted
Andy Biotech
@AndyBiotech
#covid19 Important new study demonstrates why #masks4all implementation is so urgent in this #coronavirus pandemic
arxiv.org/pdf/2004.13553.pdf
“My mask protects you; your mask protects me.”
www.vanityfair.com/news/2020/05/masks-covid-19-infections… -
soria reposted
Herbert Loong, MBBS, FASCO
@herbloong
Join my colleague @StephenLChan1 of @CUHKMedicine #hongkong together with @jsoriamd and @ASCO #president-elect Lorie Pierce for an upcoming global #webinar on #cancer care during #covid19! @OncoAlert www.asco.org/practice-policy/policy-issues-statements/asc…
-
soria
@jsoriamd
Sars-cov-2 can trigger a macrophage activation syndrome that triggers extensive immunothrombosis notably in the pulmonary space
www.thelancet.com/action/showPdf?pii=S2665-9913(20)30121-1 -
soria
@jsoriamd
Type 2 immune responses are crucial for tissue homeostasis. Distinct insults, such as allergens or infections, can induce type 2 immune responses that can lead to acute or chronic inflammation to deficits in immune regulation and tissue repair.
www.nature.com/articles/s41577-020-0301-x -
soria reposted
Crispin Hiley
@crispinhiley
Once in a lifetime 4 year clinician scientist post in #radiation sciences here - early career investigator. Please retweet @SwantonLab @TurajlicLab @ProfAJChalmers @finn_corinne @Edradonc @jsoriamd @rweichselbaum @BreastDocUK @CancerConnector @theabzlab @Samuel_Bakhoum @TimWitney
CRUK RadNet City of London
@RadNetCRUKCoL
We are hiring! An exciting opportunity for a ☢️ #clinicalacademic Consultant working on #radiationoncology and #radiationbiology @UCLmedphys. Closing date 30th May!
Apply here: atsv7.wcn.co.uk/search_engine/jobs.cgi?SID=amNvZGU9MTg2Nj… -
soria
@jsoriamd
Fascinating paper on viral load according to symptoms in patients with #covid19.
Viral loads in the very young do not differ significantly from those of adults !
zoonosen.charite.de/fileadmin/user_upload/microsites/m_cc… -
soria reposted
OncLive.com
@OncLive
ECOG performance status, cancer type, and type of prior therapy received can predict risk for clinical worsening or death in patients with cancer who contract the #covid19. @barlesi @GustaveRoussy #aacr20 www.onclive.com/view/aacr-2020-clinical-factors-predict-d…
-
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Pr Fabrice @barlesi @GustaveRoussy a présenté en plénière #covid19etcancer du congrès #aacr20 une analyse précoce de la situation et la manière dont Gustave Roussy s’est adapté avec agilité pour gérer l’épidémie de #covid19.
Lire le communiqué : www.gustaveroussy.fr/fr/congres-virtuel-aacr-pleniere-ana… -
soria reposted
Tatiana Prowell, MD
@tmprowell
#aacr20 #covid19 Dr. Fabrice Barlesi on #covid19ncancer at Gustave Roussy. Incidence #sarscov2 (12%), % asymptomatic (80%), ICU (11%), & death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG>1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos.
-
soria reposted
Annals of Oncology
@Annals_Oncology
#aacr20 Here is the link to the paper published in Annals of Oncology by Zhang et al on the clinical characteristics of patients with cancer infected by #covid19 www.sciencedirect.com/science/article/pii/S0923753420363833
-
soria
@jsoriamd
Data presented at plenary session #aacr20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #covid19 outcome among cancer patients in contrast with chemotherapy
-
soria
@jsoriamd
Data presented at plenary session #aacr20 from @GustaveRoussy by @barlesi shows that prevalence of #covid19 among cancer pediatric patients is almost 14% with a median age of 3 years
-
soria
@jsoriamd
Data at plenary session #aacr20 from @GustaveRoussy by @barlesi shows that #covid19 prevalence among cancer patients is a) 12% b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy
-
soria
@jsoriamd
Data presented at plenary session #aacr20 from @GustaveRoussy by @barlesi shows that #covid19 cancer patients have a 15% mortality . Is this good outcome notably related to the almost 10% of patients who received compassionate #tocilizumab ?
www.aphp.fr/contenu/tocilizumab-improves-significantly-cl… -
soria reposted
Gustave Roussy
@GustaveRoussy
Besoin d'un diagnostic ou d'une prise en charge pour un #cancer ? N'attendez pas, @GustaveRoussy est organisé pour accueillir les patients en toute sécurité malgré la crise #covid19, sans perdre de temps face au cancer.
📞 Pour prendre RDV, un numéro dédié : 01 42 11 43 77. -
soria reposted
OncoAlert
@OncoAlert
Not to be missed, our @OncoAlert 🚨colleague @barlesi 👨⚕️of @GustaveRoussy tomorrow at #aacr20 : The Clinical Plenary: #covid19 and #cancer ‼️
soria
@jsoriamd
Do not miss during #aacr20 tomorrow April 28th 9:00 11:00 a.m. EST the Clinical Plenary: #covid19 and Cancer
where @barlesi will present the outcome of all COVID19 cancer patients treated @GustaveRoussy
www.aacr.org/blog/2020/04/24/aacr-virtual-annual-meeting-… -
soria
@jsoriamd
Do not miss during #aacr20 tomorrow April 28th 9:00 11:00 a.m. EST the Clinical Plenary: #covid19 and Cancer
where @barlesi will present the outcome of all COVID19 cancer patients treated @GustaveRoussy
www.aacr.org/blog/2020/04/24/aacr-virtual-annual-meeting-… -
soria
@jsoriamd
Can we target IDH-mutant cholangiocarcinomas and gliomas with PARP inhibitors ?
advances.sciencemag.org/content/6/17/eaaz3221.full -
soria
@jsoriamd
Il est possible, dans chaque famille, de confectionner des masques en tissu « artisanaux », « alternatifs », « écrans » ou « barrières », lavables et réutilisables à partir de matériaux courants non onéreux
Académie de médecine de France
@acadmed
🔴#covid19 #aux #masques #citoyens !
Attendre le11mai : c’est accorder 3semaines de répit au #sarscov2 c’est accepter des milliers de nouvelles infections, des centaines d’hospitalisations et des dizaines de morts supplémentaires
COMMUNIQUÉ➡️ www.academie-medecine.fr/wp-content/uploads/2020/04/Aux-m… -
soria
@jsoriamd
Fascinating paper showing that #artificialintelligence applied to CT-scan analysis can help predict #covid19 outcome @AgoniGrammi
www.medrxiv.org/content/10.1101/2020.04.17.20069187v1 -
soria reposted
Gustave Roussy
@GustaveRoussy
📢 Déjà plus de 30 000 consultations pour les Covid-19 News de @GustaveRoussy !
Réalisées et commentées par nos experts, ces synthèses d'actualité scientifique liées au #covid19 remportent un franc succès, merci pour votre confiance.
Retrouvez-les ici : www.gustaveroussy.fr/fr/Covid19News -
soria
@jsoriamd
End of life conditions are a delicate and fundamental topic in #covid19
Sandro de Franciscis ن 🇪🇺
@a_defranciscis
#covid19 Good, moving reporting and the invaluable bonds of family!
A real story from Brescia, Italy.
Thanks @chicoharlan @StefanoPitrelli & Gianluca @InfoPanella on @washingtonpost
- Mr Carmelo Marchese now R.I.P. www.washingtonpost.com/world/2020/04/22/avoiding-loneline… -
soria reposted
Dr. Ron DePinho
@RonDePinho
Let’s not get caught flatfooted, again: long term effects from #covid19
rondepinho.com/insight/looming-health-crisis-long-term-ef… -
soria
@jsoriamd
CheckMate -743, a pivotal Phase 3 trial evaluating nivolumab + ipilimumab vs chemotherapy in previously untreated malignant pleural mesothelioma (MPM) met its primary endpoint of overall survival #immunotherapy news.bms.com/press-release/corporatefinancial-news/bristo…
-
soria
@jsoriamd
Can we target alternative splicing in cancer ?
www.nature.com/articles/s41571-020-0350-x -
soria reposted
Mehdi Touat
@MTouatMD
Thank you so much Jean-Charles ! Free access link here: rdcu.be/b3ArE
-
soria
@jsoriamd
Fascinating paper analyzing a 1000 #gliomas. High TMB is not indicative of
#immunotherapy efficacy. Chemotherapy (temozolomide) can drive the acquisition of hypermutated populations without promoting a response to PD(L)-1 blockade
www.nature.com/articles/s41586-020-2209-9 -
soria
@jsoriamd
When we speak we project droplets, the louder, the more droplets… #masks4all is necessary in the current #covid19 pandemic
www.nejm.org/doi/full/10.1056/NEJMc2007800?query=featured… -
soria reposted
Pardoux
@pardouxstephane
Magnifique mobilisation du groupe @Accor aux côtés de @GustaveRoussy depuis de nombreuses années.
France Inter
@franceinter
#coronavirus Sébastien Bazin, PDG @Accor, annonce que des hôtels du groupe accueilleront dès ce soir des patients atteints du Covid-19. "On a déjà plus de 300 hôtels volontaires pour accompagner le monde médical" #le79inter
-
soria
@jsoriamd
Targeting RET-dependent cancers @VivekSubbiah cancerdiscovery.aacrjournals.org/content/10/4/498?sf12082…
-
soria reposted
Gustave Roussy
@GustaveRoussy
| Impact du #covid19 |
@GustaveRoussy participe à la grande étude nationale SAPRIS, lancée avec @inserm et @santeprevention, pour étudier la santé et les enjeux sociaux de la pandémie et du confinement. L'enquête s'appuie notamment sur l'@EtudeE4N-E3N :
presse.inserm.fr/une-grande-enquete-nationale-pour-etudie… -
soria reposted
Gustave Roussy
@GustaveRoussy
| #covid19 : la recherche a besoin de vous |
@GustaveRoussy mène plusieurs programmes de recherche d'envergure sur le #covid19 et sur ses interactions avec le #cancer.
Soutenez nos chercheurs dans cette course contre la montre grâce à vos #dons 🤝
▶️www.gustaveroussy.fr/fr/don-recherche-covid-19 -
soria
@jsoriamd
SARS-CoV-2 infects T lymphocytes through its spike protein-mediated
membrane fusion www.nature.com/articles/s41423-020-0424-9 -
soria
@jsoriamd
The evidence is all over the place #masks4all is needed with #covid19
www.nature.com/articles/s41591-020-0843-2
medium.com/@Cancerwarrior/covid-19-why-we-should-all-wear… -
soria
@jsoriamd
First publication on Cancer patients & #covid19 : increased risk of severe cases in cancer patients www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2…
-
soria
@jsoriamd
After 27 extraordinary months with @AstraZeneca, back to Paris to lead @GustaveRoussy as its new General Director after today appointment by Minister of Health @agnesbuzyn. Looking forward to continuing the journey to improve the life of patients
www.gustaveroussy.fr/en/professor-jean-charles-soria-appo… -
soria
@jsoriamd
Great slide of key challenges of AI by @AgoniGrammi #esmo19
-
soria
@jsoriamd
Radiotherapy plan annotation: AI can over perform the physician for some organs #esmo19 @AgoniGrammi
-
soria
@jsoriamd
So much can be achieved by #ai in #pathology. In this paper Google team developed an image search tool for pathology images.
www.nature.com/articles/s41746-019-0131-z -
soria
@jsoriamd
Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival rates have moved from 50% end of the 70s to 67% in 2013.
ourworldindata.org/cancer -
soria
@jsoriamd
CT-scan analysis via radiomics can predict the presence of tumor infiltrating lymphocytes and response to PD(L)1 antibodies. Great work by @charles_ferte @Edradonc @champiatMD @AgoniGrammi @GustaveRoussy @TheLancetOncol
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1… -
soria
@jsoriamd
CT-scans can predict pathological presence of TIL #radiomics #immunotherapy www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1…
-
soria
@jsoriamd
Sun et al @GustaveRoussy with leadership of @charles_ferte @MedImmune today & @AgoniGrammi @centralesupelec presented fascinating data demonstrating that TIL presence can be inferred from CT-scan analysis via Radiomics #asco18


































































































































































































































































































































































































































































































































































































































































































































































































































































































